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GENERAL INTRODUCTION
In the early 1980’s the first reports appeared in the literature describing the harmful effects 
of performing endotracheal intubation in neonates without the use of premedication. In 
an observational trial in 10 preterm infants, Marshall et al. examined the physiological 
changes that were associated with awake endotracheal intubation. The authors observed 
a decrease in heart rate and transcutaneous oxygen tension, and an increase in systolic 
blood pressure during laryngoscopy and placement of the endotracheal tube.1 Shortly 
after this, Kelly et al. were the first to perform a randomized controlled trial in which 
awake intubation in neonates was compared to intubation with the use of premedication. 
They reported a significantly lower increase in intracranial pressure and less decrease in 
heart rate in infants who were treated with pancuronium and atropine before intubation, 
compared to infants who received only atropine or no premedication.2 
After these reports, a number of studies evaluated the effects of different premedication 
strategies compared to awake intubation. Results of these reports showed that awake 
intubation resulted in a greater increase in intracranial pressure,2-6 elevated systemic blood 
pressure,5-8 tachycardia,3,7 bradycardia2,9 and hypoxemia10 compared to the administration 
of premedication prior to endotracheal intubation. Awake intubation also resulted in a 
longer duration to complete successful intubation and a higher number of intubation 
attempts.7-11 In 2001, this knowledge about the harmful effects of awake intubation 
resulted in a consensus statement on the prevention and management of pain in the 
newborn. It was stated that endotracheal intubation should only be performed without 
analgesia or sedation for resuscitation in the delivery room or in emergency situations 
without the availability of an intravenous access.12 In all other situations, premedication 
should be used during neonatal intubation.
At that time, the routine use of premedication prior to nonemergency intubation was 
only around 40% in several countries.13-15 After the harmful effects of awake intubation 
became apparent, the routine use of premedication for nonemergency endotracheal 
intubation became subject of extensive research all around the world. In the last 20 
years, a tremendous increase in the routine use of premedication up to around 90% was 
seen.16-19 Despite the increased use of premedication, there was extensive variability in 
the drugs that were used as premedication and their dosages.13,16,17,19-21
An ideal premedication strategy for endotracheal intubation in newborns should 
eliminate pain and discomfort, minimize the physiological abnormalities that can 
accompany laryngoscopy and intubation, prevent trauma to the airway and provide 
circumstances to perform a successful procedure as quickly as possible. Besides this, 
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the premedication regimen should have a rapid onset and a short duration of action, and 
possess no substantial side effects. The American Academy of Pediatrics suggested the 
ideal premedication strategy to consist of a vagolytic drug to prevent bradycardia, an 
analgesic or hypnotic drug to control pain and/or reduce the level of consciousness, and 
a muscle relaxant to provide ideal intubating conditions.22-24 In the last decade, however, 
the focus changed more and more towards research into a single drug regimen such 
as propofol, remifentanil or fentanyl. Today, almost 40 years after the first report on the 
harmful effects of awake endotracheal intubation, the optimal premedication strategy 
for endotracheal intubation in newborns is still not known.25 
Even with the use of premedication, endotracheal intubation in newborns remains a 
difficult and high-risk procedure that often requires multiple attempts for successful 
completion. The overall first attempt success rate is only about 50%, with variations 
depending on the level of experience of the provider.26-33 Several studies have shown that 
endotracheal intubation is frequently accompanied by severe and non-severe adverse 
events.26,31,34-36 These data suggest that there is an urgent need to improve success and 
safety in neonatal endotracheal intubations. 
Although patients within the field of neonatology seem rather uniform, there are 
remarkable differences between the larger late preterm and term born neonates on one 
side and the much smaller very and extremely preterm infants on the other side. These 
differences lie for example in the underlying diseases causing respiratory insufficiency, and 
in the risk of developing ventilator-induced lung injury and bronchopulmonary dysplasia 
(BPD). In late preterm and term born neonates respiratory distress is mostly caused 
by perinatal associated complications, for example asphyxia, group B streptococcus 
infection/pneumonia or meconium aspiration syndrome. These diseases have a longer 
duration of recovery and, therefore, often need mechanical ventilation for a period 
of several days or more. Despite this, the risk of ventilator-induced lung injury for this 
category of patients is limited. 
Although in smaller preterm infants diseases such as infection, pneumonia or necrotizing 
enterocolitis are also frequent causes of respiratory insufficiency, one of the major 
conditions for respiratory insufficiency is respiratory distress syndrome (RDS).37 A 
substantial part of the preterm population requires surfactant therapy for RDS, which 
is historically administered as a bolus via the endotracheal tube during a period of 
mechanical ventilation.38 Mechanical ventilation in preterm infants can further disrupt 
alveolarization and growth of the pulmonary vasculature, and activate inflammatory 
pathways which can lead to damage to the preterm lung. Eventually, this can result in 
BPD.39
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The last decades there has been a tremendous increase in the use of non-invasive 
ventilatory strategies in preterm newborns. In accordance with these developments, 
lesser invasive methods of surfactant administration limiting the period of mechanical 
ventilation have emerged. The first technique used in clinical practice, was the INtubation 
– SURfactant – Extubation (INSURE) method. In this method, patients were intubated for 
the sole purpose of surfactant administration and were extubated as soon as possible 
thereafter.40 Compared to surfactant administration during mechanical ventilation, 
INSURE decreased the need for mechanical ventilation, and the incidence of BPD and air 
leak syndromes.41 INSURE, however, still requires a short period of mechanical ventilation 
and even these brief periods have the possibility of causing lung injury.39,42 
After that, several techniques to administer surfactant without the need for mechanical 
ventilation were developed. One of these techniques is the use of a thin catheter to 
administer surfactant to spontaneously breathing infants on nasal Continuous Positive 
Airway Pressure (nCPAP), a technique known as ‘Less Invasive Surfactant Administration’ 
(LISA) or ‘Minimally Invasive Surfactant Therapy’ (MIST).43,44 This thin catheter technique 
has been shown to reduce the incidence of death or BPD, lower the need for mechanical 
ventilation, and shorten the duration of mechanical ventilation, oxygen therapy and 
different kinds of respiratory support.45-51 In the past decade, LISA has made its way into 
clinical practice to a more or less extent.52-56 The characteristics of the INSURE and LISA 
procedures and their differences with surfactant therapy during mechanical ventilation 
are outlined in Figure 1. 
 
•Premedication for intubation: always.
• Intubation and start mechanical ventilation (ventilator).
•Surfactant administration through endotracheal tube.
•Continuing mechanical ventilation for (at least) several hours.
Surfactant during mechanical ventilation
•Premedication for intubation: commonly.
• Intubation and start mechanical ventilation (ventilator, T piece or 
comparable device). 
•Surfactant administration through endotracheal tube.
• Immediate extubation (ideally within minutes).
INtubation-SURfactant-Extubation (INSURE)
•Premedication for catheter placement: occasionally.
•Patient spontaneously breathing on nCPAP.
•Placement of thin catheter through vocal cords.
•Administration of surfactant through catheter.
•Removal of the catheter, continuation of nCPAP.
Less Invasive Surfactant Administration (LISA)
Figure 1. Characteristics of different techniques to administer surfactant
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In both INSURE and LISA, laryngoscopy is performed and an endotracheal tube (INSURE) 
or thin catheter (LISA) is placed through the vocal cords. Both procedures, therefore, have 
considerable similarities with the procedure of endotracheal intubation for the purpose 
of mechanical ventilation. Likely, the harmful effects of performing INSURE or LISA in 
awake patients are comparable with the harmful effects of performing awake intubation. 
Ideally, during INSURE and LISA premedication should be used. Studies on the use of 
INSURE do report on the use of various drugs as premedication.40,57-67 LISA, however, is 
often performed without the use of premedication.44,49,51-56 The choice of premedication 
for these procedures should be carefully made. A very short period of action to facilitate 
rapid extubation in case of INSURE and complete preservation of the respiratory drive in 
case of LISA are of utmost importance for success of both procedures.
CONTENTS OF THIS THESIS
The overall aim of this thesis was to increase patient safety and comfort during 
endotracheal intubation in newborn infants by optimizing the use of premedication. The 
specific aims of this thesis were:
1. Premedication use during INSURE and LISA: to find the most optimal premedication 
strategy for the INSURE procedure and to evaluate the need for premedication use 
during LISA by describing the effects of performing LISA without premedication.
2. Measurement of the effect of premedication: to standardize the intubation procedure 
by developing an objective scoring system to determine level of sedation after the 
administration of premedication. 
3. Propofol as premedication: to find suitable doses of propofol that provide optimal 
sedation without significant side effects in newborns of different gestational and 
postnatal ages. 
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ABSTRACT
Background: Neonatal intubation is a stressful procedure that requires premedication 
to improve intubation conditions and reduce stress and adverse physiological 
responses. Premedication used during the INSURE (INtubation, SURfactant therapy, 
Extubation) procedure should have a very short duration of action with restoration of 
spontaneous breathing within a few minutes. 
Aims: To determine the best sedative for intubation during the INSURE procedure by 
systematic review of the literature. 
Methods: We reviewed all relevant studies reporting on premedication, distress, and 
time to restoration of spontaneous breathing during the INSURE procedure. 
Results: This review included 12 studies: two relatively small studies explicitly 
evaluated the effect of premedication (propofol and remifentanil) during the INSURE 
procedure, both showing good intubation conditions and an average extubation time of 
about 20 minutes. Ten studies reporting on fentanyl or morphine provided insufficient 
information about these items. 
Conclusions: Too little is known in the literature to draw a solid conclusion on which 
premedication could be best used during the INSURE procedure. Both remifentanil 
and propofol are suitable candidates but dose-finding studies to detect effective 
nontoxic doses in newborns with different gestational ages are necessary. 
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INTRODUCTION
Endotracheal intubation is a frequently performed procedure in the neonatal intensive 
care unit (NICU).1 It is a stressful procedure associated with pain and adverse physiological 
responses when the neonate is awake. Adverse effects include hypoxia, bradycardia, 
systemic hypertension, and increased intracranial pressure with a potential risk of 
intraventricular hemorrhage, especially in preterm infants.2-6 Intubation without the use of 
premedication may lengthen the procedure, require a greater number of attempts,4-6 and 
cause traumatic damage to the face, eyes, tongue, gums, and glottic structures.6,7 With 
this in mind, clinicians have started to routinely administer premedication.2-4,8-11 However, 
there is still no consensus about the best drugs for neonatal intubations.12,13
The most frequent reason for intubation in preterm neonates is surfactant replacement 
therapy for respiratory distress syndrome (RDS). Incidence of RDS is 92% in 24-25 weeks, 
88% in 26-27 weeks, 76% in 28-29 weeks, and 57% in 30-31 weeks. Starting early with 
nasal continuous positive airway pressure (nCPAP) can reduce the need for surfactant 
replacement therapy in RDS by 50%.14 Historically, surfactant was administered via a 
tracheal tube during mechanical ventilation. As mechanical ventilation may damage the 
pulmonary system and cause bronchopulmonary dysplasia (BPD), new techniques have 
been introduced to shorten the duration of mechanical ventilation as much as possible. 
In the INSURE (INtubation, SURfactant administration, immediate Extubation) method, 
infants are endotracheally intubated only for surfactant administration and are extubated 
immediately thereafter and put on nCPAP again. A Cochrane review in 2008 showed that 
the INSURE method significantly decreased the need for mechanical ventilation (relative 
risk (RR) 0.72, 95% confidence interval (CI) 0.59– 0.87), the incidence of BPD (RR 0.68, 
95% CI 0.57–0.79) and the incidence of air leak syndromes (RR 0.52, 95% CI 0.28– 0.96).15 
Intubation in the context of the INSURE procedure still requires the administration of 
premedication. However, rapid recovery of the respiratory drive is essential for the success 
of the INSURE procedure. As extubation should take place within several minutes after 
surfactant administration, the sedative agent used must have a very short duration of 
action. There is no consensus about what agent is most suitable as premedication for 
INSURE procedures. The goal of this paper is to determine the most appropriate sedative 
for neonatal intubation during the INSURE procedure by reviewing the literature. 
24
Chapter 2
METHODS
Literature searches in Pubmed and EMBASE were performed to obtain all publications 
evaluating the effect of premedication for intubation during the INSURE procedure. 
We searched for information about the intubation conditions, the number of attempts 
needed for successful intubation, and mainly the time to awakening and extubation. The 
initial search strategy involved the following keywords: “intubation, intratracheal” (MeSH), 
“premedication” (MeSH), and “INSURE”, with the limit newborn: birth-1 month. This search 
strategy revealed only two relevant publications. 
Therefore we performed an additional search strategy for all publications describing 
the INSURE procedure and screened these publications for the following information: 
premedication used, dose of premedication, intubation conditions, number of attempts 
needed for successful intubation, time to restoration of sufficient breathing pattern, 
time to extubation, time to start nasal respiratory support, INSURE failure, intractable 
apnea as a reason for INSURE failure, and time window between extubation and INSURE 
failure. This search strategy involved the following keywords: “pulmonary surfactants” 
[MeSH], “respiratory distress syndrome, newborn” [MeSH], “positive pressure respiration” 
[MeSH], “continuous positive airway pressure” [MeSH], “infant, newborn” [MeSH], and 
“INSURE” in different combinations. Because the first publication describing the INSURE 
procedure appeared in 1990, publications in the time frame between January 1990 and 
June 2013 were sought. Because reviews describing the INSURE procedure do not 
usually provide any new data about premedication and its effects, we excluded reviews. 
Reference lists of publications describing the INSURE procedure were screened for other 
useful publications. Publications in English, Dutch, French, and German were included. 
The full text of each report describing the INSURE procedure was screened for the 
abovementioned information. 
RESULTS
The overall literature search yielded 12 studies suitable for our review. Only 2 publications, 
both by Welzing et al., explicitly evaluated the effect of premedication for intubation during 
the INSURE procedure, that is, remifentanil and propofol, respectively.16,17 The search 
strategy for publications describing the INSURE procedure revealed 36 publications. 
We excluded 24 studies, 5 because they were written in another language (Danish, 
Swedish, and Chinese), 2 because any premedication before intubation clearly was not 
given, and 17 because they did not provide any information about the premedication 
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used. Thus, ten additional publications were included, next to both studies of Welzing et 
al. The following sedatives were evaluated: remifentanil, propofol, fentanyl, morphine, and 
a combination of morphine and pentobarbital. Characteristics of the studies regarding the 
INSURE procedure are summarized in Table 1 and detailed information about the effects 
and side effects of the premedication that was used is provided in Table 2. 
Remifentanil. In the study of Welzing et al. a total of 21 preterm infants received 10 μg/kg 
atropine and 2 μg/kg remifentanil prior to intubation. Fifteen patients (71%) were intubated 
at the first attempt and six patients (29%) at the second attempt. First failed attempts were 
ascribed to inexperience of residents in training and not to insufficient sedation. Intubation 
conditions were excellent in 14 patients (67%) and good in 7 patients (33%). No serious 
side effects occurred. CPAP could be started at a mean of 10.9 minutes (range 1–30 
minutes) after surfactant administration, and mean time to extubation was 42.4 minutes 
(range 1–330 minutes).16 
Propofol. A pilot study of Welzing et al. evaluated the effect of propofol as premedication 
before intubation during the INSURE procedure. This pilot was supposed to continue 
for one year but was stopped prematurely because of significant problems with arterial 
hypotension. Thirteen preterm infants underwent the INSURE procedure and received 
10 μg/kg atropine and 1 mg/kg propofol. Intubation was successful at the first attempt in 
nine patients (69%) and at the second attempt in four patients (31%). Failed first attempts 
were ascribed to inexperience of residents in training. Intubation conditions were excellent 
in five, good in six, and inadequate in two patients, respectively. Propofol gave only a short 
period of respiratory depression and nCPAP could be started at a mean of 25 minutes 
(2 to 120 minutes) after surfactant administration. One patient needed reintubation after 
INSURE because of inadequate respiratory drive. In 5 of 13 patients significant arterial 
hypotension was observed.17 
Morphine. Five of the 10 additionally included publications concerned morphine 
monotherapy in a dosage of 100 or 200 μg/kg.18-22 The use of naloxone was optional in 
most studies,18,19,21 standard practice in one study,22 and not mentioned in one study.20 
None of these five studies provided details on intubation conditions and number of 
attempts for successful intubation. The studies of Van den Berg et al. and Flor-de-Lima 
et al. did not address time to restoration of spontaneous breathing and INSURE failure 
because of insufficient breathing or apnea.18,22 In the study of Cherif et al., all patients were 
extubated within 6.3 ± 1.7 minutes (range 5–12 minutes) after surfactant administration. 
However, INSURE failed in 35 patients (32.1%) but reasons for this failure and the time 
frame between extubation and INSURE failure were not mentioned.20 Verder et al. did not 
mention time to extubation but did mention INSURE failure in 15 patients (43%): 2 patients 
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Table 1. Characteristics of included studies
Author Kind of study Inclusion criteria INSURE Exclusion criteria INSURE Definition of intubation 
conditions
Definition of INSURE failure Predefined side 
effects
Ancora et al.26 Retrospective 
case control 
study
FiO2 requirement >0.40 on 
nCPAP >30 min to maintain 
SpO2 values 85-95% in 
presence of radiological signs 
of RDS
Not reported Not defined FiO2 > 0.40 on nCPAP, intractable 
apnea (>4 episodes of apnea/hour or 
>2 episodes of apnea/hour requiring 
bag and mask ventilation) or severe 
respiratory acidosis (pH <7.12 and 
pCO2 >70 mmHg) within 7 days from 
extubation
Not defined
Van den Berg 
et al.22
Prospective 
cohort study
Not reported Not reported Not defined Not defined Not defined
Bohlin et al.23 Retrospective 
descriptive 
study
Preterm with RDS on nCPAP 
with a/A ratio ≤0.22
Infants requiring intubation 
as part of resuscitation at 
birth
Not defined Need for MV in first week after surfactant 
treatment. Need for MV: PaCO2 ≥8.5 kPa, 
FiO2 ≥0.60, signs of severe respiratory 
distress or apnea
Not defined
Cherif et al.20 Retrospective 
case study
GA >27 weeks, a/A ratio ≤0.25 
on nCPAP
Not reported Not defined Need for MV during 24 hours after 
surfactant treatment. Criteria for MV: 
>3 episodes of apnea per 3 hours 
irresponsive of stimulation and caffeine 
treatment, arterial pH <7.20, arterial pCO2 
>65 mmHg, a/ApO2 <0.15, metabolic 
acidosis not responsive to treatment
Not defined
Gizzi et al.25 Retrospective 
case study
FiO2 requirement >0.40 on 
nCPAP >30 min to maintain 
SpO2 values 85-93% in the 
presence of radiologic signs 
of RDS
Not reported Not defined FiO2 >0.40 to maintain SpO2 85-95%, 
significant apnea defined as >4 episodes 
of apnea/hour or >2 apnea/hour 
requiring bag and mask ventilation, 
respiratory acidosis pCO2 >65 mmHg 
and pH <7.20)
Not reported
Flor-de-Lima 
et al.18
Retrospective 
case control 
study
FiO2 >0.40 with respiratory 
distress and/or arterial pCO2 
>65 mmHg and pH <7.0 on 
nCPAP
Not reported Not defined Not defined Not defined
Leone et al.27 Case control 
study
Preterm with RDS on nCPAP 
with a/A ratio ≤0.22
Infants requiring intubation 
as part of resuscitation 
at birth or later as part of 
respiratory failure
Need for MV during admission to the 
NICU. Criteria for MV: PaCO2 ≥8.5 kPa, 
FiO2 ≥0.60, signs of severe respiratory 
distress or apnea
Sandri et al.24 RCT GA 28-32 weeks, inborn, FiO2 
on nCPAP >0.40 for >30 min 
to maintain SpO2 93-96% and 
radiographic signs of RDS
Need for MV during first week. Criteria: 
FiO2 >0.40 for SpO2 85-93%, significant 
apnea (>4 apnea/hour or >2 apnea/
hour requiring bag and mask ventilation), 
respiratory acidosis (pCO2 >65 mmHg, 
pH <7.20), FiO2 rapidly increasing >0.80
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>3 episodes of apnea per 3 hours 
irresponsive of stimulation and caffeine 
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Need for MV during first week. Criteria: 
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hour requiring bag and mask ventilation), 
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pH <7.20), FiO2 rapidly increasing >0.80
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Table 1. Characteristics of included studies - continued
Author Kind of study Inclusion criteria INSURE Exclusion criteria INSURE Definition of intubation 
conditions
Definition of INSURE failure Predefined side 
effects
Verder et al. 
199419
RCT GA 25-35 weeks, clinical and 
radiologic signs of RDS, PNA 
2-72 hours, nCPAP with PEEP 
≥6 cm H2O, a/A ratio ≤0.22
AS <3 at 5 min, 
PPROM >4 days, 
severe malformations, 
pneumonia, 
pneumothorax
Not defined Not defined Not defined
Verder et 
al.199921
RCT GA <30 weeks, PNA 2-72 
hours, nCPAP with PEEP ≥6 
cm H2O for RDS, a/A ratio 
0.35-0.22 decreasing over a 
period of >30 min
AS ≤2 at 5 min, 
PPROM >3 weeks, 
lethal malformations, 
pneumonia, incompletely 
treated pneumothorax
Not defined Need for MV within 7 days of birth. 
Criteria for MV: a/A values <0.15 
decreasing further over a period >30 
min, severe apnea (>4 episodes of 
apnea/hour or need for bag and mask 
ventilation >2 times per hour), inability to 
extubate within 1 hour after INSURE
Not defined
Welzing et 
al.201017
Prospective 
cohort study
GA 29-32 weeks, PNA <8 
hours, moderate to severe 
respiratory distress (FiO2 ≥0.30 
on nCPAP for SpO2 ≥88% or 
Silverman score ≥6)
Any kind of disease not 
allowing early extubation
Score 0-2 on coughing, 
breathing, and limb movements 
(≤1 = excellent, 2-3 = good, >3 
or distinct coughing or limb 
movement = inacceptable)
Not reported Hypotension
Welzing et al. 
200916
Prospective 
cohort study
GA 29-32 weeks, PNA <8 
hours, moderate to severe 
respiratory distress (FiO2 ≥0.30 
on nCPAP for SpO2 ≥88% or 
Silverman score ≥6)
Any kind of disease not 
allowing early extubation
Score 0-2 on coughing, 
breathing, and limb movements 
(≤1 = excellent, 2-3 = good, >3 
or distinct coughing or limb 
movement = inacceptable)
Not reported Hypotension, 
bradycardia, 
chest rigidity
Abbreviations: AS, Apgar score; GA, gestational age; MV, mechanical ventilation; nCPAP, nasal 
continuous positive airway pressure; PEEP, positive end-expiratory pressure; PNA, postnatal age; 
PPROM, preterm premature rupture of membranes; RDS, respiratory distress syndrome. 
could not be extubated after surfactant administration and another 13 patients had 
to be reintubated. In 10 of these 15 patients the reason for INSURE failure was 
recurrent apnea. Information regarding the time frame between extubation and 
INSURE failure was lacking.19 In another study Verder et al. found that four patients 
(7%) could not be extubated after surfactant administration. In two patients the 
reason was intractable apnea, which is a side effect of morphine. In this study the 
use of morphine was optional and the authors did not mention if these two patients 
had received morphine.21 
In the study of Bohlin et al., patients received a combination of 200 μg/kg morphine 
and 2 mg/kg pentobarbital prior to intubation. Naloxone 100 μg/kg was administered 
to all patients before extubation. Information regarding intubation conditions, number 
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Table 1. Characteristics of included studies - continued
Author Kind of study Inclusion criteria INSURE Exclusion criteria INSURE Definition of intubation 
conditions
Definition of INSURE failure Predefined side 
effects
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Not defined Not defined Not defined
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AS ≤2 at 5 min, 
PPROM >3 weeks, 
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pneumonia, incompletely 
treated pneumothorax
Not defined Need for MV within 7 days of birth. 
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min, severe apnea (>4 episodes of 
apnea/hour or need for bag and mask 
ventilation >2 times per hour), inability to 
extubate within 1 hour after INSURE
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on nCPAP for SpO2 ≥88% or 
Silverman score ≥6)
Any kind of disease not 
allowing early extubation
Score 0-2 on coughing, 
breathing, and limb movements 
(≤1 = excellent, 2-3 = good, >3 
or distinct coughing or limb 
movement = inacceptable)
Not reported Hypotension
Welzing et al. 
200916
Prospective 
cohort study
GA 29-32 weeks, PNA <8 
hours, moderate to severe 
respiratory distress (FiO2 ≥0.30 
on nCPAP for SpO2 ≥88% or 
Silverman score ≥6)
Any kind of disease not 
allowing early extubation
Score 0-2 on coughing, 
breathing, and limb movements 
(≤1 = excellent, 2-3 = good, >3 
or distinct coughing or limb 
movement = inacceptable)
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Abbreviations: AS, Apgar score; GA, gestational age; MV, mechanical ventilation; nCPAP, nasal 
continuous positive airway pressure; PEEP, positive end-expiratory pressure; PNA, postnatal age; 
PPROM, preterm premature rupture of membranes; RDS, respiratory distress syndrome. 
could not be extubated after surfactant administration and another 13 patients had 
to be reintubated. In 10 of these 15 patients the reason for INSURE failure was 
recurrent apnea. Information regarding the time frame between extubation and 
INSURE failure was lacking.19 In another study Verder et al. found that four patients 
(7%) could not be extubated after surfactant administration. In two patients the 
reason was intractable apnea, which is a side effect of morphine. In this study the 
use of morphine was optional and the authors did not mention if these two patients 
had received morphine.21 
In the study of Bohlin et al., patients received a combination of 200 μg/kg morphine 
and 2 mg/kg pentobarbital prior to intubation. Naloxone 100 μg/kg was administered 
to all patients before extubation. Information regarding intubation conditions, number 
of attempts, and extubation time was not provided. Eight patients (19%) could not be 
extubated after surfactant administration. This was related to the premedication in only 
one patient, who received an overdose of pentobarbital.23 
Fentanyl. Four studies used fentanyl as premedication; two studies at a dose of 0.5–2 μg/
kg,24,25 one study at a dose of 1–3 μg/kg,26 and one study at a dose of 0.2 mg/kg.27 None 
of these four studies detailed the intubation conditions, number of intubation attempts, 
and time to return of spontaneous breathing and extubation. The studies of Sandri et al. 
and Leone et al. also provided no information about INSURE failure.24,27 In the study of 
Gizzi et al. INSURE failed in 11 patients (35%) who were extubated to nasal CPAP. In four 
patients the reason for INSURE failure was intractable apnea and the time frame between 
surfactant administration and INSURE failure was 48.1 hours (range 5 - 72 hours). 
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Table 2. Summary of premedication used before intubation in publications studying the INSURE 
procedure
Author Premedication and dosage Number of 
patients
Patient characteristics Time to extubation INSURE failure Reasons for INSURE 
failure
Ancora et al.26 Atropine 20 μg/kg, fentanyl 1-3 μg/kg, naloxone 40 μg/kg 
optional
38 GA < 32 weeks and BW 
<1500 grams
Not described 14 patients Severe apnea in 13 
patients
Van den Berg 
et al.22
Morphine 100 μg/kg or pethidine 1 mg/kg, naloxone 10 μg/
kg before extubation
16 GA < 32 weeks Not described Not described Not described
Bohlin et al.23 Morphine 200 μg/kg and pentobarbital 2 mg/kg, naloxone 
0.1 mg/kg before extubation
42 GA 27-34 weeks Not described 1 patient Overdose of 
pentobarbital
Cherif et al.20 Morphine 200 μg/kg 109 GA 27-35 weeks 6.3 ± 1.7 min (range 5-12 
min)
35 patients Not described
Flor-de-Lima 
et al.18
Morphine 100 μg/kg, naloxone 100 μg/kg optional 15 BW < 1500 grams Not described Not described Not described
Gizzi et al.25 Fentanyl 0.5-2 μg/kg, naloxone 40 μg/kg optional 64 GA < 32 weeks Not described 13 patients Apnea in 4 patients
Leone et al.27 Fentanyl 0.2 mg/kg 42 GA < 34 weeks Not described Not described Not described
Sandri et al.24 Fentanyl 0.5-2 μg/kg 51 GA 28-32 weeks Not described Not described Not described
Verder et al. 
199419
Morphine 100 μg/kg, atropine 10 μg/kg, naloxone 10 μg/
kg optional
35 GA 25-35 weeks Not described 15 patients Apnea in 10 patients
Verder et 
al.199921
Morphine 100 μg/kg, atropine 10 μg/kg, naloxone 10 μg/
kg optional
60 GA < 30 weeks Not described 4 patients Apnea in 2 patients
Welzing et al. 
200916
Remifentanil 2 μg/kg and atropine 10 μg/kg 21 GA 29-32 weeks Start CPAP at 10.9 min 
(1-30 min) and extubation 
at 42.4 min (1-330 min)
Not described Not described
Welzing et al. 
201017
Propofol 1 mg/kg and atropine 10 μg/kg 13 GA 29-32 weeks Start CPAP at 25 min (2-
120 min)
1 patient Inadequate 
respiratory drive
Abbreviations: BW, birth weight; GA, gestational age; CPAP, nasal continuous positive airway 
pressure. 
In patients who were extubated to nasal intermittent positive pressure ventilation (nIPPV), 
INSURE failed in two patients (6%) on account of increased oxygen requirement.25 Ancora 
et al. reported INSURE failure in 14 patients (37%), on account of insufficient respiratory 
drive in 13 patients. INSURE failure occurred at a mean of 99 hours (range 1–150 hours) 
after extubation.26 None of the studies reported the necessity of naloxone therapy after 
fentanyl. 
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Morphine 100 μg/kg, atropine 10 μg/kg, naloxone 10 μg/
kg optional
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Welzing et al. 
200916
Remifentanil 2 μg/kg and atropine 10 μg/kg 21 GA 29-32 weeks Start CPAP at 10.9 min 
(1-30 min) and extubation 
at 42.4 min (1-330 min)
Not described Not described
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Propofol 1 mg/kg and atropine 10 μg/kg 13 GA 29-32 weeks Start CPAP at 25 min (2-
120 min)
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respiratory drive
Abbreviations: BW, birth weight; GA, gestational age; CPAP, nasal continuous positive airway 
pressure. 
In patients who were extubated to nasal intermittent positive pressure ventilation (nIPPV), 
INSURE failed in two patients (6%) on account of increased oxygen requirement.25 Ancora 
et al. reported INSURE failure in 14 patients (37%), on account of insufficient respiratory 
drive in 13 patients. INSURE failure occurred at a mean of 99 hours (range 1–150 hours) 
after extubation.26 None of the studies reported the necessity of naloxone therapy after 
fentanyl. 
DISCUSSION
Although the need for premedication before neonatal intubation is well recognized, 
there is no consensus on the most effective sedative to eliminate pain, discomfort, and 
physiological instability and to provide conditions for a rapid and safe intubation without 
adverse effects. Moreover, duration of action must be as short as possible to allow for a 
sufficient breathing pattern within several minutes after surfactant administration, so that 
extubation can be performed as quickly as possible (see Figure 1). This review found that 
only two pharmacological studies evaluated the effect of premedication for the INSURE 
procedure, that is, remifentanil and propofol. 
32
Chapter 2
Remifentanil, a synthetic opioid, was introduced into clinical practice in 1996 and is 
therefore the newest opioid available.28,29 Because of hydrolysis by nonspecific tissue 
and plasma esterases, metabolism is not dependent on liver and renal function, and it is 
also not age related.30-34 Metabolism produces a metabolite known as remifentanil acid, 
which has no clinical significant activity.29,31,32 This unique pharmacokinetic profile provides 
ultrashort action, high predictability, rapid onset and offset of action, immediate recovery 
of the clinical effect after interruption of the administration, a short context-sensitive half-
life and short elimination time not influenced by the infusion time, and no accumulation 
of the drug.30,31 These positive effects of remifentanil were evident in several reviewed 
studies.32-39 
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Figure 1. Ideal sedation model for the INSURE procedure
Choong et al. investigated the effect of remifentanil as premedication in neonatal elective 
intubations. They found good intubation conditions (using a seven-point Likert scale) and 
few intubation attempts were needed. Mean time to return of spontaneous respiration 
in those patients who did not receive any additional drugs besides remifentanil was 
210 seconds.30 This finding supports our hypothesis that remifentanil is suitable for 
the INSURE procedure. In the study of Welzing et al. remifentanil was also found to 
be effective for neonatal intubation. Intubation conditions were good or excellent in all 
patients and the vast majority of patients were intubated at the first attempt.16 However, 
the authors’ conclusions about the very short period of respiratory depression and early 
reinstitution of CPAP after surfactant treatment are debatable. The time to extubation was 
rather long (42.4 minutes and still 16.9 minutes after excluding 3 patients on prolonged 
endotracheal CPAP for logistic reasons) and does not perfectly meet the criterion of 
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immediate extubation. To our opinion it therefore feels somewhat preliminary to state that 
remifentanil is an appropriate sedative to use as premedication for neonatal intubation 
during the INSURE procedure. Reduced clearance of remifentanil in the first postnatal 
days could probably explain the prolonged effect, and it would seem desirable to 
evaluate lower remifentanil doses that have not yet been studied. More research with 
remifentanil during the INSURE procedure in a larger group of preterm infants of variable 
gestational ages is needed. 
Propofol is a short acting anesthetic that is rapid in onset and short in duration and 
can preserve spontaneous respirations.40 It is a highly lipophilic compound and exhibits 
rapid distribution from blood into subcutaneous fat and the central nervous system 
with subsequent redistribution. Propofol clearance mainly depends on hepatic blood 
flow with subsequent metabolism. Although multiple hepatic and extrahepatic human 
cytochrome p450 isoforms are involved in propofol metabolism, glucuronidation is the 
major metabolic pathway.41 A study of Ghanta et al. found that, with the use of propofol 
2.5 mg/kg, successful intubation was reached twice as fast as with the combination of 
morphine, atropine and suxamethonium, fewer attempts were needed, and patients 
regained spontaneous movements twice as fast.12 
Nevertheless, several studies have shown reduced propofol clearance notably in preterm 
neonates and neonates in the first 10 days of life, leading to accumulation of the drug 
during continuous infusion and bolus administration. Preterm neonates and neonates 
in the first 10 days of life are even more prone to display reduced clearance. After 
correcting for postmenstrual age and postnatal age, there is still extensive unexplained 
interindividual variability in propofol clearance in neonates, making prediction in neonates 
more difficult.40-43
Welzing et al. evaluated the effect of propofol in a dose of 1 mg/kg in 13 patients 
undergoing INSURE. Propofol seemed to be very suitable and provided excellent or good 
intubation conditions in most patients and a very short period of respiratory depression.17 
We feel, however, that the 25 minutes’ time to extubation is too long. Also, one patient 
needed reintubation because of insufficient breathing. Again, the rather long time to 
extubation may be explained perhaps by reduced clearance of propofol in preterm 
infants in the first 10 days of life which leads to longer duration of the sedative effect. 
Dose-finding studies in preterm infants of different gestational and postnatal ages should 
be performed to determine the appropriate dose of propofol for different gestational and 
postnatal ages. 
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Further concerns about propofol in preterm neonates include the relatively high incidence 
of side effects, especially profound hypotension. The pilot study of Welzing et al. was 
stopped prematurely because of significant hypotension in five patients.17 The relatively 
long-lasting sedation and high incidence of hypotension point at excessive propofol 
doses. Evidence on the hypotensive side effect of propofol is not consistent: some 
studies report relatively high frequencies of hypotension,40,44-46 but this is not confirmed by 
others.12,31,47 Vanderhaegen et al. studied the cerebral and systemic hemodynamic effects 
of propofol in neonates and found a short lasting decrease in cerebral oxygenation of 
several minutes and a decrease in mean arterial blood pressure up to 1 hour after propofol 
administration.40 Possible age-related propofol dose response of neonates needs further 
exploration. The adequate propofol doses that provide good sedation, no hypotension or 
decreased cerebral perfusion, and fast restoration of sufficient breathing have yet to be 
found. Also, more research into the adequate doses of propofol for different gestational 
age groups during the INSURE procedure is needed. Once known, propofol should be 
compared with remifentanil in a randomized controlled manner, to evaluate which drug 
would be best with the fewest side effects. 
Of all other 10 publications describing the INSURE procedure, only the one by Cherif et al. 
on morphine reported a time to extubation, that is 6.3 ± 1.7 minutes (range 5–12 minutes).20 
Based on the PK/PD profile of morphine in newborns this seems to be quite short and 
morphine might not even have reached maximum concentration, also in view of the fact 
that INSURE failed in 32% of patients. This may have been due to recurrent apnea due 
to opioid induced respiratory depression. All other nine studies did not mention time to 
awakening and extubation but some of the studies mentioned INSURE failure because 
of intractable apneas.19,21,23,24,26 Opioid induced respiratory depression probably was the 
cause of these apneas. 
Morphine has several limitations, notably delayed onset and prolonged duration of action, 
on account of which it is unsuitable to be used as a sedative in neonatal intubation.6,11,36 This 
is confirmed by several studies. Lemyre et al. performed a randomized placebo controlled 
trial of morphine and found no differences between morphine and placebo in duration 
of distortion of vital parameters, duration of the intubation procedure, and number of 
attempts.48 Several other studies compared morphine with other premedication regimens 
and unanimously found that morphine was less effective, providing worse intubation 
conditions and necessitating a greater number of attempts.12,36,49 The prolonged duration 
of action of morphine could be antagonized with naloxone. However, naloxone also 
antagonizes endorphins and results in a direct very distressful condition and has the 
potential to cause cardiac arrest, as reported in an extremely preterm infant and two adult 
patients.50 Also, the duration of action of naloxone is much shorter than that of morphine. 
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Therefore, opioid induced respiratory depression antagonized with naloxone can easily 
return after the effect of naloxone has worn off. All this makes clear that morphine should 
not be used as premedication in neonatal intubation, especially during the INSURE 
procedure. Short acting opioids therefore probably are more suitable. 
Other short acting drugs or combinations of drugs that could theoretically be used as 
rapid sequence induction for the INSURE procedure, such as midazolam or remifentanil 
combined with propofol or with thiopental, have not been reported in the literature yet.49 
CONCLUSION
In conclusion, propofol and remifentanil both have a very short onset and duration 
of action and are in theory the most suitable candidates for INSURE procedure 
premedication. However, only two relatively small studies have evaluated the effects of 
propofol and remifentanil in this context and insufficient data are available about optimal 
dosing, effects, and side effects. Therefore, more research including dose-finding studies 
and randomized controlled trials that compare different drugs are necessary. Morphine 
should be considered unsuitable because of its delayed onset and prolonged period 
of action. This literature review revealed too little information to draw a solid conclusion. 
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ABSTRACT
Background: Neonatal intubation is stressful and should be performed with 
premedication. In the case of an INSURE (intubation/surfactant/extubation) procedure 
a short duration of action of the premedication used is needed to facilitate fast 
extubation. Given its pharmacological profile, remifentanil seems a suitable candidate. 
Objectives: The aim here was to evaluate the effect and side effects of remifentanil as 
premedication for preterm neonates undergoing INSURE. 
Methods: A prospective, single center study in a level III neonatal intensive care unit 
was conducted. The quality of sedation was assessed in preterm infants receiving 
remifentanil prior to intubation for the INSURE procedure. Intravenous remifentanil 
was administered quickly and followed by a saline flush in approximately 30 s. The 
quality of sedation was defined by a combination of adequate sedation score, good 
intubation conditions and absence of side effects. 
Results: The study was terminated after the inclusion of 14 patients because of the 
high rate of side effects and the poor intubation conditions. Adequate sedation was 
achieved in only two patients (14%). Six patients (43%) needed additional propofol to 
obtain adequate sedation. Chest wall rigidity occurred in six patients (43%). 
Conclusions: The rapid administration of remifentanil provides insufficient sedation 
and is associated with a high risk of chest wall rigidity in preterm neonates. 
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INTRODUCTION
To prevent distress and adverse physiological responses, traumatic damage and 
failed procedures, neonatal intubation should always be performed with the use of 
premedication.1-3 One of the most frequent reasons to intubate neonates is to administer 
surfactant for respiratory distress syndrome. During the INSURE (intubation, surfactant, 
extubation) procedure, patients are only briefly intubated for the administration of 
surfactant and extubated immediately thereafter. To facilitate this rapid extubation, the 
premedication used should have a rapid onset and very short duration of action. 
A recent review on the use of premedication before intubation during the INSURE 
procedure showed no conclusive evidence on the optimal premedication but stated that 
remifentanil was probably the best candidate because of its unique pharmacological 
profile.4 Remifentanil has an extremely brief action, high predictability, rapid onset and 
offset of action, and immediate recovery of the clinical effect after interruption of the 
administration.5 The results of previous studies using remifentanil as single agent were 
also encouraging.6-8 We performed an observational prospective study to evaluate 
the effects and side effects of remifentanil bolus infusion as premedication before 
the INSURE procedure and report here the results of implementing remifentanil into 
clinical practice. 
METHODS
Study population 
This prospective study was performed at the level III neonatal intensive care unit of the 
Erasmus MC Sophia Children’s Hospital in Rotterdam, the Netherlands. Before January 
2013, surfactant was always administered during a period of mechanical ventilation and 
propofol was used as premedication before intubation. In January 2013 the standard 
of care was changed to performing the INSURE procedure for the administration of 
surfactant in all infants with a gestational age ≥27 weeks and birth weight ≥750 g. As 
premedication for the INSURE procedure we started to use remifentanil. Remifentanil 
was administered intravenously as a fast bolus and followed by an intravenous 
saline flush in 30 s. After administration, the level of sedation was assessed with a 
standardized sedation score, performed by rubbing the sole of the patient’s foot and 
judging the motor reaction to that stimulus (1 = spontaneous movement; 2 = movement 
on slight touch; 3 = movement in reaction to firm stimulus; 4 = no movement).9 In case 
of inadequate sedation (score 1 or 2), another dose of remifentanil was administered 
according to the protocol. If sedation was adequate (score 3 or 4), the procedure was 
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continued. INSURE procedures were always performed by neonatologists and clinical 
fellows experienced in neonatal intubations. As soon as the respiratory drive recovered 
after surfactant administration, the patient was extubated and commenced with nasal 
continuous positive airway pressure. 
Use of remifentanil 
Based on the results of the study by Avino et al.7 and our inexperience with remifentanil, 
we decided to start with a low dose of 1 μg/kg. When sedation was inadequate, this dose 
could be repeated no more than twice (period 1). If sedation was still inadequate after 
three doses, the patient received propofol (1 mg/kg) and surfactant was administered 
in the conventional way. Because sedation was inadequate in four of the first five 
patients, the starting dose of remifentanil was increased to 2 μg/kg. When sedation was 
inadequate, another dose of remifentanil was given and each subsequent dose was 
increased with 1 μg/kg relative to the previous dose with a maximum dose of 5 μg/kg 
(period 2). If sedation was still insufficient, propofol (1 mg/kg) was given and surfactant 
was administered in the conventional way. 
Outcome measures 
The primary outcome measure was the quality of sedation, defined as the combination 
of an adequate sedation score, adequate intubation conditions and the absence of side 
effects. Intubation conditions were classified with a validated intubation score by rating 
laryngoscopy, vocal cords, coughing, jaw relaxation and limb movements (Table 1).10 
Intubation conditions were good when the total score was ≤10 with a score on each item 
≤2. Hypotension and chest wall rigidity were defined as side effects. Hypotension was 
defined as a mean blood pressure lower than gestational age and chest wall rigidity was 
defined as the inability to inflate with normal pressures. Secondary outcomes were the 
number of remifentanil doses, maximum remifentanil dose, need for propofol to achieve 
adequate sedation and intubation attempts. 
Table 1. Intubation score
Item Score 1 Score 2 Score 3 Score 4
Laryngoscopy Easy Fair Difficult Impossible 
Vocal cords Open Moving Closing Closed
Coughing None Slight Moderate Severe
Jaw relaxation Complete Slight Stiff Rigid
Limb movements None Slight Moderate Severe
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Ethics committee approval 
We received a waiver for ethical approval of the observational trial according to the 
Dutch Law of Research with Humans (No. 2014.435; Medical Ethical Committee, Erasmus 
Medical Center, Rotterdam, the Netherlands). 
RESULTS
Characteristics of included patients 
Due to insufficient sedation and a high rate of side effects, the use of remifentanil was 
terminated after the inclusion of 14 patients: 5 patients in study period 1 and 9 patients in 
study period 2. The baseline characteristics of the study patients and outcomes in study 
period 1 and study period 2 are reported in Table 2. 
Primary outcome measures 
Adequate sedation was by the combination of three key components: adequate sedation 
score, adequate intubation conditions and the absence of side effects. This was achieved 
in only two patients (14%) of our total study population. In study period 1, two patients 
had an adequate sedation score but one of them had inadequate intubation conditions 
despite this score. In the remaining three patients the sedation score was inadequate. 
Two of them were intubated with propofol while the other was intubated despite the 
inadequate sedation score. None of the patients developed chest wall rigidity. In 
summary, adequate sedation based on the three key components was only achieved in 
one patient in study period 1. In study period 2 adequate sedation scores after remifentanil 
were achieved in six patients. However, only one patient also had adequate intubation 
conditions and no side effects. One patient had inadequate intubation conditions and four 
patients developed chest wall rigidity. In two of these latter patients, intubation failed or 
was never tried and propofol was administered. The sedation score was inadequate in 
three patients. In two of these patients propofol was used and one patient was intubated 
despite an inadequate sedation score. Two of these three patients developed chest 
wall rigidity. In summary, in study period 2 adequate sedation based on the three key 
components was also only achieved in one patient. 
Chest wall rigidity was a frequently reported side effect, occurring in six patients (43%), all 
in study period 2 (67% of patients in study period 2). Chest wall rigidity always occurred 
directly after the administration of remifentanil and never after the administration of 
propofol. No other side effects such as hypotension were identified. 
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Table 2. Patient characteristics and study outcomes in study periods 1 and 2
Study period 1 
n = 5
Study period 2 
n = 9
Patient characteristics
Gestational age (weeks), median (range) 29 2/7 (28 0/7 to 35 0/7) 28 3/7 (27 3/7 to 32 0/7)
Birth weight (g), median (range) 1,320 (920 – 2,200) 1,130 (910 – 1,860)
Gender 1 male, 4 females 4 males, 5 females
Primary outcome measures – sedation parameters with remifentanil
Adequate sedation score (3 or 4) 2 (40) 6 (67)
Adequate intubation score (≤10) 2 (40) 4 (44)
Side effects (chest wall rigidity) 0 6 (67)
Adequate sedation 1 (20) 1 (11)
Secondary outcome measures
Doses of remifentanil
1 1 (20) 2 (22)
2 2 (40) 5 (56)
3 1 (20) 1 (11)
4 1 (20) 1 (11)
Propofol needed 2 (40) 4 (44)
Intubation attempts
1 2 (40) 5 (56)
2 2 (40) 3 (33)
3 1 (20) 0
Not reported 0 1 (11)
Outcome measures are presented as patients, n (%) unless otherwise indicated. 
Secondary Outcome Measures 
Overall, six patients (43%) needed propofol to reach adequate sedation. In the eight 
patients that achieved an adequate sedation score with only remifentanil, three (38%) 
needed 1 dose, four (50%) received 2 doses and one (12%) received 4 doses. The maximum 
dose was 1 μg/kg in three patients (38%), 2 μg/kg in two patients (25%) and 3 μg/kg in 
three patients (38%). Table 2 displays the number of remifentanil doses in both study 
periods. Overall, intubation was successful at the first attempt in 54% of patients, 38% of 
patients required a second and 8% a third attempt. Four intubation attempts failed due 
to inadequate sedation. 
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DISCUSSION
We aimed to evaluate the effectiveness of remifentanil premedication for the INSURE 
procedure in preterm neonates. However, the results of our observational study show 
that low doses (1 μg/kg) did not provide adequate sedation and rapidly administered 
remifentanil resulted in an unacceptable high incidence of chest wall rigidity following a 
high dose. Based on these results we conclude that remifentanil bolus infusion in 30 s is 
not suitable as premedication for neonatal intubation. 
Remifentanil as the single premedication drug has been investigated in three previous 
studies. Welzing et al. studied 2 μg/kg of remifentanil administered over 60 s in preterm 
infants undergoing the INSURE procedure.6 A single dose provided adequate sedation 
in 81% of patients, with 19% needing a second dose and none of the patients requiring 
additional medication. Intubation was successful at the first attempt in 71% of patients, 
insufficient sedation was never the reason for a second attempt and intubation conditions 
were excellent or good in all patients. No chest wall rigidity was reported. Avino et al. 
administered 1 μg/kg of remifentanil over 60 s to 36 preterm infants needing (semi-)
elective intubation and reported similar results to the previous study.7 Intubation was 
successful at the first attempt in 75% of patients but poor intubation conditions occurred 
in 24% of intubation attempts. Chest wall rigidity occurred in two patients (6%). Choong 
et al. also investigated remifentanil in elective intubation in neonates at a dose of 3 μg/
kg administered over 60 s.8 They found less positive results, with additional medication 
needed in 26.7% of patients, failed first attempts in 60% of patients, and excellent or good 
intubation conditions in only 53.6% of patients. Chest wall rigidity was observed in 13% of 
patients. In our study, remifentanil was found to provide sufficient sedation in only a small 
number of patients. An explanation may be the faster infusion rate used in our study. Fast 
infusion is related to higher peak levels, and as a consequence increased side effects 
and shorter duration of effective sedation.6,11 The window of opportunity might have been 
too short to obtain an adequate sedation score and intubation procedure. We also found 
a significantly higher incidence of chest wall rigidity, most likely also attributable to the 
faster infusion rate of 30 s. In retrospect, the chosen duration of infusion was too fast 
in our study. We used an infusion rate of 30 s to flush the small volume of remifentanil 
because this is the standard way to administer many semi-acute cardiorespiratory drugs 
in our intensive care. The results of the current study underline the danger of such a 
routine way to administer drugs. Based on our results, this is obviously not appropriate 
and represents important knowledge for other clinicians and researchers who intend to 
use remifentanil in preterm neonates. 
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Our study has several limitations, including the small number of patients, no control 
group treated with another sedative such as propofol, no blinding of doses and no 
pharmacokinetic analyses of remifentanil. However, our results are an important 
illustration of daily neonatal care. The combination of opioids with a hypnotic or sedative 
agent might be more appropriate than the use of a single agent. A slower infusion of 
remifentanil combined with a low dose of propofol might by an interesting combination 
to investigate in future studies. 
CONCLUSIONS
We conclude that remifentanil boluses administered in 30 s carry an unacceptably high 
risk of chest wall rigidity in preterm neonates. Lower doses also provide insufficient 
sedation. 
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ABSTRACT
Background: Although sedative premedication for endotracheal intubation is 
considered standard of care, less invasive surfactant administration (LISA) is often 
performed without sedative premedication. The aim of this study was to assess success 
rates, technical quality and vital parameters in LISA without sedative premedication. 
Methods: Prospective observational study in 86 neonates <32 weeks’ gestation. 
LISA was performed according to a standardized protocol without use of sedative 
premedication. Outcome measures were success rates of LISA attempts, reasons 
for failure and quality of technical conditions. In 37 neonates, heart rate and oxygen 
saturation levels form 20 min before until 30 min after start of LISA were collected. 
Results: In 48% of LISAs the first attempt failed and in 41% quality of technical conditions 
was inadequate. The success rate was significantly correlated with quality of technical 
conditions and experience of the performer. Desaturations <80% occurred in 54% of 
patients while bradycardia <80/min did not occur. 
Conclusion: This study shows a relatively low success rate of the first attempt of LISA, 
frequent inadequacy of technical quality and frequent oxygen desaturations. These 
effects may be improved by the use of sedative premedication. 
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INTRODUCTION
Respiratory distress syndrome (RDS) is one of the major causes of neonatal respiratory 
morbidity and mortality.1 Although the early use of nasal continuous positive airway 
pressure (CPAP) significantly reduced the need for surfactant replacement therapy in RDS, 
still over half of all preterm neonates with RDS require surfactant.2 Historically, surfactant 
was administered via an endotracheal tube during a period of mechanical ventilation. 
As mechanical ventilation may cause ventilator-induced lung injury and increases the 
risk of bronchopulmonary dysplasia (BPD),3 the technique of less invasive surfactant 
administration (LISA) was developed. In this technique, surfactant is administered via a thin 
catheter in spontaneously breathing infants on nasal CPAP.4 A systematic review including 
six randomized controlled trials with a total of 895 patients showed a significantly reduced 
incidence of BPD and death and a lesser need of mechanical ventilation in infants treated 
with LISA compared to infants treated with surfactant via an endotracheal tube during 
mechanical ventilation.5 
From endotracheal intubation studies in neonates it is long known that awake laryngoscopy 
is distressing and painful, and is frequently complicated by a series of serious adverse 
physiological events.6-16 Also, awake intubation increases the time and the number of 
attempts necessary for successful intubation and increases the risk of traumatic injury to 
the airway.12,13,17 Therefore, in a consensus statement on the prevention and management 
of pain in the newborn in 2001 and again by the American Academy of Pediatrics in 2010, 
it was stated that nonemergency intubation should always be performed with the use 
of premedication.18,19 There is no consensus about the optimal premedication strategy.19
Similar to endotracheal intubation, LISA involves the use of a laryngoscope to place 
the thin catheter through the vocal cords. However, most of the published randomized 
controlled trials did not use any premedication before LISA.5,20,21 Also, in studies 
investigating LISA practices in different countries, apart from the Nordic countries, LISA 
is often performed in awake patients.22-24 Only in the last 3 years, reports started to appear 
in the literature using different kinds of premedication prior to LISA.25-28 The performance 
of LISA in awake patients might be considered a relapse in neonatal medicine.20
We performed this observational cohort study to assess the success rate and quality 
of the technical conditions, and the vital parameter response in preterm newborns 
undergoing a LISA procedure without sedative premedication. 
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METHODS
Study design and patients
We conducted a prospective monocentric observational study on the level III neonatal 
intensive care unit (NICU) at Máxima Medical Center Veldhoven, the Netherlands, 
between January 2016 and February 2018. Patients <32 weeks’ gestation were included 
in the study if they had RDS and were treated with LISA. We only included every first 
LISA procedure per patient. LISA for treatment of RDS was implemented into daily 
practice in our department in 2014 and is since then standard of care. LISA is performed 
in infants with a gestational age (GA) less than 32 weeks with clinical signs of RDS, 
respiratory support with nasal CPAP with a positive end-expiratory pressure of at least 
6 cm H2O, and an oxygen requirement of 30% or more to maintain SpO2 levels between 
88 and 95%. 
Description of the LISA procedure
LISA procedures were performed according to a local standardized protocol. Prior to 
LISA, patients received a loading dose of caffeine to support the respiratory drive. A 
dose of atropine 10 μg/kg was administered 5 to 10 min before start of the procedure 
to prevent reflex bradycardia during laryngoscopy and catheter placement. About 1 to 2 
minutes before start of the procedure, sucrose 20% (0.1 ml/kg) was administered in the 
cheek pouch and facilitated tucking was applied. During the procedure, swaddling was 
performed to contain the infant and promote comfort. Sedative premedication was not 
used. A laryngoscope was then used for visualization of the vocal cords and placement 
of the catheter. At the start of the study we used a 5F umbilical catheter which was 
placed between the vocal cords with the use of a Magyll forceps. During the study we 
started to use a shorter and stiffer LISA catheter (Chiesi Pharmaceuticals, Parma, Italy), 
for which the use of a Magyll forceps was no longer needed. After placement of either 
catheter, surfactant (Curosurf, 150–200 mg/kg) was instilled over a period of 1–3 min while 
the patient was spontaneously breathing on nasal CPAP. During surfactant instillation, 
aspiration was done via the nasogastric tube to check for surfactant spill. After surfactant 
instillation was complete, the catheter was immediately removed. 
Data collection
We collected the following patient characteristics: gestational age, birth weight, postnatal 
age at the LISA procedure and gender. Data regarding starting time of the LISA procedure, 
the quality of technical conditions using a standardized scale, the number of attempts, 
reasons for failed attempts, and function of the operator of the procedure were collected 
during and immediately after the procedure on a standardized registration form. 
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In accordance with the NEAR4KIDS registry definitions of intubation encounters 
and attempts,29 we defined a LISA procedure as one complete procedure of airway 
management intervention including the administration of surfactant. An attempt was 
defined as one episode of laryngoscopy, beginning with the insertion of the laryngoscope 
into the patient’s mouth and ending when the laryngoscope was removed. A successful 
attempt was defined as an episode of laryngoscopy in which the complete amount of 
surfactant could be administered. An attempt failed if not the complete dose of surfactant 
could be administered and another laryngoscopy episode was needed to complete 
surfactant administration. Quality of technical conditions was assessed by the operator of 
the procedure with the Viby-Mogensen intubation score.30 One missing item was allowed, 
if more than one item of the intubation score was missing, quality of technical conditions 
could not be judged. Good technical quality was defined as a score on each item ≤2. A 
score on one or more items ≥3 implied inadequate technical quality. 
Vital parameters
In all infants admitted to the NICU vital parameters are continuously monitored using 
Intellivue MXI 800 patient monitors (Philips, Hamburg, Germany). All data are saved to a 
data warehouse system with a sampling rate of 1 Hz. For the purpose of this study, data 
were extracted from 20 min before until 30 min after start of the LISA procedure. Data 
were averaged per minute. Baseline heart rate and oxygen saturation were calculated 
as median heart rate and oxygen saturation in the period from 20 min to 10 min before 
start of the LISA procedure. The period from 10 min before to start of the LISA procedure 
was discarded as in this period atropine was administered and nursing handling was 
needed to install the patient properly for the LISA procedure. Changes in heart rate 
and oxygen saturation in the 30 min after the start of LISA in relation to baseline were 
calculated. Besides this, changes in heart rate and oxygen saturation after the start of 
LISA compared with baseline were calculated for patients with good versus patients with 
inadequate technical quality, and for patients with success versus patients with failure 
of the first attempt. 
Statistical analysis
SPSS (IBM SPSS Statistics for Windows, version 22.0, Armonk, NY, USA) was used to analyze 
the data. Relevant patient data were reported as numbers with percentages for qualitative 
variables and median and interquartile ranges for quantitative variables. Comparison 
between groups was performed with the Mann–Whitney U test for continuous variables 
and the Pearson Chi square test or Fisher’s exact test, as appropriate, for categorical 
variables. Comparison of vital parameters between baseline and different time points after 
baseline within the same group of patients was performed with a paired t-test. 
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Ethical approval
For this observational study we received a waiver for formal ethical approval (Medical 
Ethical Committee, Máxima Medical Center, Veldhoven, the Netherlands, No. N18.095) 
according to the Dutch Law of Research with Humans. No additional parental consent 
was required. 
RESULTS
Study population
Inclusion of patients is shown in the study flow chart in Figure 1. During the study period 
LISA was performed in 111 patients with a GA <32 weeks. Twenty-five patients were 
excluded because the standardized registration form was not completed and therefore 
data regarding quality of technical conditions and success of LISA attempts were lacking, 
leaving 86 patients to be included. In 29 patients, data on vital parameters were not 
available in data warehouse and in 20 patients these data could not be retrieved because 
the precise starting time of LISA was lacking. Therefore, heart rate and oxygen saturation 
data from 20 min before until 30 min after start of LISA were available in 37 patients. 
Patient characteristics of the study population are shown in Table 1. Patients in whom vital 
parameter data were lacking, had younger gestational and postnatal ages compared to 
patients with available data. 
Table 1. Patient characteristics
Total study 
population
Vital parameter 
analysis
No vital 
parameter 
analysis
p-value
n = 86 n = 37 n = 49
Gestational age (week), 
median (IQR)
28.3 (26.6-29.7) 29.0 (27.1-30.0) 27.9 (25.7-29.1) 0.007
Birth weight (g), median (IQR) 1,015 
(769-1,305)
1,120 
(853-1,320)
995 
(715-1,255)
0.12
Birth weight <10th percentile, 
n (%)
25 (29) 13 (35) 12 (25) 0.34
Postnatal age (hr), median (IQR) 3.3 (2.1-8.5) 5.4 (2.5-13.2) 2.7 (1.9-5.9)a 0.01
Male gender, n (%) 49 (57) 23 (62) 26 (53) 0.51
aMissing data in 7 patients.
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Total number of patients with GA <32 weeks 
treated with LISA (n = 111) 
Missing data regarding success and 
technical quality of LISA (n = 25) 
Total number of LISA procedures available for 
analysis of success and technical quality (n = 86) 
Data on vital parameters not stored in data 
warehouse (n = 29) 
Vital parameters not retrievable because 
missing exact starting time of LISA (n = 20) 
Total number of LISA procedures available for vital 
parameter analysis (n = 37) 
Figure 1. Study flow chart
Success of LISA attempts
The LISA procedure was successful at the first attempt in only 45 patients (52%). In 32 
patients (37%) 2 attempts were required and in 9 patients (11%) 3 attempts were needed. 
Reported reasons for failure of first attempts were: inability to visualize the vocal cords 
in 11 (27%), interruption of the procedure because of significant surfactant spill in 4 (10%), 
dislocation of the catheter during surfactant administration in 4 (10%), inability to introduce 
the catheter between the vocal cords in 5 (12%), worsening condition of the patient in 5 
(12%), patient resistance in 1 (2%), and other reasons in 4 attempts (10%). In 7 attempts (17%) 
the reason for failure was not reported. The first attempt was performed by a pediatric 
resident in 7 procedures (8%), a neonatal nurse specialist in 22 procedures (26%), a 
fellow in neonatology in 10 procedures (12%) and a neonatologist in 46 procedures (53%). 
Pediatric residents were successful in only 2 attempts (29%), neonatal nurse specialists 
were successful in 7 attempts (32%), fellows in neonatology were successful in 3 attempts 
(30%) and neonatologists were successful in 33 attempts (72%) (p = 0.003).
Table 2a shows patient characteristics and experience of the performer in successful and 
failed first attempts. These results show there are no statistically significant differences in 
patient characteristics between LISA procedures in which the first attempt was successful 
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compared to LISA procedures in which the first attempt failed. However, in procedures in 
which the first attempt was successful, the performer of the procedure was significantly 
more often a neonatologist than in procedures in which the first attempt failed (73% 
versus 33%, p <0.001). 
Table 2a. Patient characteristics and performer experience in relation to success rate
Success
n = 45
Failure
n = 41
p-value
Patient characteristics
Gestational age (week), median (IQR) 28.3 (26.7-29.4) 28.4 (25.9-29.9) 0.92
Birth weight (g), median (IQR) 1,030 (763-1,300) 1,000 (750-1,328) 0.94
Birth weight < 10th percentile, n (%) 13 (29) 12 (29) 1.00
Postnatal age (h), median (IQR) 3.3 (2.1-11.6) 3.3 (2.1-7.3) 0.58
Male gender, n (%) 25 (56) 24 (59) 0.83
Procedure characteristics
First attempt by neonatologist, n (%) 33 (73) 13 (33)a <0.001
Good technical quality, n (%) 34 (76) 11 (35)b 0.001
aFor one procedure the performer was not reported; bFor ten procedures quality of technical 
conditions was missing.
Technical quality assessment
Information about the quality of technical conditions was available for 76 LISA procedures 
(88%). Quality was good in 45 procedures (59%) and inadequate in 31 procedures (41%). 
Table 2b shows the patient characteristics and experience of the performer in procedures 
with good and with inadequate quality assessment. There were no statistically significant 
differences in patient characteristics or in the level of experience of the performer between 
procedures with good and with inadequate technical quality. Quality assessment was, 
however, related to the success of the first attempt. Of the 45 procedures in which the 
first attempt was successful, technical quality was good in 34 procedures (76%), whereas 
of the 31 procedures in which the first attempt failed, only 11 procedures (35%) had good 
technical quality (p = 0.001).
Vital parameters
Figure 2 shows heart rate and oxygen saturation at baseline and at different time points 
after start of the LISA procedure. Heart rate significantly increased compared to baseline 
at all time points with the exception of t = 1 min. Oxygen saturation did not change 
significantly from baseline at all time points with the exception of t = 1 and t = 2 min, in 
which oxygen saturation was significantly lower compared to baseline. 
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Table 2b. Patient characteristics and performer experience in relation to quality assessment
Good quality 
n = 45
Inadequate quality 
n = 31
p-value
Patient characteristics
Gestational age (week), median (IQR) 28.3 (26.6-29.6) 28.1 (27.0-30.0) 0.70
Birth weight (g), median (IQR) 1,050 (788-1,313) 1,000 (800-1,300) 0.76
Birth weight < 10th percentile, n (%) 12 (27) 12 (39) 0.32
Postnatal age (h), median (IQR) 3.5 (2.5-9.6) 3.2 (2.0-10.7) 0.53
Male gender, n (%) 24 (53) 21 (68) 0.24
Procedure characteristics
First attempt by neonatologist, n (%) 29 (64) 16 (52) 0.34
Success of first attempt, n (%) 34 (76) 11 (35) 0.001
In only two patients (5%) there was a brief period of bradycardia <100/min in the first 10 
min after start of the LISA procedure. In both patients, heart rate restored within 1 min 
and never dropped below 80/min. Desaturations were more frequent: in 20 patients 
(54%) oxygen saturation dropped below 80% on one or more occasions in the first 10 
min after start of LISA. 
Figure 3 shows heart rate and oxygen saturation in relation to the success rate of the first 
attempt and technical quality of each LISA procedure. Heart rate and oxygen saturation 
did not differ significantly between patients with success versus failure of the first attempt 
and between good versus inadequate technical quality. There was, however, a significant 
difference in the time until the deepest drop in oxygen saturation between patients with 
good versus inadequate technical quality. In patients with good technical quality the 
lowest oxygen saturation occurred after a median of 2 min after start of LISA versus a 
median of 5.5 min for patients in whom the technical quality was inadequate (p = 0.018). In 
patients in whom the first attempt was successful, the deepest drop in oxygen saturation 
occurred at a median of 4 min, and in patients in whom the first attempt failed the deepest 
drop in oxygen saturation occurred at median of 2 min. This difference, however, is not 
statistically significant (p = 0.136). 
Oxygen desaturations below 80% occurred in 13/19 patients (68%) with good quality 
conditions and in 7/15 patients (47%) with inacceptable quality (p = 0.30). In procedures 
with a successful first attempt (n = 19), desaturations below 80% occurred in 13 patients 
(68%), while in procedures in which the first attempt failed (n = 18) these desaturations 
occurred in 7 patients (39%). This difference was also not statistically significant (p = 0.10). 
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Figure 2. Heart rate and oxygen saturation at baseline and after start LISA
Dark grey bars indicate significant differences (p <0.05) compared to baseline. 
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Figure 3. Heart rate and oxygen saturation in relation to the success rate and quality of intubation
Light grey areas indicate the period from which baseline heart rate and oxygen saturation were 
calculated. 
DISCUSSION
This observational study was performed to assess the quality and effect on vital 
parameters of LISA procedures performed without the use of sedative premedication. 
LISA performed in awake patients had a low success rate of the first attempt, and the 
technical quality was frequently inadequate. Also, there was a significant correlation 
between failure of the first attempt and the quality of technical conditions, suggesting 
patient discomfort and intolerance as a cause for first attempt failure. Besides this, there 
was a high frequency of oxygen desaturations. Combined with the extensive existing 
evidence on the harmful effects of awake laryngoscopy during endotracheal intubation, 
our results emphasize the need for better pain reduction and patient comfort during LISA 
by using sedative premedication. 
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From 2016 onwards several reports have appeared in the literature using premedication 
during LISA. Although different strategies of sedative premedication were used, 
these reports unanimously showed better patient comfort in patients treated with 
premedication.25-27 However, sedative premedication also has adverse effects. In one 
retrospective study and one randomized controlled trial, propofol as premedication for 
LISA has shown to increase the need for non-invasive intermittent positive pressure 
ventilation.25,26 Although the need for endotracheal intubation was not increased in 
patients treated with propofol, the frequency of mechanical ventilation in the first 72 
hours of life was higher compared to those that did not receive premedication.20 Ketamine 
as premedication led to a relatively high need for endotracheal intubation.27 Since LISA 
failure causes a higher median number of days on mechanical ventilation, a higher 
incidence of supplemental oxygen at day 28 and a 20% lower survival without serious 
adverse events,31 it is important to use sedative premedication that has little to no effect 
on the respiratory drive in order to prevent LISA failure. 
Awake laryngoscopy has considerable effects on vital parameters such as oxygen 
saturation and heart rate. In our study population, oxygen desaturations <80% in the first 
10 min from start of LISA occurred in 54% of patients. This percentage is lower compared 
to the studies using premedication prior to LISA.25-28 The high incidence of oxygen 
desaturations in premedicated patients is most probably not due to laryngoscopy, but 
caused by a pronounced suppression in respiratory drive by the sedative premedication. 
Besides this, during LISA oxygen desaturations are not only an effect of laryngoscopy but 
are also caused by the administration of surfactant. The increase in heart rate found in our 
study is at least partly due to the administration of atropine prior to LISA and is therefore 
not a clear indicator of patient stress and discomfort. The administration of atropine did, 
however, prevent patients from developing bradycardia compared to the study of Dekker 
et al. who did not use atropine.26
In endotracheal intubation, and presumably also in LISA, the use of premedication can 
decrease the number of attempts needed for success,12,13,17 and improve the quality of 
technical condtions.32,33 In half of all our LISA procedures more than one laryngoscopy 
episode was needed for completion of the procedure. This success rate was comparable 
to success rates in studies using premedication prior to LISA,26,27 as well as studies 
using propofol as premedication before endotracheal intubation.34,35 Inadequate quality 
assessment was found in 41% of procedures. Technical quality seems considerably better 
when ketamine is used prior to LISA.27 To our opinion, the absence of improved success 
rate after premedication does not mean premedication should not be used. It indicates 
that we have to do better in premedicated LISA procedures and endotracheal intubation 
as well. 
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In summary, comparison of our findings in awake LISA with studies using sedative 
premedication prior to LISA shows that success rates and effects on vital parameters 
are comparable. This should not encourage neonatologists to keep on performing LISA in 
awake patients. There is enough evidence on the harmful effects of awake laryngoscopy 
during endotracheal intubation and there is no reason to believe these effects would be 
different in the context of a LISA procedure. LISA, therefore, should always be performed 
with the use of sedative premedication. This premedication, however, should have the 
least effect on the respiratory drive and should not hamper LISA success. More research 
is obviously needed to determine the best premedication strategy. 
Success of intubation attempts is not only determined by the use of sedative 
premedication. Level of experience of the operator is also an important determinator 
of success.36 In our study, we found a significant correlation between the success of 
LISA and the level of experience of the operator. Of all LISA procedures in which the first 
attempt was successful, it was performed by a neonatologist in 73%, compared with 33% 
of the procedures in which the first attempt failed. For endotracheal intubation it is known 
that the use of premedication improves the success rates of inexperienced operators.37,38 
It is likely that this is also applicable for LISA. Irrespective of the use of premedication, 
operator level of experience and number of attempts needed are important factors 
increasing the odds for endotracheal intubation related adverse events.36,39,40 Although 
there are no studies evaluating the occurrence of LISA related adverse events, it is 
presumable that the incidence of adverse events during LISA is also influenced by these 
factors. The operator for LISA should, therefore, be carefully chosen. 
Lack of data on success and technical quality because of missing registration forms led 
to the exclusion of almost 25% of patients that underwent LISA in our study, which could 
have led to selection bias. The excluded population, however, had comparable baseline 
characteristics compared with the included patients. The included patients are a good 
reflection of the total population of preterm infants undergoing LISA and, therefore, our 
results have good generalizability. 
Our study has several limitations. First limitation is the use of atropine prior to LISA. 
One of the goals of our study was to determine the effects of awake LISA on vital 
parameters. We found a significant increase in heart rate at all time points after start 
of LISA, but this is most probably due to the administration of atropine, rather than a 
reflection of patient stress and discomfort. Nevertheless, we encourage the use of 
atropine prior to LISA, since it prevents the occurrence of bradycardia and its related 
risk for hypoxia. 
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Second limitation is the lack of vital parameter data in 59% of included patients. Patients 
with available data had significantly higher gestational and postnatal ages compared to 
patients in whom vital parameter data were not available. Since we found no influence 
of gestational and postnatal age on the success rate and technical quality, we would not 
expect the effects of awake LISA on vital parameters to be different in younger compared 
to older infants. The availability of vital parameter data in only a small proportion of patients, 
therefore, will most likely not have affected the validity of our findings. Other limitations 
are the lack of blood pressure data, which could have helped make a distinction between 
atropine effect and stress in patients with a significant elevation of heart rate, and the lack 
of objective measurements of pain and discomfort. 
CONCLUSION 
In our study of LISA procedures performed without sedative premedication, the success 
rate of the first attempt was only 52%, the technical quality was frequently inadequate, 
and there was a high incidence of oxygen desaturations. Although providing patient 
comfort should be a key factor in neonatology, the adverse effects of performing LISA 
without premedication should be carefully weighed against the negative effects and risks 
of administering sedative premedication before LISA. Other forms of premedication with 
lesser effect on the respiratory drive need to be investigated. The use of atropine during 
LISA resulted in a very low incidence of bradycardia and should therefore be strongly 
considered, regardless of the use of sedative premedication. 
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ASSESSMENT OF SEDATION LEVEL 
PRIOR TO NEONATAL INTUBATION: 
A SYSTEMATIC REVIEW
ABSTRACT
Background: Adequate premedication before neonatal endotracheal intubation 
reduces pain, stress, and adverse physiological responses, diminishes duration and 
number of attempts at intubation, and prevents traumatic airway injury. Therefore, 
intubation should not be started until an adequate level of sedation is reached. It is 
not clear how this should be measured in the clinical situation. 
Objectives: The aim of this study is to provide a systematic review on the usability 
and validity of scoring systems or other objective parameters to evaluate the level of 
sedation before intubation in neonates. Secondary aims were to describe parameters 
that are used to determine the level of sedation and criteria on which the decision to 
proceed with intubation is based. 
Methods: Literature was searched (January 2017) in the following electronic databases: 
Embase, Medline, Web of Sciences, Cochrane Central Registrar of Controlled Trials, 
Pubmed Publisher, and Google Scolar. 
Results: From 1653 hits, 20 studies were finally included in the systematic review. In 7 
studies, intubation was started after a predefined time period; in 1 study preoxygenation 
was the criterion to start with intubation; and in 12 studies, intubation was started in 
case of adequate sedation and/or relaxation. Only 4 studies described the use of 3 
different objective scoring systems, all in the neonatal intensive care unit, which are 
not validated. 
Conclusion: No validated scoring systems to assess the level of sedation prior 
to intubation in newborns are available in the literature. Three objective sedation 
assessment tools seem promising but need further validation before they can be 
implemented in research and clinical settings. 
73
Sedation assessment for neonatal intubation
5
INTRODUCTION
A significant proportion of preterm and critically ill newborn infants needs endotracheal 
intubation at some point during their admission to the Neonatal Intensive Care Unit 
(NICU) or because of anesthesia. Indications range from respiratory insufficiency in case 
of pulmonary morbidity, sepsis, or necrotizing enterocolitis, and the administration of 
surfactant, to surgical procedures such as bowel surgery, surgical closure of a patent 
ductus arteriosus, laser coagulopathy in case of retinopathy of prematurity, or placement 
of a surgical central venous catheter. Endotracheal intubation is a painful and stressful 
procedure and often is associated with adverse physiological responses such as 
bradycardia, hypoxemia, systemic hypertension, and intracranial hypertension.1-7 The 
use of premedication before intubation reduces the risk of these adverse events, and 
also reduces the duration and number of attempts needed for successful intubation and 
prevents traumatic injury to face, eyes, gums, tongue, and glottic structures.6-11 Neonatal 
intubation should therefore be preceded by sedative premedication. 
The goal of administering premedication is to achieve a proper level of sedation before 
intubation is started or muscle relaxants are administered. Still the question is how this 
level of sedation should be defined and how this should be measured in the clinical 
situation. 
OBJECTIVES
Our primary objective was to provide a systematic review of studies assessing the 
usability and validity of objective scoring systems or parameters to evaluate the level 
of sedation before intubation in newborn infants. Because we presumed that very few 
studies have addressed this issue, our secondary objective was to describe common 
practice, addressing the following two questions: 
1. On what parameter(s) and/or criteria is the decision to proceed with intubation after 
the administration of premedication based? 
2. Which (objective) scores or other parameters are used to determine the level of 
sedation after administration of premedication? 
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MATERIALS AND METHODS
Study design
This systematic review was conducted according to the guidelines of the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).12
Criteria for considering studies for this review
Types of studies
For our primary objective, eligible for inclusion were randomized controlled trials (RCTs), 
quasi-RTCs, controlled clinical trials, and observational studies evaluating the use of 
objective scoring systems or parameters to assess level of sedation. For our secondary 
objectives, also single-case studies, poster presentations, editorials, and reviews were 
eligible for inclusion, provided these extensively reported on the complete procedure 
from administration of premedication to start of the intubation. Availability of full text was 
imperative.
Types of study population
The target population consisted of preterm and term neonates who needed endotracheal 
intubation. 
Types of interventions
For the primary objective, studies evaluating an objective score or parameter to assess the 
level of sedation after administration of premedication were included. For the secondary 
objectives, studies addressing any type of intervention were included. 
Data collection and analysis
Electronic searches
The following electronic databases were searched: Embase, Medline, Web of Science, 
Cochrane Central Registrar of Controlled Trials, Pubmed Publisher, and Google Scholar. 
The search strategies are outlined in Table 1. There were no restrictions on the basis 
of publication date or publication status. The search strategy also had no restriction in 
language. The search was performed on January 27, 2017. 
Selection of studies
Two authors (EdK and NH) independently assessed titles and abstracts of the search 
results. Full copies of all potentially relevant studies were obtained. Both authors made 
a decision on final inclusion after retrieval of full copies independently. Disagreements 
were resolved by consensus; if necessary, a third author was consulted (SS). Only articles 
written in English, Dutch, German, and French were selected. 
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Table 1. Search strategies
Electronic database Search strategy
Embase (intubation/de OR ‘respiratory tract intubation’/exp OR (intubat*):ab,ti) 
AND (newborn/de OR ‘newborn intensive care’/exp OR prematurity/
de OR ‘low birth weight’/exp OR ‘newborn care’/de OR (newborn* OR 
(new* NEXT/1 born*) OR neonat* OR nicu OR nicus OR prematur* OR 
preterm* OR ‘low birth weight’ OR lbw OR vlbw OR elbw):ab,ti) AND 
(premedication/exp OR ‘hypnotic sedative agent’/exp OR ‘sedative 
agent’/exp OR ‘conscious sedation’/de OR ‘deep sedation’/de OR 
‘anesthetic agent’/exp OR ‘muscle relaxation’/de OR ‘muscle relaxant 
agent’/exp OR ‘neuromuscular blocking agent’/exp OR (premedicat* 
OR sedat* OR anesthetic* OR anaesthetic* OR ((musc* OR neuromusc*) 
NEAR/3 (relax* OR block*))):ab,ti) NOT ([animals]/lim NOT [humans]/lim) 
NOT (‘cesarean section’/de OR pregnancy/exp OR ‘pregnant woman’/de 
OR (cesarean* OR caesarean* OR pregnan*):ab,ti)
Medline (intubation/ OR “Intubation, Intratracheal”/ OR (intubat*).ab,ti.) AND (exp 
infant, newborn/ OR “Intensive Care Units, Neonatal”/ OR “Intensive Care, 
Neonatal”/ OR (newborn* OR (new* ADJ born*) OR neonat* OR nicu OR 
nicus OR prematur* OR preterm* OR “low birth weight” OR lbw OR vlbw 
OR elbw).ab,ti.) AND (premedication/ OR exp “Hypnotics and Sedatives”/ 
OR “conscious sedation”/ OR “deep sedation”/ OR exp “anesthetics”/ OR 
“muscle relaxation”/ OR exp “Neuromuscular Agents”/ OR (premedicat* 
OR sedat* OR anesthetic* OR anaesthetic* OR ((musc* OR neuromusc*) 
ADJ3 (relax* OR block*))).ab,ti.) NOT (exp animals/ NOT humans/) NOT 
(“cesarean section”/ OR exp pregnancy/ OR “pregnant women”/ OR 
(cesarean* OR caesarean* OR pregnan*).ab,ti.)
Cochrane ((intubat*):ab,ti) AND ((newborn* OR (new* NEXT/1 born*) OR neonat* OR 
nicu OR nicus OR prematur* OR preterm* OR ‘low birth weight’ OR lbw 
OR vlbw OR elbw):ab,ti) AND ((premedicat* OR sedat* OR anesthetic* OR 
anaesthetic* OR ((musc* OR neuromusc*) NEAR/3 (relax* OR block*))):ab,ti) 
NOT ((cesarean* OR caesarean* OR pregnan*):ab,ti)
Web of Science TS=(((intubat*)) AND ((newborn* OR (new* NEAR/1 born*) OR neonat* OR 
nicu OR nicus OR prematur* OR preterm* OR “low birth weight” OR lbw 
OR vlbw OR elbw)) AND ((premedicat* OR sedat* OR anesthetic* OR 
anaesthetic* OR ((musc* OR neuromusc*) NEAR/2 (relax* OR block*)))) 
NOT ((cesarean* OR caesarean* OR pregnan*)) NOT ((animal* OR rat 
OR rats OR mouse OR mice OR murine) NOT (human* OR child* OR 
patient*)))
Google Scolar Intubation|intubated newborn|newborns|neonates|neonatal|nicu|ni-
cus|premature|preterm|”low birth weight”|lbw|vlbw|elbw premedica-
tion|sedation|anesthetic|anaesthetic|”muscular|neuromuscular relax-
ation|blockers” -cesarean -caesarean -pregnancy -pregnant 
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Data extraction 
Two authors (EdK and NH) extracted details of the included studies independently. The 
following data were extracted: use of premedication, used drugs or combination of drugs, 
scores or parameters determining the decision to proceed with intubation, sedation as 
parameter to proceed with intubation, actions undertaken in case of insufficient sedation. 
Quality appraisal of individual studies 
Because no studies were found reporting on the usability and validity of scoring 
systems or other parameters to assess the level of sedation, and we thus only report on 
common practice as described in the methods sections of the reports, evaluation of the 
methodological quality and the risk of bias was not relevant. 
RESULTS
Study selection
A flowchart of study selection is provided in Figure 1. The initial electronic database 
search yielded 2597 records, which number was reduced to 1652 after duplicates were 
removed. One additional record found in reference lists was added. Thus, the titles and 
abstract of in total 1653 records were screened on relevance to the primary and secondary 
objectives. None of the studies appeared relevant to the primary objective. Regarding 
the secondary objective, full text was obtained from 75 records and 1578 records were 
excluded. Of these 75 records, 5 were excluded because of language restriction (1 record) 
or unavailability (4 records). Of the remaining 70 records, full text was read. The studies’ 
methods sections were screened for information about parameters on which the decision 
to start with intubation was based. Twenty studies provided this information and these 
were included in the final analysis of our secondary objective. 
Study characteristics and results of individual studies
Table 2 shows the characteristics of the 20 included studies. In 12 studies, the decision 
to proceed with intubation after the administration of premedication was based on the 
degree of sedation or relaxation.7,13-23 Nevertheless, no more than 4 of these 12 studies 
used an objective scoring system.13-16 In one other of the 12 studies, disappearance of 
the eyelash reflex was considered an indicator of hypnosis and therefore as the criterion 
to start with intubation.21 In the control group, loss of muscle tone was the criterion to 
start with intubation.21 The methods section did not describe, however, how muscle 
relaxation was rated. In the remaining 7 studies that based the start of the intubation on 
the degree of sedation and/or relaxation, it was not clear if sedation and/or relaxation 
were rated either in an objective or a rather subjective way.7,17-20,22,23 In 8 of the 12 studies, 
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the intubating clinician’s observation of insufficient sedation led to the administration of 
more premedication to achieve an adequate level of sedation and/or relaxation.7,13,14,17-19,21,22 
In the remaining four studies, this was not mentioned at all.15,16,20,23
 
2597 records identified through database searching
Embase n = 1199; Medline n = 799; Web of Science n = 321; 
Cochrane n = 78; Google Scolar n = 200
1653 records screenend for relevance
945 of 2597 records removed because of duplicates
1 record added identified by hand searching
75 full text articles assessed for eligibility
1577 of 1653 records excluded because of non-relevance
20 articles included in the systematic review
55 of 75 full text articles excluded: no relevant outcome 
n = 50; not available n = 4; language restriction n = 1
Figure 1. Flowchart of included and excluded studies
In 7 of all 20 included studies, intubation was started after a certain period of time had 
elapsed after the administration of premedication.5,6,24-28 The methods section of these 
studies neither made clear if level of sedation also played a role, nor if all patients were 
adequately sedated upon start of the intubation procedure. In one study, preoxygenation 
was the leading parameter to start with intubation.29
Only 4 of the 20 studies used an objective scoring system to assess the level of sedation 
before proceeding with intubation. These objective scoring systems are outlined in Table 
3. The first scoring system is a sedation score used in two different reports. Smits et 
al. used this score in their dose-finding study for propofol in newborns and De Kort et 
al. used the score in a study on the use of remifentanil in preterm infants undergoing 
the INSURE procedure.13,14 The score is adopted from the study of Naulaers et al. into 
the effectiveness of methohexital as premedication for elective intubation.15 The level 
of sedation is assessed by the motor response to a firm stimulus by rubbing of the feet 
(1 = spontaneous movement, 2 = moves on slight touch, 3 = moves on stimulus, 4 = no 
movement). In both studies, sedation was presumed to be effective with scores 3 and 4, 
upon which intubation was started. 
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Table 2. Characteristics of included studies
First author, year, country Study design Premedication Parameter for start 
intubation
Start intubation Consequences insufficient 
sedation/relaxation
Smits A, 2016, Belgium Prospective observational Propofol Sedation and 
relaxation
Good sedation and relaxation 
scores
Additional propofol in case of 
unsatisfactory relaxation and 
sedation according to physician
De Kort E, 2016, the 
Netherlands
Prospective observational Remifentanil Sedation Good sedation scores Additional remifentanil until good 
sedation score
Avino D, 2014, Belgium Non-inferiority randomized 
trial
SG: remifentanil
CG: morphine, atropine, 
midazolam
Time SG: after complete remifentanil 
infusion; CG: 3 min after midazolam 
infusion
Baleine J, 2014, France Prospective observational Nasal midazolam Sedation At hypnosis, muscle relaxation or 
apnea
Second dose in case of arousal at 
introduction of tube or excessively 
awake at 5 min
Durrmeyer X, 2014, France Prospective observational Atropine, sufentanil and 
atracurium
Relaxation At onset of paralysis Extra atracurium (up to predefined 
maximum)
Thall PF, 2014, USA Not applicable Not applicable Sedation Good sedation score Not applicable
Simons S, 2013, the 
Netherlands
Prospective observational Propofol Sedation When sedation was scored yes by 
treating physician 
Extra propofol (up to a maximum of 
3 doses)
Penido MG, 2011, Brazil Double blinded randomized 
trial
SG: propofol, remifentanil
CG: propofol, midazolam
Time 2 min after remifentanil infusion
Choong K, 2010, Canada Double-blinded randomized 
controlled trial
SG: remifentanil, atropine, 
placebo
CG: fentanyl, atropine, 
succinylcholine
Time 30 s after last drug administration
Welzing L, 2010 Germany Prospective observational Propofol Time 75 s after propofol administration
Lemyre B, 2009, Canada Prospective observational Atropine, fentanyl, 
succinylcholine (only in GA ≥34 
weeks)
Relaxation Cessation of spontaneous 
movements (succinylcholine group) 
or sufficient relaxation
None mentioned
Van Looy, 2008, USA Prospective observational Midazolam and fentanyl Time 1-2 min after medication 
administration
Another dose of fentanyl in case of 
3 failed attempts
Ghanta S, 2007, Australia Randomized, open-label, 
controlled trial
SG: propofol
CG: morphine, atropine, 
suxamethonium
Hypnosis and 
relaxation
SG: disappearance of eyelash reflex
CG: muscle relaxation
SG: 1 extra dose of propofol
CG: repeating doses of 
suxamethonium
Dempsey E, 2006, Ireland Prospective observational Mivacurium and fentanyl Preoxygenation Saturation > 95%, typically 2 min 
after fentanyl infusion
Milesi C, 2006, France Prospective observational Nitrous oxide Relaxation At suppression of muscle tone 
(cessation of movements and 
hypotonia limbs and jaw)
Roberts K, 2006, USA Randomized controlled trial SG: atropine, fentanyl, 
mivacurium
CG: atropine, fentanyl
SG: relaxation
CG: time
SG: once spontaneous movements 
had ceased
CG: after fentanyl infusion
None mentioned
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CG: muscle relaxation
SG: 1 extra dose of propofol
CG: repeating doses of 
suxamethonium
Dempsey E, 2006, Ireland Prospective observational Mivacurium and fentanyl Preoxygenation Saturation > 95%, typically 2 min 
after fentanyl infusion
Milesi C, 2006, France Prospective observational Nitrous oxide Relaxation At suppression of muscle tone 
(cessation of movements and 
hypotonia limbs and jaw)
Roberts K, 2006, USA Randomized controlled trial SG: atropine, fentanyl, 
mivacurium
CG: atropine, fentanyl
SG: relaxation
CG: time
SG: once spontaneous movements 
had ceased
CG: after fentanyl infusion
None mentioned
80
Chapter 5
Table 2. Characteristics of included studies - continued
First author, year, country Study design Premedication Parameter for start 
intubation
Start intubation Consequences insufficient 
sedation/relaxation
Lemyre B, 2004, Canada Randomized study SG: morphine
CG: placebo
Time 1-2 min after preoxygenation
Oei J, 2002, Australia Randomized controlled non-
blinded trial
SG: morphine, atropine, 
suxamethonium
CG: none
Relaxation At disappearance of muscle 
fasciculations and begin of muscle 
flaccidity
Up to 4 extra doses of 
suxamethonium
Buthada A, 2000, USA Randomized placebo 
controlled non-blinded trial
SG: thiopental
CG: placebo
Time 1 min after infusion
Naulaers G, 1997, Belgium Prospective observational Methohexital Sedation No reaction to heel rubbing None mentioned 
Abbreviations: CG, control group; GA; gestational age; SG, study group.
 
Table 3. Objective scoring systems
Level of sedation Highest sedation  Lowest sedation
Sedation score 4 3 2 1
Motor response to firm 
stimulus
No movements Movement on firm stimulus Movement on slight touch Spontaneous movements
Definition Effective sedation = score 3 or 4 Effective sedation = score 3 or 4
Relaxation score 4 3 2 1
Extremities tone Hypotonic Mildly hypotonic Normal tone Hypertonic
Definition Effective relaxation = score 3 or 4 Effective relaxation = score 3 or 4
Good sedative state -2 -1 0 1 2
Crying/irritability No cry with painful stimuli Moans or cries minimally with 
painful stimuli
No sedation/no pain signs Irritable or crying at intervals, 
consolable
High-pitched or silent 
continuous cry, inconsolable
Behavior state No arousal to any stimuli, no 
spontaneous movement
Arouses minimally to stimuli, 
little spontaneous movement
No sedation/no pain signs Restless, squirming, awakens 
frequently
Arching, kicking, constantly 
awake or arouses minimally/
no movement (not sedated)
Facial expression Mouth is lax, no expression Minimal expression with stimuli No sedation/no pain signs Any pain expression 
intermittent
Any pain expression continual
Extremities tone No grasp reflex, flaccid tone Weak grasp reflex, decreased 
muscle tone
No sedation/no pain signs Intermittent clenched toes, 
fists, finger splay, body is not 
tense
Continual clenched fists, toes, 
finger splay, body is tense
Vital signs No variability with stimuli, 
hypoventilation or apnea
<1% variability from baseline, 
with stimuli
No sedation/no pain signs 10-20% increase from 
baseline, SaO2 76-85% with 
stimulation – quick recovery
20% increase from baseline, 
SaO2 < 75% with stimulation, 
slow recovery
Definition Good sedative state = total score on all 5 items -7 to -3 Good sedative state = total score on all 5 items -7 to -3
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Table 2. Characteristics of included studies - continued
First author, year, country Study design Premedication Parameter for start 
intubation
Start intubation Consequences insufficient 
sedation/relaxation
Lemyre B, 2004, Canada Randomized study SG: morphine
CG: placebo
Time 1-2 min after preoxygenation
Oei J, 2002, Australia Randomized controlled non-
blinded trial
SG: morphine, atropine, 
suxamethonium
CG: none
Relaxation At disappearance of muscle 
fasciculations and begin of muscle 
flaccidity
Up to 4 extra doses of 
suxamethonium
Buthada A, 2000, USA Randomized placebo 
controlled non-blinded trial
SG: thiopental
CG: placebo
Time 1 min after infusion
Naulaers G, 1997, Belgium Prospective observational Methohexital Sedation No reaction to heel rubbing None mentioned 
Abbreviations: CG, control group; GA; gestational age; SG, study group.
 
Table 3. Objective scoring systems
Level of sedation Highest sedation  Lowest sedation
Sedation score 4 3 2 1
Motor response to firm 
stimulus
No movements Movement on firm stimulus Movement on slight touch Spontaneous movements
Definition Effective sedation = score 3 or 4 Effective sedation = score 3 or 4
Relaxation score 4 3 2 1
Extremities tone Hypotonic Mildly hypotonic Normal tone Hypertonic
Definition Effective relaxation = score 3 or 4 Effective relaxation = score 3 or 4
Good sedative state -2 -1 0 1 2
Crying/irritability No cry with painful stimuli Moans or cries minimally with 
painful stimuli
No sedation/no pain signs Irritable or crying at intervals, 
consolable
High-pitched or silent 
continuous cry, inconsolable
Behavior state No arousal to any stimuli, no 
spontaneous movement
Arouses minimally to stimuli, 
little spontaneous movement
No sedation/no pain signs Restless, squirming, awakens 
frequently
Arching, kicking, constantly 
awake or arouses minimally/
no movement (not sedated)
Facial expression Mouth is lax, no expression Minimal expression with stimuli No sedation/no pain signs Any pain expression 
intermittent
Any pain expression continual
Extremities tone No grasp reflex, flaccid tone Weak grasp reflex, decreased 
muscle tone
No sedation/no pain signs Intermittent clenched toes, 
fists, finger splay, body is not 
tense
Continual clenched fists, toes, 
finger splay, body is tense
Vital signs No variability with stimuli, 
hypoventilation or apnea
<1% variability from baseline, 
with stimuli
No sedation/no pain signs 10-20% increase from 
baseline, SaO2 76-85% with 
stimulation – quick recovery
20% increase from baseline, 
SaO2 < 75% with stimulation, 
slow recovery
Definition Good sedative state = total score on all 5 items -7 to -3 Good sedative state = total score on all 5 items -7 to -3
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Another scoring system is the relaxation score also used in the report of Smits et al., 
combining this score with the abovementioned sedation score. After the administration of 
propofol, level of sedation and muscle relaxation were determined. For relaxation, the muscle 
tone of the extremities was assessed (1 = hypertonic, 2 = normal tone, 3 = mildly hypotonic, 4 
= hypotonic). Also, scores 3 and 4 reflect adequate relaxation. Both sedation and relaxation 
were assessed by the intubating neonatologist. Additional propofol was administered if 
sedation and relaxation were found unsatisfactory, until a satisfactory condition was achieved 
with no predefined maximum dose of propofol.13 In the report of De Kort et al., in case of 
ineffective sedation, additional remifentanil was administered up to a predefined maximum, 
with a conversion to propofol in case of persisting inadequate sedation.14
The third score is from Thall et al., in their report describing how to perform dose-
finding studies for premedication in neonatal intubation.16 For this purpose they used 
the Neonatal Pain, Agitation and Sedation Scale (N-PASS) first described by Hummel et 
al.30 The score consists of 5 variables that should all be scored within 5 minutes of the 
first sedative administration: crying/irritability, behavior state, facial expression, extremity 
tone, and vital parameters. Each item is scored on a 5-point scale from -2 to +2, with -2 
corresponding to highest sedation and +2 corresponding to highest infant discomfort. For 
the purpose of endotracheal intubation, Thall et al. considered a score between -7 and 
-3 to reflect a good sedative state.16 
DISCUSSION
This systematic review was performed to provide insight into the availability of validated 
objective scoring systems to assess newborn infants’ level of sedation prior to intubation. 
The literature as per January 27, 2017 does not provide such a validated scoring system. 
The decision to proceed with the intubation procedure after administering premedication 
should be based on the pre-intubation sedation level. However, studies reporting on this 
issue show that level of sedation is not always the key factor to proceed with intubation. In 
several studies, intubation was proceeded when a certain period of time had elapsed after 
the administration of premedication, assuming this amount of time being sufficient for drug 
effect. However, as drug pharmacokinetics and pharmacodynamics can differ considerably 
depending on gestational age and postnatal age, sufficient drug effect may need a different 
period of time in individual patients. Using the same time frame in all neonates may very 
well lead to a proportion of patients not being adequately sedated for the procedure. To 
guide individualized dosing, we strongly recommend basing the start of the intubation on 
the actual level of sedation and administering extra doses if necessary. 
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In the majority of studies included in this review, quality of sedation is indeed the key 
factor to guide intubation. However, this is assessed in very diverse ways, often rather 
subjective or not further specified. Validated scoring systems are lacking, especially prior 
to elective intubation in the operating room. However, the literature describes three 
objective assessment tools used in the NICU: the easy-to-perform sedation score first 
described by Naulaers et al., the also easy-to-perform relaxation score first used by Smits 
et al., and the more extensive scoring system suggested by Thall et al. which is based 
on the N-PASS described by Hummel et al.13,14,16,30
The purpose of validated objective scoring systems is to be able to predict effective 
sedation during the intubation procedure before actually starting the procedure, thereby 
preventing neonates from intubation without effective sedation. Validation of such scoring 
systems can be done by comparing the scoring system with the actual level of sedation 
during the intubation procedure in a larger group of patients. In neonatal intubation 
studies, the actual level of sedation during an intubation procedure is frequently 
assessed with the validated intubation score adopted from Viby-Mogensen et al.31 In this 
intubation score, the items ease of laryngoscopy, position of the vocal cords, coughing, 
jaw relaxation, and movement of the extremities are all judged on a 4-point scale. A score 
of 2 or less on each item reflects effective sedation. 
Although both using the Viby-Mogensen intubation score to qualify level of sedation 
during the intubation procedure, the reports of Smits et al. and De Kort et al. do not 
provide enough information to draw any conclusions about the accurateness of the 
sedation and relaxation scores. In the sedation score, the absence of a motor reaction 
or only a slight motor reaction to a firm stimulus is presumed to indicate the neonate 
will tolerate the insertion of the endotracheal tube into the supraglottic airway. However, 
in this assumption, the used stimulus should be stronger than the act of inserting an 
endotracheal tube. The question rises if the act of inserting an endotracheal tube, mainly 
via the nasal route, requires a stronger stimulus than heel rubbing. For example, by 
anesthesiologists, the much firmer stimulus of pinching the trapezius muscle is frequently 
used before inserting a supraglottic airway. Validation of that stimulus in a clinical study 
has not been reported. In summary, although both sedation and relaxation scores 
seem potentially useful scores in the neonatal population, validation of these scores is 
mandatory before further use. 
The scoring system suggested by Thall et al. concerns a comprehensive and precise 
scoring system, which is likely to adequately reflect the level of sedation. Also, different 
definitions can be used in case of different needs of sedation level according to its 
purpose. However, to the best of our knowledge, clinical trials using this scoring system 
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are lacking. Therefore, any conclusion about its accuracy and usability is not possible and 
validation is needed before future use. Even if validated, the scoring system must prove 
its suitability in daily practice. In neonatal intubation, fast performance of the procedure is 
mandatory, especially when fast acting agents are used. The extensiveness of the score 
could possibly make it time consuming and therefore less suitable. 
Despite the lack of validated objective scoring systems, several reports do have shown that 
premedication before neonatal intubation has become standard practice in the majority 
of neonatal units.10,11,32-38 There is, however, much debate about which premedication 
or premedication regimen is best. Studies evaluating certain premedication strategies 
are mainly focusing on using one dosing strategy for the entire neonatal population. 
However, pharmacodynamics and pharmacokinetics are influenced by factors such 
as gestational age, postnatal age and morbidity. For example, Smits et al. found that 
neonates of different gestational ages needed different doses of propofol for adequate 
sedation.13 Most important in our opinion is that the used premedication achieves effective 
sedation. It should also have a quick recovery to allow for fast extubation, and have no 
significant side effects. The search for the most suitable premedication strategy should 
be directed towards personalized medicine and focus on administering just enough 
premedication to achieve adequate sedation in the individual patient. For this purpose, 
a scoring system that adequately indicates the level of sedation is mandatory. 
The work of field and the techniques used differ between pediatric anesthesiologists and 
neonatologists. For example, they have different drug choices, pursue different levels 
of anesthesia (deep vs superficial) and require different duration of sedation (hours vs 
minutes). However, the goals of administering premedication during induction in the 
operating room and before intubation in the NICU are comparable and in both situations 
the level of sedation should be objectively assessed before continuing the procedure. 
With his in mind, neonatologists and anesthesiologists can possibly share valuable 
knowledge in this area of the field. With the availability of a validated scoring system that 
can make a distinction between different levels of sedation, it should then be possible 
to use a single scoring system for both settings. 
Limitation of this review is that we used the description of the intubation procedure 
in the methods section to answer the questions of our secondary objective. Because 
describing the entire procedure from administration of premedication to intubation was 
not the primary goal of the included studies, it is possible that these descriptions were 
not complete and that more scoring systems or other parameters were used in practice. 
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CONCLUSION
Validated scoring systems to assess the level of sedation prior to intubation in newborns 
are not available in the literature. Three objective sedation assessment tools seem 
promising but need further validation before they can be implemented into research 
and clinical settings. Future research is necessary to find a physical stimulus that enables 
clinicians to better anticipate the response to insertion of an endotracheal tube and 
laryngoscopy and to find the best premedication regimen to achieve the preset goals. 
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ABSTRACT
Background: Premedication for neonatal intubation facilitates the procedure and 
reduces stress and physiological disturbances. However, no validated scoring system 
to assess the effect of premedication prior to intubation is available. 
Objective: To evaluate the usefulness of an Intubation Readiness Score (IRS) to assess 
the effect of premedication prior to intubation in newborn infants. 
Methods: Two-center prospective study in neonates who needed endotracheal 
intubation. Intubation was performed using a standardized procedure with propofol 1-2 
mg/kg as premedication. The level of sedation was assessed with the IRS by evaluating 
the motor response to a firm stimulus (1 = spontaneous movement; 2 = movement 
on slight touch; 3 = movement on firm stimulus; 4 = no movement). Intubation was 
proceeded if an adequate effect, defined as an IRS 3 or 4, was reached. IRS was related 
to the quality of intubation measured with the Viby-Mogensen intubation score. 
Results: A total of 115 patients, with a median gestational age of 27.7 weeks (interquartile 
range 5.3) and a median birth weight of 1,005 g (interquartile range 940), were included. 
An adequate IRS was achieved in 105 patients, 89 (85%) of whom also had a good Viby-
Mogensen intubation score and 16 (15%) had an inadequate Viby-Mogensen intubation 
score. The positive predictive value of the IRS was 85%. 
Conclusions: Pre-intubation sedation assessment using the IRS can adequately 
predict optimal conditions during intubation in the majority of neonates. We suggest 
using the IRS in routine clinical care. Additional research combining the IRS with other 
parameters could further improve the predictability of adequate sedation during 
intubation. 
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INTRODUCTION
Endotracheal intubation is a frequently performed distressing procedure in the Neonatal 
Intensive Care Unit (NICU), and potentially complicated by a number of serious adverse 
physiological events.1-7 Adequate sedation by the use of premedication before intubation 
may prevent these adverse events, reduces the duration and number of attempts needed 
for successful intubation, and prevents traumatic injury to the airway.3,6-11 Routine use of 
premedication before (semi-)elective intubation has increased over the past decades.12-18 
The main goal of premedication is to achieve an adequate level of sedation to facilitate 
the intubation procedure. Therefore, intubation should not be started until this level 
of sedation is achieved. However, there is no clear definition about the target level of 
sedation, and the assessment of sedation is often subjective and may vary between 
clinicians. The literature does not provide validated tools to assess the pre-intubation 
level of sedation.19 
In their study to evaluate the effect of methohexital as premedication in neonatal intubation, 
Naulaers et al. described the effect of methohexital on sedation, relaxation, and sleep.20 
The level of sedation was assessed as the motor response to a firm stimulus (heel-
rubbing) and four degrees of reactions were defined: “moves spontaneously,” “moves 
when touched,” “moves when stimulated,” and “no reaction to stimulus.” Relaxation was 
assessed by evaluating muscle tone in arms and legs, using four categories: “hypotonic,” 
“mildly hypotonic,” “normal tone,” and “hypertonic.” The degree of sleep was noted as 
“awake,” “easily woken,” and “deep asleep.” The results of this study show that the level 
of sedation, degree of muscle relaxation, and degree of sleep correlate very well.20 
Therefore, we judged the motor reaction to a firm stimulus to be a very useful and easy-
to-perform score to assess the pre-intubation level of sedation and named this score the 
Intubation Readiness Score (IRS). The aim of our study was to evaluate the suitability of 
this IRS in adequately indicating the pre-intubation sedation level by correlating the IRS to 
the quality of intubation. We hypothesized that the IRS performed after the administration 
of premedication would adequately predict Viby-Mogensen intubation scores during 
intubation. 
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METHODS
Study population 
This prospective two-center study was performed in the level III NICUs of the Erasmus 
MC Sophia Children’s Hospital, Rotterdam and Máxima Medical Center, Veldhoven, 
both in the Netherlands, between June 2015 and January 2017. Patients admitted to 
one of these NICUs were eligible for participation in this study if they needed (semi-)
elective endotracheal intubation. The exclusion criterion was participation in other 
premedication studies at the same time. We used the NEAR4KIDS registry definitions 
regarding intubation encounters and attempts. An encounter is defined as one attempt 
of completed advanced airway management intervention including tracheal intubation. 
An attempt is defined as a single advanced airway maneuver beginning with the insertion 
of the laryngoscope into the patient’s mouth and ending when the device is removed.21 
Because we allowed patients to be included in the analysis only once, we only included 
every first intubation attempt of every first intubation encounter per patient. 
Procedure 
Intubation was performed according to a standardized procedure. Propofol 1.0-2.0 
mg/kg body weight was administered intravenously followed by a saline flush in 30 s. 
Immediately after propofol administration, IRS was assessed every 30 s by firmly rubbing 
the heel of the patients’ foot and grading the motor reaction to this stimulus (Table 1). 
Applying this stimulus and judging the reaction was always done by one of the team 
members performing the intubation procedure. Both scores 3 and 4 were presumed 
to indicate adequate sedation for the intubation procedure. Therefore, when a score of 
3 or 4 was reached, intubation was proceeded. If the IRS was still 1 or 2 after 3 min, an 
additional dose of propofol was administered, and again IRS was assessed every 30 s. 
This procedure was repeated until IRS 3 or 4 was reached. The time frame of 3 min before 
administering a new dose of medication was based on the known fast onset of action 
of propofol. Intubation was performed by pediatric residents, neonatal nurse specialists, 
fellows in neonatology, and neonatologists. 
Table 1. Intubation Readiness Score
Score Motor reaction to firm stimulus
1 Spontaneous movement
2 Movement in reaction to slight touch
3 Movement in reaction to firm stimulus
4 No movement
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Outcome measures 
The primary outcome of this study was the positive predictive value of IRS 3 and 4 in 
predicting good quality of intubation. The quality of the intubation was assessed with 
the standardized intubation score of Viby-Mogensen et al.22 Scoring included rating of 
laryngoscopy, vocal cords, coughing, jaw relaxation, and limb movements. Each item was 
assigned a score of 1 to 4 (Table 2). Good quality of intubation was defined as a score ≤2 on 
each item. A score on one or more items of ≥3 implied inacceptable quality of intubation. 
Table 2. Viby-Mogensen intubation score
Score Laryngoscopy Vocal cords Coughing Jaw relaxation Limb movements
1 Easy Open None Complete None
2 Fair Moving Slight Slight Slight
3 Difficult Closing Moderate Stiff Moderate
4 Impossible Closed Severe Rigid Severe
Adequate intubation conditions were defined as a score ≤2 on each item
Data collection 
Background characteristics as well as all IRS scores, data about all propofol doses, 
intubation conditions, and intubation attempts were collected on standardized intubation 
registration forms. 
Statistical analysis 
SPSS (IBM SPSS Statistics for Windows, version 22.0. Armonk, NY, USA) was used to 
analyze the data. Relevant patient data were reported as numbers with percentages for 
nominal variables and median and interquartile ranges (IQR) for continuous variables. 
Positive predictive values of IRS scores 3 and 4 combined as well as scores 3 and 4 
separately, in predicting good quality of intubation, were determined (criterion validity). 
Univariate analysis was performed with Fisher’s exact tests for categorical variables and 
the Mann-Whitney test for continuous variables. Two-tailed p <0.05 was considered 
statistically significant. 
Ethical approval 
The IRS and Viby-Mogensen intubation score were implemented into daily practice as 
standard of care in both units because they potentially improved patient care. The study 
was judged as a prospective observational cohort study that did not incorporate extra 
risks or burden for the patients. Formal ethical approval to conduct the observational trial, 
according to the Dutch Law of Research with Humans, was not required (Medical Ethics 
Committee, Erasmus Medical Center, Rotterdam, the Netherlands, No. MEC-2017-240).
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RESULTS
Study population 
During the study period, 195 intubation encounters were performed in 164 patients. 
Only every first intubation attempt of every first intubation encounter was included, and 
therefore 164 intubation attempts were eligible for inclusion. Of these, 49 attempts (30%) 
were excluded because data regarding IRS and/or intubation scores were lacking or 
incomplete, leaving 115 intubation attempts eligible for analysis. 
IRS and intubation conditions 
IRS and intubation scores of the 115 patients that were eligible for analysis are shown in 
the flowchart in Figure 1. In 10 patients (9%), intubation was started despite an IRS of 1 or 
2, thereby violating the standardized protocol. These patients were excluded from further 
analysis. IRS 3 or 4 was achieved in 105 patients (91%). Eighty-nine patients with IRS 3 or 
4 had good quality of intubation, leading to a positive predictive value of 85%. IRS was 3 
in 62 patients, of whom 56 patients had good quality of intubation, leading to a positive 
predictive value of 90%. IRS 4 was reached in 43 patients. Of these, 33 patients had good 
quality of intubation, leading to a positive predictive value of 77%. 
 
Eligible patients          
n = 115
IRS 3-4                   
n = 105 (91%)
Sufficient sedation 
during intubation
Good quality of 
intubation                    
n = 89 (85%)
IRS 3                  
n = 56 (63%)
IRS 4                  
n = 33 (37%)
Insufficient sedation 
during intubation
Inadequate quality 
of intubation                    
n = 16 (15%)
IRS 3                  
n = 6 (38%)
IRS 4                  
n = 10 (62%)
IRS 1-2                     
n = 10 (9%)
Exclusion from 
analysis
Figure 1. Flowchart of study patients
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Table 3. Comparison of patient characteristics in patients with good and with inacceptable 
Viby-Mogensen intubation score after adequate IRS
Good Viby-
Mogensen 
intubation 
score 
(n = 89)
Inacceptable 
Viby-Mogensen 
intubation 
score 
(n = 16)
p value
Male gender, n (%) 51 (57) 10 (63) 0.79
Gestational age, weeks 27.7 (6.8) 27.5 (5.2) 0.51
Birth weight, g 995 (810) 1,110 (1,238) 0.71
Postnatal age, days 1 (4) 0.5 (1) 0.07
Weight at intubation, g 1,032 (783) 1,100 (1,238) 0.80
Cumulative dose of propofol, mg/kg 
body weight
2.0 (1.0) 2.0 (1.3) 0.29
Amount of propofol doses, n (%) 2 (1) 1.5 (1) 0.87
IRS 3, n (%) 56 (63) 6 (37.5) 0.10
Time between reaching good IRS and 
starting intubation, min
1 (2) 1 (2) 0.57
Data are median (interquartile ranges) unless otherwise indicated.
We performed a univariate analysis to search for factors that could explain why the 
IRS did not adequately predict the sedation level during intubation in 15% of our study 
population. The results of this analysis are shown in Table 3. This table shows that 
gender, gestational age, birth weight, postnatal age, weight at intubation, cumulative 
dose of propofol, amount of propofol doses, IRS being 3 or 4, and time in minutes 
between reaching good IRS and starting the intubation did not differ significantly 
between patients who had good Viby-Mogensen intubation scores and patients who 
had inacceptable Viby-Mogensen intubation scores. In 55 of the patients with good 
Viby-Mogensen intubation scores and in 6 patients with inacceptable Viby-Mogensen 
intubation scores, the function of the person who performed the intubation was 
registered. In patients with good Viby-Mogensen intubation scores, the intubation 
was performed by a pediatric resident in 13 patients (24%), a nurse specialist in 20 
(36%), a neonatal fellow in 5 (9%), and a neonatologist in 17 patients (31%). In patients 
with inacceptable Viby-Mogensen intubation scores, intubation was performed by a 
pediatric resident in 3 patients (50%), a nurse specialist in 1 (17%), and a neonatologist in 
2 patients (33%). These differences were not statistically significant (p = 0.28). The reason 
for intubation was reported for 87 patients with good Viby-Mogensen intubation scores 
and for 15 patients with inacceptable Viby-Mogensen intubation scores. Respiratory 
distress syndrome was the reason in 39 (45%) and 11 (73%) patients, respectively, and 
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respiratory insufficiency was the reason in 45 (52%) and 4 (27%) patients, respectively. 
Three patients with good Viby-Mogensen intubation scores were intubated for elective 
reasons versus none of the patients with inacceptable Viby-Mogensen intubation 
scores. Differences in reasons for intubation between both groups were not statistically 
significant (p = 0.116). 
DISCUSSION
Premedication should be used for intubation in neonates whenever possible to minimize 
adverse physiological events, to reduce duration and number of attempts, to prevent 
traumatic injury to the airway, and to provide comfort. Accordingly, the intubation 
procedure should only be started when the given premedication has achieved a sufficient 
degree of sedation. However, validated objective scoring systems to assess the readiness 
for intubation are lacking.19 This study aimed to evaluate the suitability of an IRS to assess 
if a newborn is ready for intubation after administration of premedication. We showed 
that this IRS can predict good quality of intubation in 85% of patients. 
In the literature, no previous studies can be found that investigated the readiness for 
intubation. A recent systematic review shows only three potentially suitable scoring systems, 
all of them not validated.19 One of these scores is the sedation score described by Naulaers 
et al. that we used to develop our IRS.20 Another score to assess the level of sedation prior to 
intubation in neonates is the “good sedation state” from Thall et al.23 This score is based on 
the Neonatal Pain, Agitation and Sedation Scale developed by Hummel et al.24 and consists 
of 5 variables: crying/irritability, behavior state, facial expression, extremity tone, and vital 
parameters. Each item is scored on a 5-point scale from –2, corresponding to highest 
sedation, to +2, corresponding to highest infant discomfort. According to Thall et al., good 
sedation for endotracheal intubation is defined as a total score between –7 and –3.23 To the 
best of our knowledge, further evaluation of this score has not been performed. Though 
this score might reflect the degree of sedation very accurately, it is an extensive and time 
consuming score that makes it less suitable to perform in a semi-acute situation. We have 
therefore chosen to further evaluate the sedation score of Naulaers et al.20 
Adequate prediction of the quality of intubation in 85% of patients also means that in 15% 
of patients the IRS did not adequately predict the level of sedation during the intubation 
procedure. This might be explained by the fact that heel rubbing is a weaker stimulus 
than the introduction of the endotracheal tube into the nose or laryngoscopy. In this 
case, a stronger stimulus that better reflects the pain and stress of laryngoscopy and/or 
introducing the endotracheal tube into the nose should be used. However, introducing 
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a stronger, repetitive stimulus, to evaluate the level of sedation, thereby repeatedly 
exposing neonates to painful stimuli, is considered unethical. Another explanation for 
inadequate prediction of the level of sedation by IRS could be the short period of action 
of propofol. This pharmacological characteristic can cause the medication effect to be 
already expired at the moment the intubation is started, despite an IRS of 3 or 4 just 
before. This would mainly be the case in patients in whom a long period of time elapsed 
between reaching IRS 3 or 4 and starting the intubation attempt. However, statistical 
analysis revealed no significant difference in this time between patients with good and 
with inacceptable intubation conditions. We included only patients who received propofol 
as premedication. Future studies that use other sedative drugs are needed to further 
evaluate the IRS, which would increase the generalizability of our findings. 
In our study, IRS 3 and IRS 4 were both hypothesized to predict sufficient sedation for 
the intubation procedure. Therefore, we combined both scores in our evaluation. Taking 
both scores apart, we expected that IRS 4 would better predict sufficient sedation during 
intubation than IRS 3. However, the results of our study show a nonsignificant higher 
positive predictive value of IRS 3 compared to IRS 4 (90% compared to 71%, respectively, 
p = 0.10). This could possibly be explained by the difference in patient numbers in both 
groups (56 vs. 33) or by the hypothesis that in patients with IRS 4 propofol has already 
reached its peak effect and by the time intubation is started, the effect is expired. 
Though we belief that a positive predictive value of 85% makes the IRS certainly suitable 
for clinical practice, we should seek for methods to further improve this positive predictive 
value. It might be valuable to combine the motor reaction to heel rubbing with the 
degree of muscle relaxation. In the original report of Naulaers et al., the level of muscle 
relaxation was also scored on a 4-point scale (1 = hypertonia, 2 = normal muscle tone, 3 
= mild hypotonia, 4 = profound hypotonia).20 Adding this relaxation score to our IRS could 
possibly increase the number of patients in whom effective sedation can adequately be 
predicted before the intubation is started. Using both the sedation and the relaxation 
score was already done by Smits et al. studying propofol dosing in neonates.25 They 
defined sufficient relaxation as mild or profound hypotonia. However, no conclusions 
about the usability of both scores can be drawn from their results. 
In this study, we did not determine interrater variability of the IRS. This is an important 
limitation of this study. Where “spontaneous movements” and “no movement at all” are 
obvious scores and will most certainly not lead to much disagreement between clinicians, 
more disagreement could arise with the items “movement in reaction to touch” and 
“movement in reaction to a firm stimulus.” Besides this, there could be variation in the 
meaning of the term “firm stimulus.” Thus, interrater variability in IRS should be determined. 
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In conclusion, our study shows that by using the IRS, 85% of patients are adequately 
sedated for the procedure. Our protocol also enables the standardization of a highly 
complex procedure in vulnerable patients. We therefore advocate that the IRS should be 
used in every neonate who receives premedication prior to intubation. Further research 
combining the IRS with other parameters such as degree of muscle relaxation could 
increase the predictability of adequate intubation conditions even further. 
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ABSTRACT
Objective: To find propofol doses providing effective sedation without side effects in 
neonates of different gestational ages (GA) and postnatal ages (PNA). 
Design and setting: Prospective multicenter dose-finding study in 3 neonatal intensive 
care units. 
Patients: Neonates with a PNA less than 28 days requiring non-emergency endotracheal 
intubation. 
Interventions: Neonates were stratified into 8 groups based on GA and PNA. The first 
5 neonates in every group received a dose of 1.0 mg/kg propofol. Based on sedative 
effect and side effects, the dose was increased or decreased in the next 5 patients 
until the optimal dose was found. 
Main outcome measures: The primary outcome was the optimal single propofol 
starting dose that provides effective sedation without side effects in each age group. 
Results: After inclusion of 91 patients, the study was prematurely terminated because 
the primary outcome was only reached in 13% of patients. Dose-finding was completed 
in 2 groups, but no optimal propofol dose was found. Effective sedation without side 
effects was achieved more often after a starting dose of 2.0 mg/kg (28%) than after 
1.0 mg/kg (3%) and 1.5 mg/kg (9%). Propofol-induced hypotension occurred in 59% of 
patients. Logistic regression analysis showed that GA and PNA did not predict effective 
sedation or the occurrence of hypotension. 
Conclusions: Effective sedation without side effects is difficult to achieve with propofol 
and the optimal dose in different age groups of neonates could not be determined. 
The sedative effect of propofol and the occurrence of hypotension are unpredictable 
and show large inter-individual variability in the neonatal population. 
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INTRODUCTION
As awake intubation has multiple harmful effects,1–7 the routine use of premedication 
before non-emergency intubation in neonates has become standard of care.8–11 However, 
there is insufficient knowledge and lack of consensus about the most effective and 
safe strategy. Propofol is considered one of the acceptable options, despite being off-
label for use in newborns, gaps in knowledge regarding optimal dosing and concerns 
about safety.12 Because of its rapid onset and recovery, and its ease of use, propofol as 
a sedative for endotracheal intubation has been implemented into clinical practice in 
several neonatal intensive care units (NICUs).13-17 Previous trials have shown conflicting 
results on sedative effect and concerning effects on blood pressure.16-19
Used propofol starting doses range from 1.0 to 2.5 mg/kg, with cumulative doses ranging 
from 1.0 to 6.0 mg/kg for successful intubation.15-19 Although gestational age (GA) and 
postnatal age (PNA) are important determinants of propofol pharmacokinetics,20 fixed 
propofol starting doses are often used for the entire neonatal population regardless of GA 
and PNA. The Exploratory Propofol Dose-Finding Study in Neonates (NEOPROP) is the only 
available dose-finding study in newborns that recently determined the effective propofol 
dose in 50% of patients (EC50) for three different GA groups. This study also showed a great 
decrease in mean arterial blood pressure and a 62% incidence of hypotension.21 
It is crucial to find propofol doses that are safe and effective in the entire newborn 
population. Therefore, we performed the NEOPROP-2 trial, which aimed to find age-
specific propofol starting doses that provide effective sedation without side effects in 
neonates. 
METHODS
Study design and setting
A prospective multicenter dose-finding study was conducted at three level III NICUs in the 
Netherlands between July 2014 and January 2018. An interim analysis was planned after 
every 6 months of inclusion, by an independent data and safety monitoring committee. 
The parents of all included patients provided written informed consent.
Participants
Neonates were eligible if they had a PNA <28 days and required non-emergency 
endotracheal intubation. Exclusion criteria were major congenital anomalies or 
neurological disorders, upper airway anomalies, sedative or opioid administration in the 
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preceding 24 hours and previous inclusion in the trial. The use of propofol was left to 
the discretion of the attending physician. If the hemodynamic status was judged to be 
sufficiently stable to use propofol, the patient could be included. Patients were stratified 
into eight different groups by GA and PNA (Figure 1), based on expected variation in effect 
and propofol clearance.
 
Gestational age Postnatal age Group allocation
<26 weeks
<10 days Group 1, n = 18
≥10 days Group 2, n = 8
26 0/7 - 29 6/7 weeks
<10 days Group 3, n = 25
≥10 days Group 4, n = 10
30 0/7 - 36 6/7 weeks
<10 days Group 5, n = 26
≥10 days Group 6, n = 1
≥37 weeks
<10 days Group 7, n = 2
≥10 days Group 8, n = 1
Figure 1. Group allocation
Interventions
Intubation procedure
Propofol was used as standard of care for endotracheal intubation in our units. Propofol 
(Fresenius Kabi, Schelle, Belgium) was administered as intravenous bolus followed by a 
saline flush for a total duration of 30 s. After propofol administration, the pre-intubation 
sedation level was assessed every 30 s up to 3 min after the infusion, using the Intubation 
Readiness Score (IRS).22 When the pre-intubation sedation level was adequate, intubation 
was continued. In the case of insufficient sedation after 3 min, additional propofol was 
administered until sufficient sedation was reached. The amount of each additional 
propofol dose was left to the discretion of the attending physician. After intubation, 
the quality of intubation was measured by the Viby-Mogensen intubation score.23 Data 
regarding propofol doses and intubation attempts were reported.
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Dose-finding approach
A sample size of five patients per dose per group was used, based on the large inter-
individual variability in effects of propofol that was found previously.17 The first five patients 
in every group received a starting dose of 1.0 mg/kg propofol. Based on these five 
patients, the dose was increased or decreased with 0.5 mg/kg in the next five patients 
up to a maximum starting dose of 3.5 mg/kg because of expected toxicity. If needed 
for further optimization, a change of 0.25 mg/kg was applicable in the final dose-finding 
stage. Once the optimal propofol dose had been found, it was confirmed in another five 
patients. Dose-finding was completed per group when the optimal propofol dose was 
found, or when the maximum starting dose of 3.5 mg/kg was reached. 
Primary outcome measures
The primary outcome of the study was the optimal single propofol starting dose for 
intubation in neonates with different GAs and PNAs, defined as the single starting dose 
that provided effective sedation without significant side effects. Effective sedation was 
determined with two variables that both needed to be adequate: pre-intubation sedation 
level and quality of intubation. Pre-intubation sedation level was determined with the 
IRS, and adequate pre-intubation sedation level was defined as IRS 3 or 4.22 Quality of 
intubation was determined with the Viby-Mogensen intubation score.23 Good quality of 
intubation was defined as a score of ≤2 on each of the five items. 
Pre-defined side effects included hypotension, myoclonus, chest wall rigidity, persistent 
respiratory and/or circulatory failure, and bronchospasm. Blood pressure was measured 
invasively if an indwelling arterial catheter was present. Data were collected every minute 
from 5 min before until 30 min after the start of propofol administration, every 5 min 
from 30 to 60 min and every hour thereafter up to 24 hours. When no arterial catheter 
was present, blood pressure was measured non-invasively by an appropriately sized 
cuff every 5 min from 5 min before until 60 min after propofol administration and every 
hour thereafter until 24 hours. Propofol-induced hypotension was defined as a mean 
blood pressure (MBP) below postmenstrual age (PMA) detected in the first hour after 
propofol administration. Treatment of hypotension was left to the discretion of the treating 
physician.
For the primary outcome both effective sedation and absence of serious side effects 
needed to be positive. When either sedation was not effective or there were serious side 
effects, the primary outcome was not reached. Since both items needed to be positive, 
in case of one negative item and one missing item, the primary outcome was also not 
reached. 
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Secondary outcome measures
Secondary outcomes were the optimal propofol starting dose in the entire study 
population (regardless of age group), the need for additional doses of propofol and 
side effects in the entire study population and sedative effect and side effects in the 
most frequently used propofol starting doses. Finally, a logistic regression analysis was 
performed to find potential variables predicting the sedative effect and side effects after 
propofol.
Statistical analysis
The predefined sample size depended on which propofol dose was found to be 
adequate in five consecutive patients per group. Data were analyzed using SPSS 
(IBM SPSS Statistics for Windows, version 22.0. Armonk, NY, USA), and R 3.5 (R Core 
Team, Vienna, Austria). Patients were analyzed according to the intention-to-treat 
principle. Baseline characteristics were described by percentages for qualitative 
variables and median (interquartile range [IQR]) for quantitative variables. Comparison 
between dosing groups was performed with the Mann-Whitney U test for continuous 
variables and the Pearson’s Chi square test or the Fisher’s exact test, as appropriate, 
for categorical variables. Logistic regression analysis was performed to identify 
factors influencing the sedative effect and side effects of propofol with primary 
outcome, effective sedation, and hypotension as outcome variables. We analyzed 
the effects of gestational age (weeks), birth weight <10th percentile, male gender, 
postnatal age (hours), and propofol starting dose (mg/kg) on primary outcome and 
effective sedation. Total amount of propofol (mg/kg) was added as a confounder in 
the logistic regression analysis with hypotension as outcome variable. We used the 
Firth’s method to reduce the bias in logistic regression that arises as a consequence 
of the relatively small sample size.24,25 
RESULTS
Study population
The study population consisted of 91 patients (see Table 1). Three patients were included 
despite their PNA exceeding 28 days (two patients in group 2 [39 and 32 days] and one 
patient in group 4 [29 days]). 
Study termination
An interim analysis after inclusion of 91 patients demonstrated a low inclusion rate in 
several groups and a 59% incidence of hypotension. In two age groups a propofol dose 
that provided effective sedation was found but caused hypotension in the majority of 
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patients. Therefore, an optimal dose as predefined in the primary outcome in these 
two groups was not established. The study was prematurely terminated, therefore, in 
consultation with the data safety monitoring committee.
Primary outcome 
Dose-finding was only completed in groups 3 and 5, without finding an optimal propofol 
dose. The results of the dose-finding approach in sequential patients in groups 3 and 
5 are presented in Figure 2. In both groups, starting doses of 1.0 and 1.5 mg/kg almost 
never led to effective sedation. A starting dose of 2.0 mg/kg led to effective sedation 
in many patients, but also led to a high incidence of hypotension, even after confirming 
this dose in another five patients per group. The dose, therefore, was decreased to 
1.75 mg/kg, which did not provide effective sedation in the majority of patients in both 
groups.
Secondary outcomes
In the entire study population, effective sedation without side effects was achieved in 
only 12 patients (13%). Additional propofol was administered to 65 patients (71%) and the 
median cumulative propofol dose for successful intubation was 3.0 mg/kg (range 1.0 to 
6.0 mg/kg, IQR 2.0-3.75). 
Propofol starting doses of 1.0, 1.5 and 2.0 mg/kg were used in further in-depth 
analyses. There were no differences in patient characteristics between the three 
groups, with the exception of PNA (Table 2). This was lower in the 2.0 mg/kg dosing 
group, due to the higher inclusion numbers at younger postnatal ages. A starting 
dose of 2.0 mg/kg much more often led to effective sedation than starting doses of 
1.0 and 1.5 mg/kg. The incidence of hypotension, however, was not different between 
the three starting doses. 
Sufficient MBP data after propofol administration were available for 82 patients (90%). 
Propofol-induced hypotension occurred in 48 patients (59%). Of these, 26 patients 
(54%) were treated with volume resuscitation. Therapy with inotropes was started in 
nine patients (10%) at a median of 298 min after propofol administration (IQR 125-917 
minutes). In seven of these patients, inotropes were started >2 hours after the start of 
propofol administration. In two other patients, inotropes were started within 2 hours and 
the hypotension is probably attributable to propofol. Comparison of MBP data before 
and after propofol was possible in 80 patients (88%). MBP decreased with a median of 
34% (95% CI 36.5 to 29.1%) compared to baseline MBP. The lowest MBP was measured at 
a median of 21 min (95% CI 19.3 to 26.2 min).
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Table 1. Patient characteristics
Characteristic Entire 
population
n = 91
Group 1
n = 18
Group 2
n = 8
Group 3
n = 25
Group 4
n = 10
Group 5
n = 26
Group 6
n = 1
Group 7
n = 2
Group 8
n = 1
Gestational age (wk), median (IQR) 27.7
(25.9-30.6)
25.3
(24.8-25.6)
24.8
(24.4-25.6)
28.0
(26.9-28.9)
26.8
(26.3-27.1)
32.0
(30.4-33.6)
30.7 38.1 37.9
Birth weight (gr), median (IQR) 1,045
(825-1,560)
720
(634-864)
740
(716-791)
1,045
(890-1,223)
938
(886-1,076)
1,678
(1,480-2,129)
1,290 3,845 2,865
Birth weight < 10th percentile, n (%)
23 (25) 5 (28) 0 8 (32) 1 (10) 8 (31) 1 (100) 0 0
Postnatal age (hr), median (IQR) 29
(9-213)
129 
(38-173)
405
(384-681)
10
(6-31)
371
(307-524)
20 (5-26) 432 50 593
Actual weight (gr), median (IQR) 1,100
(830-1,560)
705 
(643-838)
923
(825-1,084)
1,065
(910-1,193)
1,105
(925-1,123)
1,678
(1,460-2,125)
1400 3848 3100
Male gender, n (%) 58 (64) 12 (67) 7 (88) 13 (52) 6 (60) 16 (62) 1 (100) 2 (100) 1 (100)
Reason for intubation, n (%)
IRDS 44 (48.4) 2 (11.1) 0 17 (68) 0 23 (88.5) 0 2 (100) 0
Apnea 19 (20.9) 9 (50) 5 (62.5) 2 (8) 3 (30) 0 0 0 0
Sepsis/NEC 11 (12.1) 5 (27.8) 1 (12.5) 3 (12) 1 (10) 1 (3.8) 0 0 0
Respiratory insufficiency 13 (14.3) 1 (5.6) 2 (25) 3 (12) 4 (40) 2 (7.7) 0 0 1 (100)
Elective* 2 (2.2) 0 0 0 1 (10) 0 1 (100) 0 0
Other 2 (2.2) 1 (5.6) 0 0 1 (10) 0 0 0 0
Propofol starting dose, n (%)
0.5 mg/kg 1 (1) 1 (6) 0 0 0 0 0 0 0
1.0 mg/kg 30 (33) 4 (22) 5 (63) 5 (20) 6 (60) 6 (23) 1 (100) 2 (100) 1 (100)
1.5 mg/kg 23 (25) 5 (28) 3 (37) 5 (20) 4 (40) 6 (23) 0 0 0
1.75 mg/kg 9 (10) 0 0 5 (20) 0 4 (15) 0 0 0
2.0 mg/kg 26 (29) 6 (33) 0 10 (40) 0 10 (38) 0 0 0
2.5 mg/kg 2 (2) 2 (11) 0 0 0 0 0 0 0
*Including prior to surgery or tube exchange. Abbreviations: IRDS, infant respiratory distress 
syndrome; IQR, interquartile range; NEC, necrotizing enterocolitis.
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Table 2. Patient characteristics and outcomes in 3 starting doses 
Dosing groups Dosing groups Comparison between groups (p-values)
1.0 mg/kg 
n = 30
1.5 mg/kg 
n = 23
2.0 mg/kg 
n = 26 1.0 vs 1.5 1.0 vs 2.0 1.5 vs 2.0
Patient characteristics
Gestational age (wk), median (IQR) 27.5 (25.86-30.93) 26.86 (25.57-30.14) 29.07 (26.43-31.71) 0.37 0.66 0.20
Birth weight (gr), median (IQR) 1,075 (784-1,410) 908 (780-1,600) 1,215 (895-1,568) 0.46 0.51 0.19
Postnatal age (hr), median (IQR) 156 (12-397) 37.35 (21-387) 19.58 (8-43) 0.68 0.01 0.04
Male gender, n (%) 22 (73) 12 (52) 18 (69) 0.16 0.77 0.25
Propofol dosing
Extra propofol administered, n (%) 25 (83) 20 (87) 11 (42) 1.0 0.002 0.002
Cumulative propofol dose (mg/kg), median (IQR) 3.0 (1.9-4.0) 3.4 (2.5-4.5) 2.0 (2.0-3.0) 0.06 0.97 0.03
Primary outcome
No. of patients with data available 30 (100)* 23 (100)† 25 (96)‡
Effective sedation without side-effects, n (%) 1 (3) 2 (9) 7 (28) 0.57 0.02 0.15
Sedative effect of propofol
Adequate pre-intubation sedation level, n (%) 7 (23) 7 (30) 24 (92) 0.75 <0.001 <0.001
Quality of intubation
No. of patients with data available 3 (10) 7 (30) 19 (73)
Good quality of intubation 1 (33) 3 (43) 18 (95) 0.18 0.02 0.003
Effective sedation
No. of patients with data available 28 (93) 23 (100) 21 (81)
Effective sedation, n (%) 1 (4) 3 (13) 18 (86) 0.21 <0.001 <0.001
Hypotension
No. of patients with data available 24 (80) 21 (91) 26 (100)
Occurrence of hypotension, n (%) 15 (63) 11 (52) 16 (62) 0.55 1.0 0.57
Volume resuscitation, n (% of hypotensive patients) 7 (47) 4 (36) 12 (75) 0.86 0.18 0.09
*Both patients with missing data on effective sedation had side effects and all six patients with 
missing data on side effects had insufficient sedation. Therefore, a conclusion on the primary 
outcome could be drawn for all 30 patients. †Both patients with missing data on side effects had 
inadequate sedation and, therefore, a conclusion on the primary outcome could be drawn on 
all 23 patients. ‡In four patients with missing data on effective sedation, side effects were present 
and in only one patient both data on effective sedation and side effects were missing. Therefore, 
a conclusion on the primary outcome could be drawn in 25 out of 26 patients.
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Figure 2. Dose-finding in groups 3 and 5
*Missing data on blood pressure, in the dose-finding approach considered to be normal in the 
absence of evidence of hypotension; # Missing data on intubation score, effective sedation only 
judged by pre-intubation sedation level. In group 5, the 1.0 and 1.5 mg/kg dosing subgroups both 
contain 6 instead of 5 patients. This was due to initial uncertainty of the suitability of the data for 
the primary outcome in 1 patient in both subgroups. An extra patient in both groups was included 
to ensure a total of 5 patient with viable data on the primary outcome. After re-evaluation, the data 
of all 6 patients in both subgroups turned out to be suitable. 
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Other side effects occurred in 10 patients (11%), including myoclonus in 8 patients (9%), 
bronchospasm in 1 patient (1%), and vocal cord spasm in 1 patient (1%). A total of 15 patients 
(16%) died at a median of 12 days after inclusion in this trial (range 0-57 days). Twelve 
patients died >72 hours after inclusion in the trial. One patient died from sepsis within 
24 hours, and two patients died from necrotizing enterocolitis between 24 and 48 hours 
after inclusion. None were judged as directly attributable to the propofol administration.
The results of the logistic regression analysis (Table 3) showed that GA and PNA did not 
influence the effectiveness or safety of propofol. 
Table 3. Logistic regression analysis with different outcome variables: primary outcome, 
effective sedation, and hypotension
OR 95% CI p-value
Primary outcome
Gestational age (weeks) 0.94 0.77 - 1.15 0.54
Birth weight < 10th percentile (yes/no) 0.85 0.22 - 3.34 0.82
Male gender (yes/no) 1.72 0.46 - 6.40 0.42
Postnatal age (in hours) 1.00 0.99 - 1.00 0.69
Starting dose of propofol (mg/kg) 4.50 0.92 - 22.11 0.06
Effective sedation
Gestational age (weeks) 1.00 0.80 - 1.23 0.98
Birth weight < 10th percentile (yes/no) 1.07 0.27 - 4.27 0.93
Male gender (yes/no) 2.67 0.76 - 9.36 0.13
Postnatal age (in hours) 1.00 0.99 - 1.00 0.65
Starting dose of propofol (mg/kg) 57.04 7.58 - 429.49 <0.001
Hypotension
Gestational age (weeks) 1.09 0.94 - 1.26 0.26
Birth weight < 10th percentile (yes/no) 1.55 0.52 - 4.25 0.47
Male gender (yes/no) 0.94 0.36 - 2.45 0.90
Postnatal age (in hours) 1.00 0.99 - 1.00 0.45
Starting dose of propofol (mg/kg) 1.09 0.35 - 3.39 0.88
Cumulative dose of propofol (mg/kg) 0.74 0.48 - 1.14 0.18
Corrected by Firth’s method to reduce bias because of relatively small sample size.
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DISCUSSION
This dose-finding trial was designed to find the optimal single propofol dose for non-
emergency endotracheal intubation providing effective sedation without significant side 
effects in neonates of different GAs and PNAs. To the best of our knowledge, this is the 
largest drug dose-finding study performed in the neonatal population. Unfortunately, 
dose finding could only be completed in two of the eight defined age groups without 
determination of the optimal propofol dose. Our results show a dose-dependent 
relationship for propofol to reach effective sedation. However, we also found the sedative 
effect to be unpredictable in the individual patient, and propofol is associated with a high 
incidence of hypotension. Based on these results, propofol might probably be not the 
most suitable premedication prior to endotracheal intubation in all neonates. In contrast 
to our results, Smits et al. were able to calculate specific propofol doses for preterm 
newborns in the first days of life that increased with GA.21 Their suggested propofol 
doses were lower than the doses that resulted in adequate sedation in our study. This 
difference could be explained by different ways of analyses and outcome parameters in 
both studies. We did not calculate the EC50, but showed that 2.0 mg/kg propofol starting 
dose is effective in 86% of patients. 
The available literature shows conflicting results on the sedative effect of propofol. Doses 
of 1.0 and 2.5 mg/kg are found to provide sufficient sedation in some studies,16,18 while 
other studies found insufficient sedation with doses of 1.0, 2.0 and 2.5 mg/kg.17,19 These 
conflicting data underline that the sedative effect of propofol is difficult to predict. The 
indication for intubation could also play a role. For the Intubation-SURfactant-Extubation 
(INSURE) procedure, duration of sedation should be very short.26 Therefore, clinicians 
might accept lower levels of sedation to diminish the risk of insufficient respiratory drive 
after the administration of surfactant and, therefore, the inability to immediately extubate 
the patient. However, regardless of the procedures that follow intubation, the act of 
laryngoscopy is equally stressful and equal levels of sedation should in our opinion be 
pursued. 
GA and PNA are known covariates in propofol pharmacokinetics.20 Therefore, we 
hypothesized that infants of different GAs and PNAs would need different propofol doses. 
Logistic regression analysis did not show a statistically significant effect of GA and PNA 
on the outcomes effective sedation and hypotension. Although unclear, the extended 
inter-individual variability in the effect of propofol seems much more important than GA 
and PNA in predicting the effect. Titrating propofol until the desired effect is achieved 
in the individual patient is probably the only way to ensure effective sedation in every 
patient. This, however, might still lead to a high incidence of hypotension.
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Propofol is known for its pronounced effect on blood pressure in the neonatal population. 
We found a median decrease in MBP of 34%, which is in accordance with other studies.16,17,21 
The incidence of hypotension of 59% was comparable to that reported by Smits et al. 
(64%),21 but much higher than found by Welzing et al. (38%).16 This could be explained 
by the much smaller study sample, the lower dosages, and the different definition of 
hypotension.16 Ghanta et al. did not report hypotension.18 This could be explained by 
the possibility that MBP measurements were not continued long enough to detect 
hypotension, as hypotension appears at a median of 10-20 min after propofol.16,17 Because 
of the pronounced effect that propofol can have on blood pressure, the hemodynamic 
status of the patient should be carefully evaluated before propofol is administered. In case 
of (impeding) hemodynamic compromise, other premedication with less pronounced 
effects on blood pressure should be considered. 
Although blood pressure decrease after propofol is marked and there is a high incidence 
of hypotension, the implications for the short-term and long-term outcome are unclear. 
Blood pressure alone is a poor indicator of cardiovascular status.27 In 95% of patients in the 
dose-finding study by Smits et al., cerebral autoregulation was intact during episodes of 
hypotension.28 In the absence of clinical signs of shock, they labelled these episodes of 
hypotension as permissive.21 Two other small studies on the cerebral effects of propofol in 
the neonatal population also showed no important correlation between blood pressure 
and cerebral oxygenation.29,30 Although these findings are certainly reassuring, there 
is insufficient evidence on the short-term and long-term consequences of propofol-
induced hypotension and blood pressure decrease to draw final conclusions. Until 
this is clarified in further studies, we should in our opinion be careful with designating 
propofol-induced hypotension and blood pressure decrease as permissive. On the other 
hand, the negative effects of propofol must be set against the negative effects of other 
premedication strategies. Almost all opioids, hypnotics and muscle relaxants also carry 
a risk of hypotension, and with fentanyl and remifentanil, there is also a risk of chest wall 
rigidity.12
Our study has several limitations. First, we were unable to perform dose-finding as 
planned because patient inclusion in several groups proved to be very difficult. Reasons 
were insufficient time for achieving parental consent, and the very low incidence of 
endotracheal intubation in the higher gestational age groups. Second, we used a very 
strict definition of hypotension. Even a single measurement of MBP below PMA in the first 
60 min after propofol was marked as hypotension. It is questionable whether this single 
measurement of MBP below PMA has any clinical relevance. Adding a time element 
to the definition may better reflect the patients with clinically relevant hypotension. 
Unfortunately, we were unable to provide synchronized neuro-monitoring data, which 
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could have helped to study the clinical relevance of hypotension on cerebral oxygenation 
and perfusion in greater detail. Third, the treatment of hypotension was left to the 
discretion of the treating physician, which is likely to have caused variability between 
clinicians and between centers.
CONCLUSIONS
The results of this large dose-finding study suggest that in the neonatal population it is 
difficult to achieve effective sedation without the occurrence of significant side effects with 
a single propofol bolus. The effects and side effects of propofol in the neonatal population 
are highly variable and unpredictable. Propofol in the neonatal population should only 
be used after careful consideration in each individual patient and should be titrated 
based on the sedative effect with strict monitoring of blood pressure and hemodynamic 
status. As long as the ideal premedication strategy in the neonatal population has not 
been elucidated, the pros and cons of different strategies including propofol should be 
balanced against each other. A greater effort should be made to move forward from a 
one-strategy-fits-all idea towards personalized neonatal pharmacology.
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ABSTRACT
Aim: To analyze the effects of different propofol starting doses as premedication for 
endotracheal intubation on blood pressure in neonates. 
Methods: Neonates who received propofol starting doses of 1.0 mg/kg (n = 30), 1.5 mg/
kg (n = 23) or 2.0 mg/kg (n = 26) as part of a previously published dose-finding study 
were included in this analysis. Blood pressure in the 3 dosing groups was analyzed in 
the first 60 minutes after start of propofol. 
Results: Blood pressure declined after the start of propofol in all 3 dosing groups 
and was not restored 60 minutes after the start of propofol. The decline in blood 
pressure was highest in the 2.0 mg/kg dosing group. Blood pressure decline was 
mainly dependent on the initial propofol starting dose rather than the cumulative 
propofol dose. 
Conclusion: Propofol causes a dose-dependent profound and prolonged decrease 
in blood pressure. The use of propofol should be carefully considered. When using 
propofol, starting with a low dose and titrating according to sedative effect seems the 
safest strategy. 
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INTRODUCTION
It is known that awake endotracheal intubation in newborns causes multiple harmful 
effects.1-3 Therefore, in 2001 consensus was reached that only in the delivery room and 
in life-threatening situations associated with the unavailability of intravenous access, 
tracheal intubation should be performed without the use of analgesia or sedation.4 Almost 
twenty years later, the most effective and safe premedication strategy in the newborn 
population is still to be determined. Propofol is considered one of the acceptable options5 
and is shown to be very easy in use.6 Therefore, propofol has been implemented into 
clinical practice.7-11
In the past decade, several studies have appeared reporting on the use of propofol for 
neonatal intubation, with somewhat conflicting results about the sedative effect related 
to dose.6,9,10,12,13 Results regarding the hypotensive effect of propofol are probably even 
more conflicting, varying from no or only a slight decrease in blood pressure,6,11 to a 
more pronounced decrease in blood pressure and a high incidence of hypotension.9,10,13 
Therefore, questions have been raised about the effectiveness and safety of propofol. In 
our recently performed propofol dose-finding trial (NEOPROP-2) we showed that propofol 
starting doses of 1.0 and 1.5 mg/kg were less effective in providing effective sedation 
compared to a propofol starting dose of 2.0 mg/kg. However, independent of the starting 
dose, propofol carried an unpredictable high risk of hypotension.14
The aim of the current study was to further analyze the effects of different propofol 
starting doses on blood pressure. With this in-depth analysis of the effects of propofol on 
blood pressure we aimed to provide guidelines for the use of propofol in clinical practice. 
METHODS
Participants
Neonates from the previously published NEOPROP-2 trial were considered for inclusion.14 
The NEOPROP-2 trial was a prospective multicenter dose-finding trial conducted at three 
level III Neonatal Intensive Care Units in the Netherlands. Neonates with a postnatal age 
of less than 28 days who needed nonemergency endotracheal intubation were eligible 
for inclusion. Exclusion criteria were major congenital anomalies or neurologic disorders, 
upper airway anomalies, sedative or opioid administration in the preceding 24 hours 
and previous inclusion in the trial. Hemodynamic instability and underlying illnesses 
that are accompanied with a greater risk of hemodynamic instability were no specific 
exclusion criteria. The hemodynamic status and risk of hemodynamic insufficiency were 
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judged by the attending physician. If the attending physician judged the patient to be 
hemodynamically stable enough to receive propofol, the patient could be included in the 
trial. The study was registered at ClinicalTrials.gov (NCT02040909; EudraCT number 2013-
005572-17) and approved by the local medical ethics committee (NL47607.078.14, MEC-
2014-0.68). For further details concerning patient stratification, dose-finding approach 
and the assessment of effective sedation we refer to the initial publication.14 In summary, 
dose-finding was performed by using a step-up-step-down approach, starting with a 
propofol dose of 1.0 mg/kg in five consecutive patients and adjusting the dose with 
steps of 0.5 mg/kg for the next five patients based on sedative effect and side effects of 
the previous dose. For this analysis, all patients from the NEOPROP-2 trial who received 
a propofol starting dose of 1.0, 1.5 and 2.0 mg/kg were included. Patients who received 
a different starting dose were excluded.
Blood pressure assessment
Blood pressure was measured invasively if an indwelling arterial catheter was present. 
Data were collected every minute from 5 minutes before until 30 minutes after the 
start of propofol administration, every 5 minutes from 30 to 60 minutes and every hour 
thereafter up to 24 hours. When no arterial catheter was present, blood pressure was 
measured noninvasively by an appropriately sized cuff every 5 minutes from 5 minutes 
before until 60 minutes after propofol administration and every hour thereafter until 24 
hours. Propofol-induced hypotension was defined as a mean blood pressure (MBP) 
below postmentrual age (PMA) detected in the first hour after propofol administration. 
Treatment of hypotension was left to the discretion of the treating physician. 
Primary outcome measure
The primary outcome measure was the course of blood pressure over time in the first 
hour after start of propofol infusion relative to baseline blood pressure in three different 
initial propofol starting doses (1.0, 1.5 and 2.0 mg/kg). Blood pressure measured within 5 
minutes before start of the propofol infusion was considered as baseline. Blood pressure 
data were obtained every 5 minutes from 5 minutes before to 60 minutes after the start 
of propofol infusion. 
Secondary outcome measures
Since the hemodynamic status of the patient could influence the patients’ tolerability 
for propofol, we evaluated the incidence of hypotension and the change in MBP after 
start of propofol relative to the baseline MBP in relation to the hemodynamic status 
of the patient. For this purpose we included all patients in whom sufficient information 
regarding baseline MBP and MBP in the first hour after propofol was available, and 
divided these patients into three groups: group 1, hemodynamically stable patients (no 
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baseline hypotension and no sepsis/NEC); group 2, patients with baseline hypotension; 
and group 3, patients with a high risk of hemodynamic failure because of sepsis or NEC 
as indication for intubation. To elucidate the influence of cumulative propofol doses on 
blood pressure, we also performed a secondary analysis into the maximum decrease in 
MBP after different cumulative propofol doses. 
Statistical analysis
Data analysis was performed using SPSS (IBM SPSS Statistics for Windows, version 
22.0. Armonk, NY, USA) and Stata (Stata, version 15, StataCorp LLC, TX, USA). Baseline 
characteristics were described by numbers and percentages for qualitative variables 
and median and interquartile range (IQR) for quantitative variables. Comparison between 
groups was performed with the Mann-Whitney U test for continuous variables and the 
Fisher’s exact test for categorical variables. Development of MBP over time-epochs was 
expressed as absolute change compared to baseline. Comparison of MBP development 
between groups was determined using a linear mixed model analysis to take into account 
the dependency of observations within patients. The linear mixed models included time 
(added to the model as a categorical variable represented by dummy variables), dose group 
and the interaction between time and dose group. Besides a crude analysis, also analyses 
adjusted for volume resuscitation and the administration of additional doses of propofol 
were performed. This was done by adding volume resuscitation and the administration of 
additional doses of propofol to the linear mixed models as time-dependent covariates. 
In addition, a linear mixed model analysis was performed with the cumulative dose of 
propofol as independent variable and the repeatedly measured MBP values as outcome. 
RESULTS
Study population
Of the 91 patients in the NEOPROP-2 study, 79 patients received a starting dose of either 
1.0, 1.5 or 2.0 mg/kg of propofol and were included in this analysis. Median gestational 
age was 27.71 weeks (IQR 25.86-30.71), median birth weight was 1,065 grams (IQR 860-
1,560) and the median postnatal age at intubation was 33.53 hours (IQR 8.37-279.53). 
Fifty-two patients (66%) were boys and 18 patients (23%) had a birth weight below the 10th 
percentile. Thirty patients (38%) received a propofol starting dose of 1.0 mg/kg, 23 patients 
(29%) received a propofol starting dose of 1.5 mg/kg and 26 patients (33%) received a 
propofol starting dose of 2.0 mg/kg. Patient characteristics, sedative effect of propofol 
and need for extra propofol doses in these three dosing groups are presented in detail 
in the initial publication.14 A summary of these findings relevant to the purpose of this 
analysis is presented in Table 1. 
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Table 1. Patient characteristics and sedative effect in 3 different propofol starting doses (see 
original report14 for details)
Dosing groups Dosing groups Comparison between groups (p-values)
1.0 mg/kg 
n = 30
1.5 mg/kg 
n = 23
2.0 mg/kg 
n = 26
1.0 vs 1.5 1.0 vs 2.0 1.5 vs 2.0
Gestational age (wk), median (IQR) 27.5
(25.86-30.93)
26.86
(25.57-30.14)
29.07
(26.43-31.71)
0.37 0.66 0.20
Birthweight (g), median (IQR) 1,075 (784-1,410) 908 (780-1,600) 1,215 (895-1,568) 0.46 0.51 0.19
Postnatal age (h), median (IQR) 156 (12-397) 37.35 (21-387) 19.58 (8-43) 0.68 0.01 0.04
Male gender, n (%) 22 (73) 12 (52) 18 (69) 0.16 0.77 0.25
Reason for intubation, n (%) 0.53 0.27 0.35
RDS 12 (40) 8 (34.8) 17 (65.4)
Apnea 6 (20) 8 (34.8) 4 (15.4)
Sepsis/NEC 4 (13.3) 3 (13) 2 (7.7)
Respiratory insufficiency 7 (23.3) 2 (8.7) 2 (7.7)
Elective 1 (3.3) 1 (4.3) 0
Other 0 1 (4.3) 1 (3.8)
Effective sedation, n (%) 1/28 (4) 3/23 (13) 18/24 (86) 0.21 <0.001 <0.001
Extra propofol administered, n (%) 25 (83) 20 (87) 11 (42) 1.0 0.002 0.002
Cumulative propofol dose (mg/kg), median (IQR) 3.0 (1.9-4.0) 3.4 (2.5-4.5) 2.0 (2.0-3.0) 0.06 0.97 0.03
Abbreviations: IQR, interquartile range; NEC, necrotising enterocolitis; RDS, respiratory distress 
syndrome.
Primary outcome measure
Occurrence of hypotension and lowest MBP in three dosing groups
In Table 2 data on MPB before administration of propofol, the definition of hypotension, and 
data on MBP after start of propofol in the three dosing groups are presented. These data 
show that the incidence of hypotension was not significantly different between the three 
groups. In the 2.0 mg/kg group more patients were treated with volume resuscitation 
(75%) compared to the 1.0 mg/kg (47%) and 1.5 mg/kg (36%) groups, but this difference 
did not reach statistical significance. The maximum decrease in MBP as percentage from 
baseline was equal in all three groups. However, this maximum decrease was reached 
significantly earlier in the 1.0 mg/kg group (18.2 minutes) compared to the 2.0 mg/kg 
group (28.6 minutes; p = 0.03). 
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Table 1. Patient characteristics and sedative effect in 3 different propofol starting doses (see 
original report14 for details)
Dosing groups Dosing groups Comparison between groups (p-values)
1.0 mg/kg 
n = 30
1.5 mg/kg 
n = 23
2.0 mg/kg 
n = 26
1.0 vs 1.5 1.0 vs 2.0 1.5 vs 2.0
Gestational age (wk), median (IQR) 27.5
(25.86-30.93)
26.86
(25.57-30.14)
29.07
(26.43-31.71)
0.37 0.66 0.20
Birthweight (g), median (IQR) 1,075 (784-1,410) 908 (780-1,600) 1,215 (895-1,568) 0.46 0.51 0.19
Postnatal age (h), median (IQR) 156 (12-397) 37.35 (21-387) 19.58 (8-43) 0.68 0.01 0.04
Male gender, n (%) 22 (73) 12 (52) 18 (69) 0.16 0.77 0.25
Reason for intubation, n (%) 0.53 0.27 0.35
RDS 12 (40) 8 (34.8) 17 (65.4)
Apnea 6 (20) 8 (34.8) 4 (15.4)
Sepsis/NEC 4 (13.3) 3 (13) 2 (7.7)
Respiratory insufficiency 7 (23.3) 2 (8.7) 2 (7.7)
Elective 1 (3.3) 1 (4.3) 0
Other 0 1 (4.3) 1 (3.8)
Effective sedation, n (%) 1/28 (4) 3/23 (13) 18/24 (86) 0.21 <0.001 <0.001
Extra propofol administered, n (%) 25 (83) 20 (87) 11 (42) 1.0 0.002 0.002
Cumulative propofol dose (mg/kg), median (IQR) 3.0 (1.9-4.0) 3.4 (2.5-4.5) 2.0 (2.0-3.0) 0.06 0.97 0.03
Abbreviations: IQR, interquartile range; NEC, necrotising enterocolitis; RDS, respiratory distress 
syndrome.
Primary outcome measure
Occurrence of hypotension and lowest MBP in three dosing groups
In Table 2 data on MPB before administration of propofol, the definition of hypotension, and 
data on MBP after start of propofol in the three dosing groups are presented. These data 
show that the incidence of hypotension was not significantly different between the three 
groups. In the 2.0 mg/kg group more patients were treated with volume resuscitation 
(75%) compared to the 1.0 mg/kg (47%) and 1.5 mg/kg (36%) groups, but this difference 
did not reach statistical significance. The maximum decrease in MBP as percentage from 
baseline was equal in all three groups. However, this maximum decrease was reached 
significantly earlier in the 1.0 mg/kg group (18.2 minutes) compared to the 2.0 mg/kg 
group (28.6 minutes; p = 0.03). 
Absolute changes in MBP after propofol in the 3 dosing groups
The absolute changes in blood pressure compared to baseline at different time intervals 
after the start of propofol infusion for the three dosing groups are presented in Figure 
1. These data show that MBP declined in all three groups compared to baseline, and 
that this decline was highest in the 2.0 mg/kg dosing group. In the 1.0 mg/kg group 
the decline in MBP from baseline was significant at 20, 25, 35 and 45 minutes after 
start of propofol administration. In the 1.5 mg/kg group the decline from baseline was 
significant at time points 5 up to and including 30 minutes and 55 minutes after start of 
propofol. Finally, in the 2.0 mg/kg group the decline in baseline was significant at all time 
points with the exception of 5 minutes after the start of propofol. Correcting for volume 
resuscitation and the administration of extra doses of propofol did not alter the results 
from the initial analysis (Figure 2). 
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Table 2. Blood pressure data in 3 different dosing groups
Dosing groups Comparison between groups (p-values)
1.0 mg/kg 
n = 30
1.5 mg/kg 
n = 23
2.0 mg/kg
 n = 26
1.0 vs 1.5 1.0 vs 2.0 1.5 vs 2.0
Baseline MBP (mmHg), mean (SD) 40 (11.2) 43 (9.7) 42 (12.3) 0.22 0.73 0.30
Hypotension before propofol, n (%) 4/29 (14) 0/21 3 (12) 0.13 1.0 0.24
Hypotension at any time point after start of propofol, n (%) 15/24 (63) 11/21 (52) 16/26 (62) 0.56 1.0 0.57
Treatment of hypotension with volume resuscitation, n (%) 7/15 (47) 4/11 (36) 12/16 (75) 0.70 0.15 0.06
Lowest MBP (mmHg) after start of propofol, mean (SD) 28 (9.5) 28 (6.9) 27 (5.5) 0.85 0.73 0.88
Time after start of propfol (min) of lowest MBP, mean (SD) 18.2 (12.5) 22.4 (14.3) 28.6 (18.2) 0.24 0.04 0.25
Maximum decrease in MBP as % from baseline, mean (SD) -30 (16.5) -36.4 (14.0) -32.6 (18.7) 0.07 0.15 0.73
Abbreviations: MBP, mean blood pressure; SD, standard deviation.
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b. Diastolic BP
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c. Mean BP
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Figure 1. Changes of systolic, diastolic and mean blood pressure after start of propofol in 3 
dosing groups
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Table 2. Blood pressure data in 3 different dosing groups
Dosing groups Comparison between groups (p-values)
1.0 mg/kg 
n = 30
1.5 mg/kg 
n = 23
2.0 mg/kg
 n = 26
1.0 vs 1.5 1.0 vs 2.0 1.5 vs 2.0
Baseline MBP (mmHg), mean (SD) 40 (11.2) 43 (9.7) 42 (12.3) 0.22 0.73 0.30
Hypotension before propofol, n (%) 4/29 (14) 0/21 3 (12) 0.13 1.0 0.24
Hypotension at any time point after start of propofol, n (%) 15/24 (63) 11/21 (52) 16/26 (62) 0.56 1.0 0.57
Treatment of hypotension with volume resuscitation, n (%) 7/15 (47) 4/11 (36) 12/16 (75) 0.70 0.15 0.06
Lowest MBP (mmHg) after start of propofol, mean (SD) 28 (9.5) 28 (6.9) 27 (5.5) 0.85 0.73 0.88
Time after start of propfol (min) of lowest MBP, mean (SD) 18.2 (12.5) 22.4 (14.3) 28.6 (18.2) 0.24 0.04 0.25
Maximum decrease in MBP as % from baseline, mean (SD) -30 (16.5) -36.4 (14.0) -32.6 (18.7) 0.07 0.15 0.73
Abbreviations: MBP, mean blood pressure; SD, standard deviation.
Figure 1. Changes of systolic, diastolic and mean blood pressure after start of propofol in 3 
dosing groups
Table 3. Analysis of blood pressure in relation to hemodynamic stability 
Group 1
n = 53
Group 2
n = 7
Group 3
n = 9
P -value
Propofol starting dose, n (%)
1.0 mg/kg
1.5 mg/kg
2.0 mg/kg
16 (30.2)
16 (30.2)
21 (39.6)
4 (57.1)
0
3 (42.9)
4 (44.4)
3 (33.3)
2 (22.2)
Baseline MBP (mmHg), mean (SD) 44.5 (10.2) 25.3 (3.1) 42.7 (10.5) <0.001
Absolute difference between baseline MBP and 
MBP indicating hypotension (mmHg), mean (SD)
15.0 (9.8) -4.1 (4.0) 14.9 (9.8) <0.001
Relative difference between baseline MBP and 
MBP indicating hypotension (%), mean (SD)
54 (35.9) -13.6 (12.4) 53 (34.2) <0.001
Hypotension at any time point after propofol 
administration, n (%)
28 (52.8) 7 (100) 6 (66.7) 0.05
Treatment of hypotension with volume 
resuscitation, n (%)
10/28 (36) 3/7 (43) 2/6 (33) 0.28
Lowest MBP (mmHg) after start of propofol, 
mean (SD)
28.5 (7.2) 20.9 (4.3) 27 (7.8) 0.01
Time after start of propofol (min) of lowest MBP, 
mean (SD)
23.5 (16.2) 19.9 (12.5) 24.8 (17.7) 0.88
Maximum decrease in MBP as % from baseline, 
mean (SD)
-34.3 
(16.6)
-16.9 
(16.1)
-35.9 (11.7) 0.05
Group 1 = hemodynamically stable (no baseline hypotension and no sepsis/NEC); group 2 = 
baseline hypotension; group 3 = high risk of hemodynamic failure based on sepsis or NEC as 
underlying morbidity. Abbreviations: MBP, mean blood pressure; NEC, necrotizing enterocolitis; 
SD, standard deviation.
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a. Systolic BP corrected for volume resuscitation
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b. Systolic BP corrected for extra propofol
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c. Diastolic BP corrected for volume resuscitation
0 5 10 15 20 25 30 35 40 45 50 55 60
-15
-10
-5
0
5
10
1.0 mg/ kg 1.5 mg/ kg 2.0 mg/ kg
Time after start propofol (min)
Ch
an
ge
 in
 d
ia
st
ol
ic
 B
P 
 (m
m
H
g)
d. Diastolic BP corrected for extra propofol
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e. Mean BP corrected for volume resuscitation
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f. Mean BP corrected for extra propofol
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Figure 2. Changes in blood pressure after correcting for volume resuscitation and extra propofol 
administration
137
Blood pressure after propofol in neonates
8
Secondary outcome measures
Changes in MBP in relation to hemodynamic status
For this analysis we included 69 patients of whom sufficient data regarding baseline MBP 
and MBP in the first hour after propofol were available. The results of the analysis are 
presented in Table 3. The incidence of hypotension was, as expected, significantly higher 
in group 2, and the lowest MBP after start of propofol was significantly lower in this group. 
The incidence of hypotension, the lowest MBP after start of propofol and the maximum 
decrease in MBP after propofol were equal between group 1 and group 3. 
Changes in MBP in relation to cumulative propofol dose
Independent of the propofol starting doses that were administered, we also analyzed the 
average change in MBP over time for different cumulative doses of propofol, independent 
of the propofol starting dose. The results of this analysis are shown in Table 4. In all 
cumulative doses, MBP significantly declined compared to baseline, with the largest 
declines in the 1.0 and 2.5 mg/kg cumulative doses. These results have to be interpreted 
with some caution because of the small patient numbers, but could indicate that the 
cumulative dose of propofol did not influence the decline in MBP after propofol. 
Table 4. MBP changes in different cumulative propofol doses
Cumulative 
propfol dose
Change in MBP 
relative to baseline
95% Confidence interval p-value
1 mg/kg -8.9 -12.8 -5.0 <0.001
1.5 mg/kg -4.8 -8.8 -0.9 0.02
2 mg/kg -2.8 -5.2 -0.4 0.02
2.5 mg/kg -9.4 -14.7 -4.2 <0.001
3 mg/kg -4.9 -7.6 -2.3 <0.001
≥ 3.5 mg/kg -4.3 -6.7 -1.8 0.001
DISCUSSION
This post-hoc analysis was performed to explore the effects of different propofol 
starting doses as premedication for endotracheal intubation on blood pressure. The 
results of this analysis show that propofol starting doses of 1.0 mg/kg, 1.5 mg/kg 
and 2.0 mg/kg all caused a profound and prolonged decline in blood pressure. In 
all three dosing groups, MBP decreased by a maximum of 30%-35% in comparison 
with the baseline MBP, and MBP was not restored after one hour. The decrease in 
blood pressure was most pronounced with a propofol starting dose of 2.0 mg/kg. 
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The incidence of hypotension was over 50% in all groups. The blood pressure decline 
was mainly dependent on the starting dose that was used, and less influenced by the 
cumulative propofol dose that was administered to achieve successful endotracheal 
intubation. 
To the best of our knowledge, this is the first study to evaluate the effect of different propofol 
doses on blood pressure. Comparison with data from the literature, therefore, is somewhat 
difficult. In our analysis, propofol-induced hypotension was observed in 63%, 52% and 62% 
of the patients receiving a propofol starting dose of 1.0 mg/kg, 1.5 mg/kg and 2.0 mg/
kg, respectively. Previous literature shows somewhat controversial effects of propofol on 
blood pressure in newborns. Smits et al., in their dose-finding study, found an incidence 
of hypotension of 64% in the entire population irrespective of the starting dose that was 
administered.13 Welzing et al. and Simons et al. both reported an incidence of propofol-
induced hypotension of 39%.9,10 In their randomized controlled trial comparing propofol to 
sufentanil and atracurium, Durrmeyer et al. found hypotension to occur in 13.3% of patients 
in the propofol group.12 In contrast to these findings, others reported no hypotension to 
occur in their study population treated with propofol for endotracheal intubation.6,11
Part of these controversial results might be found in different definitions used for 
hypotension in preterm infants. Even in the 21st century, there is no generally accepted 
definition. Without any evidence to support it, the most popular criterion to define 
hypotension is mean blood pressure below gestational age.15,16 The second most used 
definition is a MBP below the 10th or 5th percentile.16 There are numerous reference ranges, 
often based on gestational age, birth weight and postnatal age criteria, with considerable 
variation among these reference ranges.15,17 Finally, MBP below 30 mmHg is used to 
define hypotension, because some studies found loss of cerebral autoregulation below 
this threshold.16,18,19
In our study and in the study of Smits et al. the MBP below gestational age criterion was 
used. Both studies also used this definition for infants beyond the first 72 hours of life 
and therefore somewhat modified the definition to MPB below postmenstrual age.13,14 
Simons et al. also used the MBP below gestational age criterion but only reported on 
hypotension of a severity that required treatment.9 This could explain why they found a 
lower incidence of hypotension of 39%. Should we have only reported on hypotension 
that required treatment, our incidence of hypotension would have been 32%. Welzing et 
al. used a much more liberal definition of MBP less than 25 mmHg in a study population 
with a gestational age of 29 to 32 weeks and 28 to 34 weeks respectively.10 Should they 
have used the MBP below gestational age criterion, the incidence of hypotension would 
have been much higher. 
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Hypotension in the preterm infant has been associated with mortality, cerebral injury 
such as intraventricular hemorrhage and periventricular leukomalacia, and long-term 
neurologic sequelae.16,20-24 The question rises, however, if every infant with low blood 
pressure needs treatment for hypotension. Blood pressure is only one aspect of 
cardiovascular status and may not directly correlate with tissue perfusion. Infants with 
hypotension in the absence of biochemical or clinical signs of shock presumably have 
adequate tissue oxygen delivery, a phenomenon indicated as permissive hypotension.15 
It has been shown that infants with permissive hypotension who did not receive 
treatment for hypotension had similar outcomes as normotensive patients.25 A recent 
French population-based cohort study, however, showed that preterm infants below 
29 weeks’ gestation who were treated for hypotension in the first 72 hours of life had 
significantly higher survival rates without major morbidity and a lower rate of severe 
cerebral abnormalities, compared to infants with hypotension who were untreated.26 
These conflicting results indicate that the importance of hypotension in the preterm 
population is still to be elucidated. 
Despite the statement that the hemodynamic status of the patients needed to be 
sufficiently stable to administer propofol, seven patients were hypotensive before the 
start of propofol. Besides this, nine patients received propofol while being at risk for 
hemodynamic insufficiency based on sepsis or NEC as underlying illness. Inclusion of 
these (possible) hemodynamically instable patients could have influenced the results 
and could have magnified the effect of propofol on blood pressure. Our analysis on 
the influence of hemodynamic status on the effect of propofol on blood pressure, 
however, shows that the effect of propofol on blood pressure is not different between 
patients who are presumed to be hemodynamically stable and patients who are 
presumed to have an increased risk of hemodynamic failure based on sepsis or 
NEC. Although caution with the interpretation of the results is warranted because 
of the small patient numbers, these data suggest that the tolerance for propofol in 
hemodynamically stable patients is not different from hemodynamically compromised 
patients. It should also be kept in mind that these results could also indicate that the 
hemodynamically stable patients in group 1 were not as hemodynamically stable as 
they were presumed to be. 
In our initial analysis we showed that a propofol starting dose of 2.0 mg/kg provided 
effective sedation in 86% of patients, compared to 4% and 13% of the patients receiving 
a starting dose of 1.0 mg/kg or 1.5 mg/kg respectively.14 Solely based on the sedative 
effect of propofol, a starting dose of 2.0 mg/kg of propofol would be the best strategy. 
However, despite an equal incidence of hypotension compared to the 1.0 mg/kg 
starting dose, a dose of 2.0 mg/kg had a much more profound decrease in blood 
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pressure despite a lower cumulative propofol dose compared to the 1.0 mg/kg group. 
Therefore, when using propofol as premedication for endotracheal intubation, the 
safest strategy seems to start with a low dose of 1.0 mg/kg and titrating until effective 
sedation has been reached. 
The above-mentioned advice answers the question which propofol strategy for 
endotracheal intubation in preterm neonates is the safest. The question if this is safe 
enough and if it is justified to continue using propofol as premedication for endotracheal 
intubation in newborns still needs to be answered. The statement on hypotension 
without clinical and biochemical signs of poor perfusion being permissive, concerns 
the spontaneous course of blood pressure of extremely preterm infants in the first 72 
hours.17 Although most of the patients in our analysis were within their first 72 hours 
of life, the occurrence of hypotension was not spontaneous but induced by the 
administration of propofol. Although one third of patients in each of our 3 study groups 
did not fulfill our criteria of hypotension, MBP significantly decreased relative to baseline 
in almost all patients and this decrease was not restored 60 minutes after the start of 
propofol administration. Thewissen et al. showed that cerebral autoregulation stayed 
intact during episodes of hypotension caused by propofol.27 Two other reports also 
could not demonstrate an important correlation between blood pressure and cerebral 
oxygenation in the neonatal population.28,29 Although this finding is somewhat reassuring, 
the possible negative effects on short and long term outcomes of hypotension induced 
by the use of propofol are not known and possibly by far not as permissive as we might 
think. Neonatologists should ask themselves if they would expose the most vulnerable 
(extremely preterm) neonates to this side effect with unknown consequences on the 
short and on the long term. In our opinion the effect of propofol on blood pressure 
is a safety concern and the use of propofol should be carefully considered in every 
individual patient. Studies into the short term and long term effects of propofol-induced 
hypotension and comparison to alternative premedication strategies are warranted if 
propofol is continued to be used for this purpose in this population. 
There are some limitations to our study. At first, not all patients in our study population 
had indwelling arterial catheters and therefore invasively and noninvasively measured 
blood pressure data were combined. Secondly, data of near infrared spectroscopy 
monitoring were missing on a large scale and consequently we have no data on cerebral 
oxygenation during propofol treatment. 
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CONCLUSION
Propofol used as premedication to sedate neonates for endotracheal intubation 
causes a profound and prolonged decrease in MBP which is more pronounced with a 
higher starting dose. It also causes a high incidence of propofol-induced hypotension, 
irrespective of the starting dose that is used. Although premedication for endotracheal 
intubation is essential, propofol might not be the preferred drug. When propofol is used 
in neonates, starting with a low dose and titrating according to sedative effect seems the 
safest strategy with the least pronounced effect on blood pressure.
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CHAPTER 9
GENERAL DISCUSSION AND 
FUTURE PERSPECTIVES
GENERAL DISCUSSION
Endotracheal intubation in neonates is a frequently performed procedure that often 
requires multiple attempts for successful completion,1-8 and is frequently accompanied 
by intubation related adverse events and severe oxygen desaturations.1,6,9,10 This 
makes endotracheal intubation a high-risk procedure. Success and quality of neonatal 
endotracheal intubation can be influenced by several factors, including the physiological 
stability and airway anatomy of the patient, the use of suitable premedication and 
equipment, and the experience and competency of the health care giver.11 Patient 
characteristics, such as the airway anatomy, physiological stability, underlying illness 
and reason for intubation, cannot be changed and can only be anticipated upon. 
Procedure characteristics such as the use of premedication, and the experience of the 
health care givers performing the procedure, however, can and should be influenced 
to pursue optimal success and the best quality of the procedure. In this context, we 
are “ready to tack”. It is time for the available evidence, some of it already existing for 
years, to be implemented into clinical practice and to individualize the premedication 
strategy rather than using a population-based strategy, all to improve patient safety 
and to give optimal care during this high-risk procedure. 
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NEED FOR PREMEDICATION USE
The multiple intubation attempts that are often needed for successful intubation in 
neonates are not without consequences. Exposing neonates to multiple intubation 
attempts is associated with adverse events on the short as well as on the long term. 
Multiple intubation attempts are related to a higher frequency of intubation related 
adverse events and severe oxygen desaturations,12 with each additional intubation 
attempt doubling the odds for these adverse events.1,10 Besides this, multiple intubation 
attempts have been related to the occurrence of intraventricular hemorrhage. Sauer 
et al. showed that in preterm infants with a birth weight less than 750 gram, severe 
intraventricular hemorrhage was almost 28 times more likely to develop in infants 
who were exposed to 3 or more intubation attempts.13 On the long term, multiple 
intubation attempts have been linked to neurodevelopmental impairment in preterm 
infants. Wallenstein et al. showed that the odds for developing neurodevelopmental 
impairment were almost doubled when exposed to multiple intubation attempts 
compared to successful intubation at the first attempt.14 Both studies are limited by 
their retrospective nature, the relatively small sample size and the lack of information 
regarding illness severity of the included patients. Further research to elucidate a 
causal relationship between an increased number of intubation attempts, and 
intraventricular hemorrhage and neurodevelopmental impairment is necessary. The 
results, however, are enough to warrant caution exposing preterm infants to multiple 
intubation attempts. 
The possibility of premedication decreasing the number of attempts needed for successful 
intubation has been known for several decades.15-20 Recent studies have added evidence 
to this. Sawyer et al. demonstrated a relation between the use of sedatives or analgesics 
and paralytic premedication, and the number of intubation attempts.12 Besides this, the 
use of paralytic premedication has been found to be independently associated with 
a decrease in the odds for intubation related adverse events.1,9 This protective effect 
of paralytic premedication could not be confirmed by Hatch et al.10 The frequency of 
paralytic premedication use in their study population, however, could have been too 
low to capture any beneficial effect. Added to the already existing evidence, the results 
of these recent studies again stress the need for appropriate premedication prior to 
endotracheal intubation. The results also suggest that the specific use of paralytic 
premedication could improve patient safety during the procedure. 
The need for using premedication prior to endotracheal intubation is not new. The harmful 
effects of awake intubation and the possibility to reduce or eliminate these harmful effects 
by using premedication are known for decades.15-18,20-24 Also the recommendation to use 
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premedication for nonemergency endotracheal intubations in neonates already exists 
about 20 years. Intubation without premedication should only be performed in the delivery 
room and in emergency situations when there is no intravenous access available.25,26 Studies 
evaluating premedication use by asking clinicians about their premedication practices, 
showed that the routine use of premedication is about 90 to 100%.27-30 Although these 
percentages are reassuring, the results of recent studies evaluating intubation practices 
in the NICU are alarming. The percentages of endotracheal intubations performed without 
premedication vary from 14% to as high as 38%.1,2,9,10 These data might indicate that what 
clinicians say they do, is not always what they actually do in clinical practice. 
Why was there such a high incidence of awake intubation in these studies? This question 
is difficult to answer, since all four abovementioned studies do not provide information 
regarding this issue. Intubations in the delivery room were not included in these studies 
and, therefore, to justify the absence of premedication according to the recommendation 
from 2001, it all should have been emergency intubations with no availability of 
intravenous access. Durrmeyer et al. previously showed that of all patients not receiving 
premedication before intubation, 85% did have an intravenous access at the time of 
intubation.31 This indicates that there might be other reasons that keep neonatologists 
from administering premedication when intubating a neonate. 
Several factors could play a role in a neonatologists’ decision not to administer 
premedication, one of them being a risk for complications. However, serious complications 
after the administration of premedication before endotracheal intubation were not 
demonstrated by several randomized controlled trials.32 In a multicenter observational 
study from France, Simon et al. showed that the rate of complications was not influenced 
by the use of premedication.33 Insufficient evidence about efficacy and safety could be 
another reason for a neonatologist not to administer premedication.34 Not only 20 years 
ago but even in the present time, premedication is less often used in smaller and younger 
neonates.33,35,36 This apparent reluctance of neonatologists to administer premedication 
to extremely low birth weight infants could possibly be attributed to a greater concern 
about the side effects of premedication in these patients, or to the misconception that 
smaller and younger neonates would not need premedication. There is, however, no 
evidence that shows that extremely low birth weight infants have less adverse effects of 
awake intubation and experience less discomfort and pain. Just because these patients 
do not have the strength to struggle and fight the health care giver, does not mean 
they do not need premedication. Ozawa et al. also showed that premedication was 
less often used when surfactant administration and unstable hemodynamics were the 
intubation indications.36 This could indicate concern for suppression of the respiratory 
drive and concerns for the effects of premedication on the patients’ hemodynamic status. 
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Although these concerns are justified, awake intubation in these patients is probably 
not. Instead of not using premedication, the premedication strategy must be aligned 
with the indication for intubation and the underlying condition of the patient. In addition, 
the absence of guidelines for the use of premedication probably also plays a role. The 
presence of a clear local guideline regarding the use of premedication, also including 
types of drugs and dosages, could encourage neonatologists to use premedication. 
Finally, preparation times can be a factor withholding premedication use.37 Studies have 
shown that preparation times can take up to 16 minutes.38,39 This can be resolved by the 
use of pharmacy prepared prefilled syringes. 
READY TO TACK – Towards improvement in the use of premedication
Recommendations for clinical practice
•	 Previous and recent evidence has sufficiently shown the harmful effects of 
awake intubation in neonates. The need for using premedication should no 
longer be questioned. 
•	 There is no good reason to perform endotracheal intubation in awake neonates, 
except when it concerns an emergency situation in which the endotracheal 
tube should be placed without any delay. 
•	 The unavailability of an intravenous access in itself should not be a contra-
indication for the use of premedication. The possibility of stabilizing the patient 
with non-invasive ventilatory support or bag and mask ventilation to create 
time for providing an intravenous access should be considered. 
•	 The harmful effects of awake intubation apply to all neonates, regardless of 
age, underlying illness and clinical condition. Therefore, these factors should 
be taken into account when choosing the most appropriate premedication 
strategy, but should not be an absolute reason to perform awake intubation. 
•	 The use of premedication and the choice for a certain drug or combination 
of drugs should not be left at the discretion of the individual physician. Every 
neonatal unit should have a written guideline for the use of premedication in 
neonatal endotracheal intubation, which must describe specific premedication 
strategies for specific patient conditions. To eliminate preparation times, 
premedication should be readily available, for example in pharmacy prepared 
prefilled syringes. 
152
Chapter 9
Recommendations for future research
•	 To prevent the necessity of an intravenous access to administer premedication, 
future research should focus on the possibility of administering premedication 
via other routes, for example oral, nasal and buccal routes. 
ASSESSMENT OF PREMEDICATION EFFECT
The administration of premedication is not a goal in itself. The aim of administering 
premedication is to provide an adequate level of sedation to provide comfort, minimalize 
pain, stress and physiological disturbances, and facilitate the procedure. Therefore, it 
is not only important to administer premedication but also to evaluate the effect and 
pursue an adequate sedation level before proceeding with the intubation procedure. In 
clinical practice, however, the level of sedation after the administration of premedication 
was often not assessed before intubation was started, or was assessed in a variable 
and subjective way. Objective validated scoring systems to assess the level of sedation 
in the neonatal population were not available. A literature search did, however, reveal 
three objective sedation assessment tools, which are all promising but need validation 
before they can be implemented into clinical practice.40 We, therefore, developed an 
Intubation Readiness Score (IRS) to assess the level of sedation, that was based on the 
sedation score described by Naulaers et al.41 Based on correlation of the IRS with the 
quality of intubation assessed by the intubation score of Viby-Mogensen,42 the IRS was 
shown to accurately indicate the level of sedation during the intubation procedure in 
85% of neonates.43 
The IRS is currently the best available easy to perform tool to evaluate the effect of 
premedication. In 85% of patients the actual level of sedation is well predicted by the 
IRS. In 15% of patients, however, sedation during the intubation was inadequate even 
though the IRS indicated otherwise.43 This stresses the need for further developing and 
expanding the IRS to improve its accurateness. It must, however, be ensured that the 
score does not become too extensive and time consuming for use in the acute situation 
of endotracheal intubation. A possibility would be to expand the IRS with the relaxation 
score, also described by Naulaers et al.41 This score assesses the muscle tone of the 
extremities on a 4-point scale. Incorporating this relaxation score into the IRS, might 
improve its accurateness in assessing the level of sedation. Further studies have to be 
performed to validate this expanded IRS, by comparing the IRS with a gold standard for 
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assessing sedation level. As a gold standard for example the Viby-Mogensen intubation 
score can be used, as we did in our validation of the IRS.42,43 In addition, heel rubbing as 
a tactile stimulus should be reconsidered. For certain patients, this stimulus might not 
be strong enough to reflect the pain and stress of laryngoscopy and introducing the 
endotracheal tube into the nostril. The use of a stronger stimulus, however, might raise 
ethical issues. Finally, the interobserver variability of the IRS has not been previously 
assessed. Since significant interobserver variation in the firmness of heel rubbing as well 
as the interpretation of the motor reaction following heel rubbing is possible, future 
research should address this issue. 
READY TO TACK – Towards pursuing an adequate level of sedation
Recommendations for clinical practice
•	 After the administration of premedication, the level of sedation should be 
closely monitored by using objective scoring methods such as the Intubation 
Readiness Score. 
•	 Intubation should only be performed when an adequate level of sedation 
is reached. Additional medication to achieve adequate sedation should be 
administered whenever needed. 
Recommendations for future research
•	 Possibilities for expanding the Intubation Readiness Score to increase its 
positive predictive value for adequate sedation level should be investigated.
•	 The use of a stronger stimulus better reflecting the pain and discomfort that 
accompany the act of endotracheal intubation should be considered. 
•	 The issue of interobserver variability in applying the firm stimulus and judging 
the motor reaction to that stimulus should be addressed. 
THE USE OF DIFFERENT PREMEDICATION STRATEGIES
The effectivity of a premedication strategy that consists of a vagolytic, an analgesic 
and a muscle relaxant is supported by several studies. The atropine-opioid-muscle 
relaxant combination has been shown to have a higher first attempt success rate and, 
as a consequence, a lower total number of attempts, compared to the combination of 
atropine and an opioid without a muscle relaxant.34,44,45 Roberts et al. also showed that 
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adding a muscle relaxant led to fewer and shorter oxygen desaturations.34 Observational 
studies also showed a relatively high first attempt success rate and a high frequency 
of adequate intubating conditions.46,47 More recent studies have shown that the use 
of paralytic medication in combination with a sedative or analgesic compared to a 
sedative or analgesic alone leads to fewer intubation attempts and a lower incidence 
of intubation related adverse events.1,9,48 The use of an analgesic or sedative without 
a paralytic even led to more severe desaturations.1,48 These results could indicate that 
the use of an analgesic or sedative alone is more harmful than awake intubation. These 
data, however, should be interpreted with caution. Of all patients treated with only an 
analgesic or a sedative in this study population, 35% were treated with morphine.36 
Because of its delayed onset of action, morphine is not a suitable candidate to be 
used as premedication.49 The results do indicate that the use of a muscle relaxant 
besides an analgesic or a sedative improves patient safety during intubation. The use 
of a muscle relaxant can improve intubation conditions but can also be used to prevent 
or treat chest wall rigidity that is a common side effect of analgesics, mainly fentanyl 
and remifentanil. 
Multiple muscle relaxants are available but there is no clear evidence on which muscle 
relaxant is most effective and safe in the neonatal population. Succinylcholine was 
frequently used previously, but has been abandoned because of rare but serious side 
effects such as malignant hyperthermia and acute rhabdomyolysis with hyperkalemia.34,46 
This has led to the use of the non-depolarizing muscle relaxants atracurium, mivacurium 
and rocuronium in the neonatal population,34,44,46,47 but without comparison between 
different muscle relaxants. Important for a muscle relaxant when used as premedication 
for endotracheal intubation is a short duration of action, to allow for quick recovery of 
spontaneous respirations which contribute to tidal volumes and, therefore, lead to lower 
inspiratory peak pressures during volume targeted ventilation. Mivacurium seems a 
suitable candidate, with a short onset of effect and a mean duration of action between 
11 and 16 minutes in the newborn population.34,46 There have been availability issues with 
mivacurium in some countries, for example North America,32 but this does not apply for 
the Netherlands. Rocuronium also has a rapid onset of action but has a longer duration 
of muscle relaxation of up to 1 hour, which is probably to long for this purpose. Feltman 
et al. could not reproduce this relative long duration of action and found a duration of 
paralysis of 16 minutes.44 This could make rocuronium a suitable candidate, but further 
research is needed. Another important factor is that the muscle relaxant should have 
a shorter period of action compared to the analgesic/sedative that is used, to prevent 
patients from being consciously paralyzed. 
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The majority of studies investigating the combination of a vagolytic, an analgesic and a 
muscle relaxant, used fentanyl as the analgesic.34,44-46,50 The choice for fentanyl is based 
on its fast speed of onset and its cardiovascular stability. There are no clear guidelines 
as to the dose of fentanyl that should be used to provide sufficient analgesia for this 
purpose, and the fentanyl dose that was used differed across studies.34,44,46,50 Data on 
the pharmacodynamic effects of fentanyl as premedication for endotracheal intubation 
are not available. It is, therefore, unclear how much fentanyl should be administered 
to eliminate the pain and discomfort that accompany the act of laryngoscopy. More 
research into the effects of fentanyl for this purpose is needed, but when administered 
as part of a premedication strategy also containing a muscle relaxant, this is difficult to 
examine because paralysis has a clear influence on the behavioral responses to pain. 
Chest wall rigidity is one of the most frequent and serious complications of fentanyl. In 
the neonatal population, the risk of chest wall rigidity after fentanyl administration has 
been estimated at 1.4 to 4%.51,52 More recent studies did find comparable incidences.34,45 
Chest wall rigidity can be prevented by slow infusion, and can be treated with the use 
of a muscle relaxant or naloxone,32 the latter obviously also abolishing the analgesic 
effect of fentanyl. Dempsey et al. used a strategy in which the muscle relaxant was 
administered prior to fentanyl to prevent chest wall rigidity, and indeed this side effect 
did not appear in their study population.46 The use of a muscle relaxant prior to an 
analgesic, however, causes the patient to be conscious while being paralyzed and 
raises ethical questions. 
Over the past decade, interest arose into single drug premedication strategies with 
a short duration of action. Based on its rapid onset of action and very short half-life, 
remifentanil seemed a suitable candidate in this perspective. Four studies have used 
different doses of remifentanil as a single drug and found conflicting results both on 
sedative effect and on the occurrence of side effects. A remifentanil dose of 2 μg/kg 
was found to cause adequate sedation in all patients in one study, while two studies 
found doses of 1 μg/kg and 3 μg/kg to cause insufficient sedation in one third of study 
patients.50,53,54 In our observational study we found that both with starting doses of 1 
μg/kg and 2 μg/kg adequate sedation was very difficult to achieve.55 Welzing et al. 
did not observe chest wall rigidity in their patient population and both Avino et al. and 
Choong et al. found low incidences of 6% and 13% respectively.50,53,54 We found a much 
higher incidence of 43%.55 The dramatic results in our study could be attributed to the 
fast infusion rate of 30 seconds, causing a shorter duration of effect and higher peak 
levels with more side effects as a consequence. But even with a more appropriate 
infusion rate of 60 seconds, the results of several of the abovementioned studies raise 
concerns about effectivity as well as safety of remifentanil as premedication in the 
neonatal population. Dose-finding studies are clearly needed to address these issues. 
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Instead of using remifentanil as a single bolus, it could also be administered as careful 
continuous infusion with titration up untill sufficient effects are reached, but this strategy 
also needs further study. 
One of the reasons for single drug premedication strategies could be a reduction in 
preparation times. From this angle, remifentanil might be a less suitable option. Choong 
et al. described a preparation process including two dilution steps.50 In our remifentanil 
study three dilution steps were needed. Although preparation times were not measured, it 
was time consuming. Besides this, such a complicated preparation process with multiple 
dilation steps could increase the risk for preparation errors. The predictability of the final 
concentration in such complicated preparation could also be questioned. We performed 
a simulated preparation and assessed remifentanil concentrations. In 22% of the tested 
solutions the actual concentration was below 90% of the intended concentration and 
in 3% it was above 110%, confirming predictability issues with complicated preparation 
including several dilutional steps. This issue could be overcome by the use of pharmacy 
prepared prefilled syringes. The possibility and costs for using remifentanil in this way 
should be examined. 
Another potential single drug candidate is propofol. In 2007, Ghanta et al. published 
the first randomized controlled trial comparing propofol to the atropine-morphine-
suxamethonium combination. Based on the time to successful intubation being more than 
twice as fast with propofol, the authors concluded that propofol was superior in facilitating 
endotracheal intubation in neonates. Propofol also had the advantage of maintaining 
spontaneous respiration, causing less profound hypoxemia and less procedure related 
trauma.38 It took more than 10 years for the second report comparing propofol with the 
opioid-muscle relaxant combination appeared. Durrmeyer et al. showed that there was 
no difference in the primary outcome of occurrence of prolonged desaturations between 
atropine-propofol and atropine-sufentanil-atracurium.56
Although based on the primary outcomes of these two randomized controlled trials, 
propofol seemed superior or at least not inferior to the combination of an opioid with a 
muscle relaxant, some critical remarks should be made. Achieving sufficient sedation 
appeared much more difficult with propofol. In the study of Durrmeyer et al. additional 
doses of propofol were needed in over 50% of patients compared to the need for 
additional atracurium in only about 10% of patients. As a consequence, the use of propofol 
led to longer procedure times. Also, the quality of sedation based on the intubation 
conditions was poorer in the propofol group.55 Ghanta et al. did not specifically report on 
the need for additional propofol or on the intubating conditions.38 From a pharmacokinetic 
perspective, morphine is not a suitable candidate for use as premedication in neonatal 
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intubation, because of the slow onset of action and slow clearance.49 The superior effect 
of propofol compared to the combination of morphine and suxamethonium used by 
Ghanta et al., therefore, could possibly be influenced by insufficient analgesia and/or 
sedation by the time intubation was performed. Results could have been different if 
short-acting opioids had been used. 
Several studies provided conflicting results on the sedative effect of different propofol 
doses.38,56-58 In all studies equal propofol doses in the entire population of neonates were 
used, despite the fact that gestational age and postnatal age have been proven to be 
important determinants of propofol pharmacokinetics.59 Smits et al. were the first to show 
that different doses of propofol were needed to provide adequate sedation in groups 
of neonates with different gestational and postnatal ages.60 In our NEOPROP-2 trial, a 
multicenter dose-finding study, we aimed to find the single propofol starting dose that 
provides effective sedation without side effects in eight groups of patients with different 
gestational and postnatal ages. Unfortunately, we were not able to establish this propofol 
dose in any of the eight age groups. We did find that, regardless of gestational age or 
postnatal age, single propofol starting doses of 1.0 and 1.5 mg/kg almost never led to 
effective sedation. Only a single dose of 2.0 mg/kg led to effective sedation in the majority 
of patients. Logistic regression analysis showed that the sedative effect of propofol was 
not influenced by gestational or postnatal age.61 From these findings it can be concluded 
that the sedative effect of propofol is dose-dependent in general, but unpredictable in the 
individual patient. A meta-analysis of the available studies might provide final conclusions 
about the appropriate propofol doses.
The existing evidence on the effect of propofol on blood pressure is also conflicting. While 
in some studies hypotension did not appear38,62 or did only appear in a small proportion 
of patients,56,63 other authors reported a 38 to 65% incidence of hypotension.57,58,60 The 
high incidence of hypotension was confirmed in our NEOPROP-2 trial. We found an 
overall incidence of 59% and incidences of 63%, 52% and 62% in 1.0 mg/kg, 1.5 mg/
kg and 2.0 mg/kg starting doses.61 In a post-hoc analysis of the NEOPROP-2 data we 
showed that there was a significant decline in blood pressure in all three dosing groups, 
which was not restored after one hour. This decline in blood pressure was dependent 
on the starting dose and not on the cumulative propofol dose.64 In a multiple regression 
analysis with gestational age, postnatal age, growth restriction (defined as a birth weight 
below 10th percentile) and male gender as patient variables, we were not able to define 
factors that could influence the occurrence of propofol-induced hypotension.61 Other 
possible influencing factors such as underlying illness and disease severity need further 
investigation. 
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Controversy exists regarding the definition of hypotension in neonates as well as the 
importance of hypotensive episodes in general for the patient. Hypotension in preterm 
infants has been associated with mortality and serious morbidities.65-70 Blood pressure, 
however, is not always the best indicator of circulation and organ perfusion. In this 
light it has been thought that hypotension in the absence of signs of inadequate tissue 
perfusion does not yield any long-term negative effects and should not be treated. This 
phenomenon is referred to as permissive hypotension.71-73 
To date, there are different opinions as to the importance of propofol-induced hypotension 
for the neonate. The study of Welzing et al. was terminated prematurely because of the 
high incidence of hypotension, but the necessity of this termination has been questioned 
by others.57,74 Smits et al. found an overall hypotension incidence of 64% but, in the absence 
of clinical signs of shock, the majority of hypotension episodes were designated as 
being permissive.60 Several small studies investigated the relationship between cerebral 
oxygenation and systemic hypotension after treatment with propofol. An important 
correlation between blood pressure and cerebral oxygenation was not found in all three 
studies.75-77 Although these findings seem to be reassuring, it concerned only small sample 
sizes and focused on near infrared spectroscopy (NIRS) data only. Clinical short-term and 
long-term consequences of propofol-induced hypotension have never been investigated. 
Therefore, the importance of propofol-induced hypotension on the short and long term is 
yet to be elucidated and might not be as permissive as is thought. 
In conclusion, both remifentanil and propofol as single drug premedication strategies possess 
significant difficulties in providing adequate sedation for the procedure. In addition, both drugs 
are accompanied by a high risk of side effects. The use of remifentanil as well as propofol 
as premedication for endotracheal intubation, therefore, should be seriously reconsidered. 
Based on the current available evidence, in general, the combination of an opioid with a 
muscle relaxant is the most effective and safe strategy. Fentanyl seems the most suitable 
opioid candidate. Chest wall rigidity, being a known side effect of fentanyl as well, can be 
prevented by slower infusion times and can also be overcome by the subsequent use of a 
muscle relaxant. To prevent patients from being paralyzed while not being sedated, sufficient 
time should be taken to reach the effect of fentanyl before the muscle relaxant is being 
administered. Morphine, although one of the drugs most used as premedication,28-30 should 
not be used any longer because of its delayed onset and prolonged duration of action. 
Remifentanil as a single bolus also does not seem a suitable candidate in combination with 
a muscle relaxant, because its ultrashort period of action that is shorter than that of most 
muscle relaxants brings the risk of leaving patients paralyzed while the sedative effect has 
already ceased. Continuous infusion of remifentanil could be considered in combination with 
a muscle relaxant, but this strategy needs further investigation first. 
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Rather than focusing on a single premedication strategy that is used within the entire 
neonatal population, the course should be changed towards a more personalized 
approach. In the choice for the most suitable premedication strategy, factors such as 
gestational age and postnatal age, underlying illness, reason for intubation, hemodynamic 
stability and expected duration of mechanical ventilation should all be considered. In 
a patient that is being intubated for the purpose of mechanical ventilation for at least 
several hours, the use of premedication with a very short period of action is probably 
less important. In these patients, a combination of fentanyl and a short-acting muscle 
relaxant seems the most appropriate strategy. Propofol should not be used in patients 
with hemodynamic instability, and probably also in patients who are being at risk for 
developing hemodynamic instability, such as patients with a sepsis or necrotizing 
enterocolitis. In these patients, fentanyl in combination with a short-acting muscle 
relaxant is probably a more appropriate choice. Although muscle relaxants can improve 
intubation conditions and first attempt success rates, and decrease the incidence of 
hypoxic events, the use of a muscle relaxant should be carefully considered in every 
individual patient. Muscle relaxants cause paralysis, also in the respiratory muscles, with 
subsequent cessation of spontaneous breathing. This is not desirable in every patient or 
even contraindicated in some categories of patients. This concerns patients with a known 
or anticipated difficult airway, in whom maintaining a spontaneous breathing pattern is 
of utmost importance in case of failed intubation and possible difficulty with bag and 
mask ventilation. Also, in patients with severe respiratory failure, diaphragmatic paralysis 
due to the use of a muscle relaxant can impair pulmonary function, thereby seriously 
worsening the course of the disease. In these patients, propofol could be used, provided 
that the hemodynamic condition is stable. In case of hemodynamic instability in a patient 
with a known or anticipated difficult airway, both fentanyl and remifentanil as single drug 
regimens could be considered. However, both should be used with caution with specific 
attention to the prevention of chest wall rigidity, because this often needs treatment with 
a muscle relaxant that hampers the respiratory drive. 
A significant proportion of drugs in the neonatal intensive care unit is used off label and 
there are only a limited number of clinical trials on efficacy, dosage and safety of drugs 
in the neonatal population.78 This lack of knowledge results in different drug therapies in 
clinical practice.79 This certainly applies to the different drugs that are used as premedication 
for endotracheal intubation in neonates. Information on dosing of these drugs is lacking 
and doses for the neonatal population are often extrapolated from data in older children 
and adults. Dose-finding studies in large populations of neonates with clear definitions 
of effect and side effects are urgently needed to resolve this issue. These studies are, 
however, difficult to perform. Our NEOPROP-2 trial demonstrates the difficulties that 
could be encountered when performing such dose-finding trials. Our study had to be 
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terminated prematurely, one of the reasons for this early termination being the difficulty in 
including patients in several of the age groups that we defined.61 Smits et al. encountered 
the same difficulties in their propofol dose-finding study, with only three out of eight strata 
containing a sufficiently large sample size.60 This inclusion difficulty can be explained by 
the significantly smaller number of neonates with older gestational and postnatal ages that 
need endotracheal intubation. Awaiting further dose-finding studies, valuable information 
can be obtained by collecting data on effects and side effects in observational trials. 
Procedures need to be standardized and effect and side effect registration needs to be 
part of standard clinical care. To obtain sufficient patient numbers, neonatal centers should 
pursue collaboration and data-sharing on a national and international level. 
READY TO TACK – Towards an individualized premedication strategy 
Recommendations for clinical practice
•	 The choice for a certain premedication strategy should be individualized in 
every patient, and should be dependent on factors such as gestational and 
postnatal age, underlying illness, reason for intubation, hemodynamic status 
and expected duration of mechanical ventilation. 
•	 In general, based on the available evidence, a strategy consisting of a short-
acting opioid and a short-acting muscle relaxant seems most effective and 
safe. 
•	 The use of a muscle relaxant should be carefully considered in every patient. It 
should not be used in patients with a known or anticipated difficult airway and 
strongly discouraged in patients with severe respiratory insufficiency.
•	 Because of difficulties in achieving effective sedation and the significant 
negative effects on blood pressure, propofol should not be used as a standard 
premedication regimen. It should only be used in very specific circumstances 
such as patients with a known or anticipated difficult airway or in whom only a 
short period of action of the premedication is absolutely required.
•	 Propofol should not be used in patients with hemodynamic insufficiency 
and should be carefully considered in patients with a risk of hemodynamic 
instability. 
•	 When using propofol as premedication, it should be started in a low dose and 
be titrated according to the sedative effect, under close monitoring of blood 
pressure.
•	 Caution is required with the use of remifentanil because of the high risk of 
chest wall rigidity.
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Recommendations for future research
Future research into the most effective and safe premedication strategy for 
endotracheal intubation should focus on the following aspects:
•	 Dose-finding of fentanyl and remifentanil as bolus administration.
•	 The use of remifentanil as a short continuous infusion.
•	 Comparison of different muscle relaxants.
•	 Comparison of different premedication strategies in different circumstances. 
•	 National and international collaboration and data-sharing regarding 
pharmacodynamic and pharmacokinetic data of different strategies. 
PREMEDICATION IN LESS 
INVASIVE SURFACTANT TECHNIQUES
The use of premedication for the INSURE (INtubation – SURfactant – immediate 
Extubation) procedure has never been questioned. To make immediate extubation 
after the administration of surfactant possible, the respiratory depression that is often 
cause by premedication should be very short. Therefore, the premedication strategy 
should be carefully chosen. A systematic review showed there is not enough evidence 
on which premedication strategy is most effective and safe in the context of the INSURE 
procedure.80 In two smalls studies, remifentanil and propofol as premedication for INSURE 
were evaluated.53,57 Both seemed to be effective in providing adequate sedation, but the 
duration of effect on the respiratory drive was somewhat questionable.80 In a pilot study 
on the use of remifentanil for this purpose, we were confronted with serious difficulties in 
achieving adequate sedation and an unacceptable high incidence of chest wall rigidity, 
necessitating a premature ending of our study.55 We had to conclude that remifentanil, 
at least at a fast infusion rate of 30 seconds, was not suitable for this purpose. In the past 
years, to the best of our knowledge no new studies have appeared on the use of different 
premedication strategies prior to INSURE. The question which premedication strategy is 
best for this purpose, therefore, still remains unanswered. It is, however, undeniable that 
premedication should be used for the INSURE procedure. 
In the past decade, INSURE and also conventional surfactant administration during 
mechanical ventilation, have increasingly given way to LISA (Less Invasive Surfactant 
Administration). Comparable to endotracheal intubation and INSURE, LISA requires 
laryngoscopy, which is known to cause pain and distress. Despite this, LISA procedures 
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are often performed without premedication to maintain a spontaneous breathing 
pattern.81-88 Since LISA failure is associated with a higher need for mechanical ventilation, 
a higher incidence of supplemental oxygen at day 28 and a 20% lower survival rate 
without adverse events,89 maintaining the respiratory drive to prevent LISA from failing is 
of utmost importance. There is, however, no evidence that laryngoscopy in the context 
of LISA is not accompanied with pain, discomfort and harmful effects. 
In an observational study on LISA without sedative premedication we showed a relatively 
low first attempt success rate of 52%, a high rate of inadequate technical quality of 41% 
and a 54% incidence of oxygen desaturations.90 These results could indicate patient 
discomfort and intolerance to the procedure and promotes the use of sedative 
premedication in LISA. In the past three years, several studies have been published 
evaluating the effect of different kinds of premedication for LISA procedures. Although 
patient comfort significantly improved,91,92 both propofol and ketamine did have important 
negative effects on the respiratory drive.91-94 Comparing our findings in non-sedated LISA 
with studies using premedication, showed that our incidence of oxygen desaturations 
was lower compared to the premedicated population in those studies.90,92-94 This is 
most probably due to respiratory depression caused by the premedication. Also, first 
attempt success rate of LISA was comparable between our study and the studies using 
premedication.90,92,94 Premedication did, however, provide better intubating conditions.90,94 
These comparisons do not mean performing LISA in awake patients is acceptable and 
even better than using premedication. These data do indicate we have to do better in 
premedicating patients for LISA, using drugs with the least effect on the respiratory drive. 
READY TO TACK – Towards premedication use in less invasive surfactant 
administration
Recommendations for clinical practice
•	 Laryngoscopy for LISA probably causes equal stress, discomfort and 
physiological disturbances compared to laryngoscopy for intubation. LISA 
should, therefore, be performed with premedication. 
•	 The premedication that is used, should have a very short duration of action 
and should not influence the respiratory drive. 
•	 Results from studies on the use of propofol as premedication for LISA indicate 
that propofol might have to great an effect on the respiratory drive. Propofol, 
therefore, seems probably not suitable for this purpose. 
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Recommendations for future research
•	 Future research should focus on the most suitable premedication strategy for 
LISA, that should be very short-acting and without any effect on the respiratory 
drive. 
•	 Remifentanil is a possible candidate and should be subjected to further 
research. 
•	 Also, comparative studies of different premedication strategies, preferably in 
a randomized controlled manner, should be performed to determine the most 
effective and safe strategy for this purpose.
EXPERIENCE AND COMPETENCE 
OF THE HEALTH CARE PROVIDER
Endotracheal intubation is a difficult procedure with a relatively low first attempt success 
rate, even when performed by experienced personnel. However, success of intubation 
is highly influenced by the degree of experience of the health care provider. Health 
care providers with variable experience are successful in intubation at the first attempt 
in 44% to 73% of intubations. Pediatric residents have much lower first attempt success 
rates that are mainly between 20% and 45%.3,4,6-9,95,96 In only one study, a success rate 
of 63% for pediatric residents was found.5 Pooled data of 8 individual studies showed 
a first attempt success rate of 42% for pediatric residents, compared to 52% for fellows 
and 64% for attendings.11 These data indicate that when being intubated by a pediatric 
resident the patient is more frequently exposed to multiple intubation attempts. Since an 
increasing number of attempts increases the risk of adverse events and severe hypoxic 
events and is also associated with intraventricular hemorrhage and neurodevelopmental 
impairment, intubation of vulnerable preterm infants by inexperienced airway providers 
should be prevented. 
The opportunities for pediatric residents to acquire and maintain proficiency in neonatal 
endotracheal intubation is a topic of serious concern. Evidence from anesthesia literature 
suggests that proficiency at intubation of adults takes over 40 procedures.97-99 There is 
no clear evidence as to the amount of procedures needed to become proficient with 
neonatal intubation. Given the difficulty of the procedure due to the small size of mouth 
and airway and the anatomy of the larynx in neonates, it is not assumable that the amount 
of procedures needed to become proficient is lower compared to the adult population. 
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Due to factors such as an increased presence of advanced practice providers in the NICU 
and an increased use of non-invasive ventilation strategies, opportunities for pediatric 
residents to perform neonatal intubation are limited.1-8,96,100 Nowadays, pediatric residents 
are graduating without having achieved the competency to intubate a neonate.7,101 This 
certainly can be a problem, since pediatricians involved in the care of newborns will 
be confronted with a neonate requiring endotracheal intubation at some point during 
their further career. Ways to improve neonatal intubation skills of pediatric residents lay 
in structured simulation training programs targeting on gaining the skills of neonatal 
intubation before performing the procedure in real patients.11 Also, the use of a video 
laryngoscope, which gives the instructor a view of the upper airway, making it possible 
to provide clear guidance, has been shown to significantly increase the first attempt 
success rate of pediatric residents.102,103 
READY TO TACK – Towards intubation by experienced health care providers 
Recommendations for clinical practice
•	 In each intubation procedure the airway provider should be chosen with 
careful consideration. Gestational age, weight, the indication for endotracheal 
intubation and the condition of the patient should be taken into account when 
deciding who will perform the intubation. 
•	 Urgent and emergency intubations, and intubations in small or unstable 
patients should be performed by an airway provider skilled in neonatal 
intubation.
•	 Efforts to provide adequate intubating experience for pediatric residents 
should focus on the larger and more stable neonatal population and on 
simulation training.
•	 The use of a video laryngoscope can improve the first attempt success rates 
of inexperienced airway providers and should be considered. 
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PREMEDICATION DURING INSURE AND LISA
Respiratory Distress Syndrome (RDS) in preterm infants is often treated with surfactant. 
Historically, surfactant was administered during a period of mechanical ventilation. To 
prevent ventilator-induced lung injury, lesser invasive ways to administer surfactant were 
developed: the INSURE (INtubation-SURfactant-Extubation) procedure and the LISA 
(Less Invasive Surfactant Application) procedure. 
During the INSURE procedure, an endotracheal tube is placed in the trachea and 
surfactant is administered, followed by immediate extubation. To facilitate immediate 
extubation, the premedication that is used to provide sedation and comfort during 
placement of the endotracheal tube, should have a very short period of action, to allow 
for quick restoration of the respiratory drive. 
To determine which drug or combination of drugs would be most appropriate as 
premedication prior to the INSURE procedure, we performed a systematic review of 
the literature (chapter 2). Our literature search only revealed two publications explicitly 
evaluating the effect of a certain premedication for the INSURE procedure: remifentanil 
(2 μg/kg) and propofol (1 mg/kg). Both strategies provided adequate sedation, but 
the study on propofol was prematurely ended because of serious side effects. In both 
studies, the time to start with continuous positive airway pressure (CPAP) and the time 
to extubation were rather long but reasons for this were not provided. The period of 
action of both remifentanil and propofol could have been too long to enable immediate 
extubation. An additional search and inclusion of 10 publications describing the use of 
premedication during INSURE, did not provide enough information about the period of 
action of different premedication strategies that were used. The results of this review 
concluded that, although propofol and remifentanil should in theory both be appropriate 
candidates, further research into the optimal dose, side effects and period of action of 
both drugs is needed. 
Based on its pharmacological profile and the results from our systematic review, we 
performed a pilot study aiming to evaluate the effect and side effects of remifentanil as 
premedication prior to INSURE, described in chapter 3. Remifentanil was administered 
as a bolus followed by a saline flush with a total duration of 30 seconds. We started 
with a remifentanil dose of 1 µg/kg, to be repeated twice in the same dose in case of 
insufficient sedation. Because this strategy only provided sufficient sedation in one out 
of five patients, we changed the dosing regimen into a starting dose of 2 µg/kg, with 
additional doses increasing with 1 µg/kg relative to the previous dose up to a maximum 
dose of 5 µg/kg in case of insufficient sedation. This regimen led to sufficient sedation 
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in a higher proportion of patients but also to a high incidence of chest wall rigidity. The 
study was prematurely ended after the inclusion of 14 patients. The high incidence of 
chest wall rigidity could have been caused by the fast infusion rate of remifentanil that we 
used in our study. A fast infusion rate can cause higher peak levels with increased side 
effects as a consequence. In conclusion, remifentanil as a fast bolus over 30 seconds is 
not appropriate as premedication for the INSURE procedure. 
During LISA, mechanical ventilation is completely avoided and surfactant is administered 
through a thin catheter that is placed between the vocal cords by laryngoscopy in patients 
who are spontaneously breathing on nCPAP. Because of the possible depressant effects 
of premedication on the respiratory drive, LISA is most often performed without the use 
of premedication, despite the previously gained knowledge on the harmful effects of 
awake laryngoscopy. 
In a prospective observational study described in chapter 4, we evaluated the effects 
of performing a LISA procedure without sedative premedication on the success rate, 
technical quality of the procedure and vital parameters in preterm newborns. The 
success rate of the first attempt was 52% and in 41% of procedures the technical quality 
was inadequate. There was also a strong correlation between success and technical 
quality. These results could point to patient discomfort and intolerance. Analysis of vital 
parameters in a subpopulation of study patients in whom vital parameter data were 
available, showed that heart rate was significantly higher in the first 30 minutes after 
start of the LISA procedure compared to baseline. Bradycardia <80/min did not occur. 
These results are most probably attributable to the administration of atropine, which 
was standard procedure. At 1 and 2 minutes after the start of the LISA procedure oxygen 
saturation was significantly lower compared to the oxygen saturation before start of the 
LISA procedure. Besides this, oxygen desaturations <80% in the first 30 minutes occurred 
in 54% of patients. These desaturations probably do not only reflect an effect of awake 
laryngoscopy, but also the administration of surfactant. From the results of this study it 
can be concluded that performing LISA procedures without sedative premedication is 
accompanied by a low success rate and frequent inadequate technical quality. The use 
of sedative premedication could improve success and technical quality, and possibly 
also decrease the incidence of oxygen desaturations to some extent. The use of atropine 
seems to have a preventive effect on bradycardia and should, therefore, be considered. 
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MEASUREMENT OF THE EFFECT OF PREMEDICATION
It is well known that laryngoscopy and endotracheal intubation in awake neonates are 
often associated with adverse physiological events, which can be minimized or prevented 
by the use of premedication. The purpose of administering premedication, therefore, is to 
provide a level of sedation sufficient to perform the procedure of intubation without serious 
adverse events and in the least amount of time. The intubation procedure, therefore, 
should only be started after this level of sedation is achieved. There is, however, no 
uniform definition of sufficient sedation and there is much variability in the determination 
of the level of sedation in clinical practice. In the second part of this thesis we aimed 
to standardize the intubation procedure by developing an objective scoring system to 
determine the level of sedation after the administration of premedication. 
The first step was to provide insight into the availability of objective and validated scoring 
systems to assess the level of sedation in the neonatal population. For this purpose, we 
performed a systematic review of the literature, as described in chapter 5. This systematic 
review showed that there are no validated scoring systems available. A search into studies 
describing common practice on how level of sedation is determined, revealed 20 studies 
to be included. In eight of the included studies (40%), the decision to proceed with the 
intubation after the administration of premedication was not based on the level of sedation. 
In these studies, intubation was started after a period of time presumed to be enough for 
drug effect had elapsed, or after the patient was pre-oxygenated. In another eight studies 
(40%) the decision to proceed with intubation was based on the sedation level, but this was 
determined subjectively or it was unclear how this was determined. In only four studies (20%) 
sedation level was evaluated objectively by certain scores. From these studies, a total of 
three objective sedation assessment tools could be retrieved: the sedation score, based on 
the motor response after applying a firm stimulus assessed on a 4-point scale; the relaxation 
score, based on the muscle tone of the extremities also assessed on a 4-point scale; and the 
sedative state, based on the Neonatal Pain Agitation and Sedation (N-PASS) scale in which 
5 items are all assessed on a 5-point scale. The sedation and relaxation scores are both very 
easy and quickly to perform, the sedative state is a more extensive and time consuming score 
that is probably less suitable for a situation as acute as neonatal intubation. In conclusion, this 
systematic review revealed three promising sedation assessment tools, all needing further 
validation before they can be implemented into clinical practice. 
As a second step in this part of the thesis, we developed an Intubation Readiness Score 
(IRS) that was based on the sedative score that came forward from the systematic review. 
It consisted of the application of a firm stimulus, rubbing the heel of the patient's foot, 
and judging the motor reaction to that stimulus on a 4-point scale: 1 = spontaneous 
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movements; 2 = movement on slight touch; 3 = movement in reaction to the firm stimulus; 
4 = no movement. Scores 3 and 4 were believed to indicate a level of sedation that is 
sufficient to tolerate the act of laryngoscopy and placement of the endotracheal tube. 
Intubation was only proceeded when a score of 3 or 4 was reached. We implemented 
this IRS into clinical practice and performed a prospective observational study (chapter 
6) to evaluate the usefulness of this IRS in predicting the actual level of sedation. For this 
purpose, the positive predictive value of IRS 3 and 4 in predicting adequate sedation 
during the intubation procedure was determined. Sedation level was assessed by the 
intubation score of Viby-Mogensen and adequate sedation was defined as a good 
intubation score. The results of this study showed a positive predictive value of IRS 3 
and 4 of 85%. In 15% of patients there was an inadequate level of sedation based on 
the intubation score, despite IRS 3 or 4. Univariate analysis revealed no patient factors 
influencing the ability of IRS 3 and 4 to predict an adequate level of sedation. Based on 
these results it can be concluded that the IRS is suitable for use in clinical practice but 
efforts should be made in expanding the score to further improve the positive predictive 
value. Also, the interrater variability in the firmness of the stimulus and the judgement of 
the motor reaction should be taken into account. 
PROPOFOL AS PREMEDICATION
Although the administration of premedication in nonemergency endotracheal 
intubation is recommended for almost 20 years, there is still no consensus on which 
premedication strategy is most effective and safe. Propofol is one of the acceptable 
options and made its way into clinical practice in the last decade. Previously published 
studies on the use of propofol for endotracheal intubation in the neonatal population 
showed inconsistencies in the sedative effect of different propofol doses and concerns 
about its safety. 
In the last part of this thesis we aimed to find the optimal single propofol dose providing 
effective sedation without significant side effects in neonates of different gestational 
and postnatal ages. We performed a prospective multicenter dose-finding trial, that 
is described in chapter 7. Included patients were stratified into eight different groups 
based on their gestational age and postnatal age. Dose-finding according to a step-
up-step-down model based on sedative effects and side effects was performed in 
every of the eight groups. After an interim analysis of 91 included patients showed 
difficulty with inclusion in several of the age groups and a high risk of hypotension, 
the study was terminated. In two age groups the dose-finding procedure was finished 
but an optimal single propofol dose providing effective sedation without side effects 
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could not be established. In both groups, a propofol dose of 2.0 mg/kg was found to 
achieve effective sedation, but caused hypotension in more than half of the patients. 
Further in-depth analysis of the three most used propofol starting doses showed that 
starting doses of 1.0 and 1.5 mg/kg almost never led to effective sedation. Only a 
starting dose of 2.0 mg/kg caused effective sedation in the majority of patients. In all 
three dosing groups, however, more than half of all patients developed hypotension. 
In the total study population, mean blood pressure after propofol administration 
decreased with a median of 34% compared to the mean blood pressure at baseline. 
The lowest mean blood pressure occurred at a median of 21 minutes after the start of 
propofol administration. Logistic regression analysis showed that gestational age and 
postnatal age, as well as other patient characteristics, did not influence the sedative 
effect of propofol and the occurrence of hypotension. Based on these results it can 
be concluded that effective sedation without the occurrence of side effects is difficult 
to achieve with a single propofol bolus. Effects as well as side effects of propofol in 
the neonatal population are variable and unpredictable. Therefore, propofol in the 
neonatal population should only be used after careful consideration and should be 
titrated based on sedative effect with strict monitoring of blood pressure. 
A post-hoc analysis of the propofol dose-finding trial, aiming to provide guidelines for the 
use of propofol in clinical practice, studied the effects of different propofol starting doses 
on blood pressure (chapter 8). In both the 1.0 mg/kg, 1.5 mg/kg and 2.0 mg/kg starting 
doses blood pressure declined after the start of propofol compared to baseline blood 
pressure before propofol. This decline was dose-dependent, being the largest in the 2.0 
mg/kg dosing group. In all three dosing groups, blood pressure was not restored one 
hour after the start of propofol. The decline in blood pressure was mainly dependent on 
the starting dose of propofol that was used and not on the cumulative propofol dose that 
was eventually administered to provide sufficient sedation and accomplish successful 
intubation. The incidence of hypotension, the treatment of hypotension with volume 
resuscitation and the maximum decrease in blood pressure as percentage from baseline 
were all not statistically different between the 1.0 mg/kg, 1.5 mg/kg and 2.0 mg/kg 
dosing groups. The maximum decrease in blood pressure, however, was significantly 
earlier in the 1.0 mg/kg dosing group compared to the 2.0 mg/kg dosing group. In 
conclusion, propofol causes a profound and prolonged decrease in blood pressure that 
is mainly dependent on the propofol starting dose that is used. These results again 
stress the need for careful consideration of propofol as premedication in the newborn 
population. When propofol is used, starting with a low dose and titrating until sufficient 
sedation is reached, seems to cause the least decline in blood pressure and therefore, 
seems the safest or least unsafe strategy. 
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PREMEDICATIE TIJDENS 
DE INSURE EN LISA PROCEDURES
Pasgeborenen met het Respiratoir Distress Syndroom (RDS) worden vaak behandeld 
met surfactant. Aanvankelijk werd surfactant toegediend via een endotracheale tube 
tijdens een periode van positieve druk beademing. Om beschadiging van de longen 
door positieve druk beademing te voorkomen, werden minder invasieve technieken 
voor de toediening van surfactant ontwikkeld: de INSURE (INtubation – SURfactant - 
Extubation) procedure en de LISA (Less Invasive Surfactant Application) procedure. Het 
eerste gedeelte van dit proefschrift beschrijft onderzoek dat is gericht op het gebruik 
van premedicatie voor deze procedures. 
Tijdens de INSURE procedure wordt een endotracheale tube geplaatst in de trachea, 
surfactant wordt toegediend en onmiddellijk gevolgd door extubatie. Om deze 
onmiddellijke extubatie mogelijk te maken, dient de premedicatie die wordt gebruikt ter 
sedatie en comfort bij het plaatsen van de endotracheale tube een korte werkingsduur 
te hebben, zodat herstel van de eigen ademhaling snel optreedt. 
Om te bepalen welk middel of combinatie van middelen het meest geschikt is als 
premedicatie voor de INSURE procedure, voerden we een systematische review van de 
literatuur uit (hoofdstuk 2). Uit de zoekstrategie kwamen slechts twee publicaties naar 
voren die expliciet de effecten van premedicatie voorafgaand aan de INSURE procedure 
evalueerden: remifentanil (2 μg/kg) en propofol (1 mg/kg). Met beide medicijnen werd 
adequate sedatie verkregen, maar de studie naar het gebruik van propofol werd voortijdig 
beëindigd vanwege ernstige bijwerkingen. In beide studies duurde het relatief lang 
voordat werd overgegaan naar continuous positive airway pressure (CPAP) en extubatie. 
Redenen hiervoor werden niet beschreven. Dit zou gebaseerd kunnen zijn op een te lange 
werkingsduur van zowel remifentanil als propofol om onmiddellijke extubatie mogelijk 
te maken. Een aanvullende zoekstrategie naar studies die het gebruik van premedicatie 
tijdens de INSURE procedure hebben beschreven, leidde tot de inclusie van 10 studies. 
Geen van deze studies verschafte voldoende informatie over de werkingsduur van de 
verschillende premedicatie strategieën die werden gebruikt. Uit de resultaten van deze 
systematische review kon worden geconcludeerd dat propofol en remifentanil in theorie 
beiden geschikte kandidaten zouden kunnen zijn als premedicatie voor de INSURE 
procedure. Verder onderzoek is echter nodig naar de optimale dosering, bijwerkingen 
en werkingsduur van zowel propofol als remifentanil. 
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Gebaseerd op de farmacologische eigenschappen en de resultaten van de 
bovengenoemde systematische review, startten we in de klinische praktijk met het 
gebruik van remifentanil als premedicatie voor de INSURE procedure. In een prospectieve 
observationele studie evalueerden we de effecten en bijwerkingen van remifentanil. Deze 
studie wordt beschreven in hoofdstuk 3. Remifentanil werd toegediend als bolus gevolgd 
door een flush fysiologisch zout met een totale duur van 30 seconden. We startten met 
een dosering remifentanil van 1 µg/kg. Wanneer onvoldoende sedatie werd bereikt, 
kon deze dosering tweemaal worden herhaald. Deze strategie leidde slechts bij één 
van de vijf patiënten tot voldoende sedatie. We veranderden daarom de strategie naar 
een startdosering van 2 µg/kg. Wanneer sprake was van onvoldoende sedatie, werden 
extra giften remifentanil toegediend waarbij de dosering steeds werd verhoogd met 1 
µg/kg ten opzichte van de voorgaande gift, tot een maximale dosering van 5 µg/kg per 
gift. Met deze strategie werd bij een groter aantal patiënten voldoende sedatie bereikt, 
maar het leidde ook tot een hoge incidentie van thorax rigiditeit, een kortdurende maar 
zeer ernstige bijwerking. Daarop werd na behandeling van 14 patiënten met remifentanil, 
besloten remifentanil niet meer te gebruiken voor INSURE procedures en werd de studie 
beëindigd. De hoge incidentie van thorax rigiditeit zou veroorzaakt kunnen zijn door 
de snelle toediening van remifentanil. Dit zou geleid kunnen hebben tot hogere piek 
concentraties met een toename van bijwerkingen tot gevolg. Concluderend kan worden 
gesteld dat remifentanil als bolus in 30 seconden niet geschikt is als premedicatie in het 
kader van de INSURE procedure.
Tijdens de LISA procedure worden patiënten niet meer invasief beademd, maar wordt 
surfactant toegediend door een dunne katheter die met behulp van een laryngoscoop 
tussen de stembanden wordt geplaatst bij patiënten die spontaan ademen met nasale 
CPAP-ondersteuning. Omdat premedicatie een depressie van de ademdrive kan 
veroorzaken, wordt LISA meestal uitgevoerd zonder het gebruik van premedicatie, 
ondanks de kennis over de schadelijke effecten van het verrichten van laryngoscopie in 
wakkere patiënten. 
In een prospectieve observationele studie (hoofdstuk 4), evalueerden we de effecten van 
het verrichten van een LISA procedure zonder het gebruik van sedatieve premedicatie 
op het succespercentage, de technische kwaliteit van de procedure en de vitale 
parameters in prematuur geboren neonaten. De eerste LISA poging was succesvol 
in 52% van de procedures en in 41% van de procedures was sprake van onvoldoende 
technische kwaliteit. Daarnaast werd een sterke correlatie gevonden tussen succes 
en technische kwaliteit. Deze resultaten zouden kunnen wijzen op discomfort en 
verzet van de patiënt. In een subpopulatie van patiënten van wie de vitale parameters 
beschikbaar waren, werden de hartfrequentie en zuurstofsaturatie geanalyseerd. In de 
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eerste 30 minuten na de start van de LISA procedure was de hartfrequentie significant 
verhoogd ten opzichte van de basis hartfrequentie. Bradycardieën <80/min kwamen 
niet voor. Deze resultaten kunnen waarschijnlijk het beste worden toegeschreven aan 
het gebruik van atropine voorafgaand aan LISA, wat standaard was in deze studie. Op 
1 en 2 minuten na de start van de LISA procedure was de zuurstofsaturatie significant 
lager dan de basis zuurstofsaturatie voorafgaand aan de LISA procedure. Daarnaast 
traden bij 54% van de patiënten desaturaties <80% op in de eerste 30 minuten na de 
start van de LISA procedure. Deze desaturaties zijn waarschijnlijk niet alleen gebaseerd 
op een effect van de laryngoscopie maar ook op de toediening van surfactant. Uit de 
resultaten van deze studie kan worden geconcludeerd dat een LISA procedure zonder 
sedatieve premedicatie leidt tot een laag succespercentage en vaak gepaard gaat 
met inadequate technische kwaliteit. Het gebruik van sedatieve premedicatie zou het 
succes en technische kwaliteit kunnen verbeteren. Mogelijk kan ook de incidentie van 
desaturaties hierdoor worden verlaagd. Het gebruik van atropine lijkt een beschermend 
effect te hebben op het optreden van bradycardieën en zou daarom overwogen 
moeten worden. 
BEPALEN VAN HET EFFECT VAN PREMEDICATIE
Sinds langere tijd is bekend dat het uitvoeren van laryngoscopie en endotracheale intubatie 
in wakkere neonaten vaak gepaard gaat met nadelige fysiologische gebeurtenissen. 
Deze kunnen verminderd of voorkomen worden door het gebruik van premedicatie. Het 
doel van het toedienen van premedicatie is dan ook een niveau van sedatie te verkrijgen 
dat voldoende is om de intubatie procedure uit te kunnen voeren zonder ernstige 
nadelige effecten en in een zo kort mogelijke duur. De intubatie procedure zou dan ook 
slechts gestart mogen worden wanneer dit niveau van sedatie is bereikt. Er is echter geen 
uniforme definitie van voldoende sedatie en er is veel variabiliteit in het bepalen van het 
sedatie niveau in de klinische praktijk. Het tweede deel van dit proefschrift had tot doel 
om de intubatieprocedure te standaardiseren door het ontwikkelen van een objectief 
scoresysteem waarmee het niveau van sedatie na de toediening van premedicatie 
bepaald kan worden. 
Allereerst werd inzicht verkregen in de beschikbaarheid van objectieve gevalideerde 
scoresystemen om het niveau van sedatie te bepalen in de neonatale populatie, 
door het uitvoeren van een systematische review van de literatuur (hoofdstuk 
5). Uit deze systematische review kwam naar voren dat er geen gevalideerde 
scoresystemen beschikbaar zijn. Er volgde een aanvullende zoekstrategie naar 
studies die beschreven hoe het niveau van sedatie in de praktijk werd bepaald. Dit 
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leidde tot inclusie van 20 studies. In acht van deze studies (40%) was de beslissing 
om over te gaan tot intubatie na de toediening van premedicatie niet gebaseerd 
op het bereikte niveau van sedatie. Intubatie werd gestart nadat een bepaalde tijd 
was verstreken waarin het effect van de premedicatie werd verondersteld op te 
treden, of nadat de patiënten gepreoxygeneerd waren. In eveneens acht studies 
(40%) was het besluit om verder te gaan met de intubatie wel gebaseerd op het 
niveau van sedatie, maar werd dit niveau subjectief beoordeeld of was onduidelijk 
hoe dit werd beoordeeld. In slechts vier van de geïncludeerde studies (20%) werd 
het sedatie niveau objectief beoordeeld, gebruikmakend van verschillende scores. In 
totaal konden uit deze studies drie objectieve instrumenten ter beoordeling van het 
sedatie niveau verkregen worden: de sedatie score, gebaseerd op de beoordeling 
van de motorische reactie na het toedienen van een stevige stimulus op een 4-punts 
schaal; de relaxatie score, gebaseerd op de beoordeling van de spiertonus van 
de extremiteiten op een 4-punts schaal; en de sedatieve status, gebaseerd op de 
Neonatale Pijn Agitatie en Sedatie Schaal (N-PASS) waarbij in totaal 5 items allen op 
een 5-punts schaal worden beoordeeld. De sedatie en relaxatie scores zijn beiden 
zeer gemakkelijk in gebruik en snel uit te voeren. De sedatieve status is uitgebreider 
en tijdrovender en daardoor mogelijk minder bruikbaar voor een acute situatie zoals 
intubatie bij neonaten. Concluderend zijn er drie veelbelovende instrumenten voor 
het beoordelen van het niveau van sedatie beschikbaar, welke allen gevalideerd 
dienen te worden voordat ze kunnen worden gebruikt in de klinische praktijk. 
Als tweede stap werd een zogenaamde Intubation Readiness Score (IRS) ontwikkeld 
om het niveau van sedatie te bepalen. Deze score is gebaseerd op de sedatieve score 
die naar voren kwam in de systematische review. De IRS bestaat uit de toediening 
van een stevige stimulus, het krachtig wrijven over de hiel, en het beoordelen van de 
motorische reactie op deze stimulus op een 4-punts schaal: 1 = spontane bewegingen; 
2 = bewegingen op lichte aanraking; 3 = bewegingen in reactie op de stevige stimulus; 4 
= geen bewegingen. Bij scores 3 en 4 wordt verondersteld sprake te zijn van voldoende 
sedatie om de laryngoscopie en het plaatsen van de endotracheale tube te kunnen 
verdragen. De IRS werd geïmplementeerd in de klinische praktijk en er werd een 
prospectieve observationele studie verricht (hoofdstuk 6) om de geschiktheid van de 
IRS in het voorspellen van het werkelijke sedatie niveau te evalueren. Hiervoor werd de 
positief voorspellende waarde van IRS 3 en 4 in het voorspellen van adequate sedatie 
tijdens de intubatie procedure bepaald. Het niveau van sedatie tijdens de intubatie 
procedure werd vastgesteld met de intubatie score van Viby-Mogensen. Adequate 
sedatie werd gedefinieerd als een goede intubatie score. De resultaten van deze studie 
toonden dat IRS scores 3 en 4 tezamen een positief voorspellende waarde van 85% 
hadden. In 15% van de patiënten echter, bleek het niveau van sedatie gebaseerd op 
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de intubatie score inadequaat, ondanks een IRS van 3 of 4. Er werden geen factoren 
gevonden die invloed hadden op de geschiktheid van IRS 3 en 4 om adequate sedatie 
te kunnen voorspellen. Gebaseerd op deze resultaten kan worden geconcludeerd dat 
de IRS een bruikbaar instrument is in de klinische praktijk. Mogelijkheden om de score uit 
te breiden en daarmee de positief voorspellende waarde te verbeteren moeten worden 
onderzocht. Eveneens moet meer aandacht besteed worden aan de variabiliteit tussen 
beoordelaars in het aanbrengen van de stimulus en het beoordelen van de motorische 
reactie. 
PROPOFOL ALS PREMEDICATIE
Hoewel al 20 jaar geleden werd vastgesteld dat premedicatie altijd gebruikt moet worden 
voorafgaand aan niet-acute endotracheale intubatie in de neonatale populatie, is de 
meest effectieve en veilige premedicatie strategie nog altijd niet vastgesteld. Propofol 
wordt genoemd als een van de mogelijk geschikte opties. In de afgelopen 10 jaar heeft 
propofol zijn opwacht gemaakt in de klinische praktijk. Eerder gepubliceerde studies 
naar het gebruik van propofol in de neonatale populatie toonden tegenstrijdigheden 
in het sedatief effect van verschillende propofol doseringen en tevens zorgen over de 
veiligheid van propofol gebruik. 
Het laatste gedeelte van dit proefschrift is gericht op het vinden van de enkele optimale 
propofol dosering waarmee effectieve sedatie zonder bijwerkingen wordt verkregen 
in neonaten. We voerden een prospectieve multicenter dose-finding trial uit, die wordt 
beschreven in hoofdstuk 7. Geïncludeerde patiënten werden onderverdeeld in acht 
verschillende groepen, gebaseerd op zwangerschapsduur en postnatale leeftijd. In 
iedere van de acht groepen werd de dose-finding procedure verricht volgens een 
step-up-step-down model, gebaseerd op de sedatieve effecten en bijwerkingen. Een 
interim analyse van 91 geïncludeerde patiënten toonde moeilijkheden met de inclusie 
van patiënten in verschillende leeftijdsgroepen en een hoge incidentie van hypotensie. 
Om deze reden werd de studie voortijdig beëindigd. In twee van de acht groepen kon de 
dose-finding procedure volledig doorlopen worden, maar een optimale enkele propofol 
dosering kon niet worden vastgesteld. In beide groepen bleek dat met een dosering 
van 2.0 mg/kg voldoende sedatie bereikt kon worden, maar ontwikkelde meer dan de 
helft van de patiënten hypotensie. Er werd een verdere analyse verricht in de drie meest 
gebruikte propofol startdoseringen in de gehele studie populatie. Hierbij werd gevonden 
dat met startdoseringen van 1.0 mg/kg en 1.5 mg/kg bijna nooit voldoende sedatie 
werd verkregen. Alleen een startdosering van 2.0 mg/kg leidde tot effectieve sedatie 
bij de meerderheid van de patiënten. In alle drie de groepen ontwikkelde meer dan de 
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helft van de patiënten hypotensie. Een logistische regressieanalyse toonde dat zowel 
zwangerschapsduur als postnatale leeftijd niet van invloed waren op het sedatief effect 
van propofol noch op het optreden van bijwerkingen. Gebaseerd op deze resultaten kan 
worden geconcludeerd dat het moeilijk is om effectieve sedatie te verkrijgen zonder 
bijwerkingen met een enkele dosering propofol. De effecten en bijwerkingen van 
propofol in de neonatale populatie zijn variabel en onvoorspelbaar. Er moet dan ook een 
voorzichtige afweging gemaakt worden omtrent het gebruik van propofol in de neonatale 
populatie. Bij gebruik van propofol is strikte monitoring van de bloeddruk noodzakelijk. 
Na afronding van de propofol dose-finding trial, voerden we een verdere analyse uit naar 
de effecten van verschillende propofol startdoseringen op de bloeddruk (hoofdstuk 8). 
In zowel de 1.0 mg/kg, 1.5 mg/kg en 2.0 mg/kg doseringsgroepen daalde de bloeddruk 
na de start van propofol in vergelijking met de basis bloeddruk voor propofol toediening. 
Deze daling was afhankelijk van de dosering, en was het meest uitgesproken bij een 
startdosering van 2.0 mg/kg. In alle drie de groepen was de bloeddruk niet hersteld 
binnen een uur na de start van de propofol toediening. De daling van de bloeddruk was 
voornamelijk afhankelijk van de startdosering propofol en niet zozeer van de cumulatieve 
propofol dosering die uiteindelijk werd toegediend om voldoende sedatie te bereiken 
en de intubatie te voltooien. Er werden geen verschillen gevonden in de incidentie van 
hypotensie, de behandeling van hypotensie met volume toediening en de maximale 
procentuele daling van de bloeddruk tussen de drie doseringsgroepen. Echter, in de 
1.0 mg/kg doseringsgroep trad de maximale daling in bloeddruk significant eerder op 
vergeleken met de 2.0 mg/kg doseringsgroep. Concluderend veroorzaakt propofol een 
uitgesproken en langdurige daling van de bloeddruk die voornamelijk afhankelijk is van 
de propofol startdosering die wordt gebruikt. Deze resultaten benadrukken opnieuw dat 
het gebruik van propofol als premedicatie in de neonatale populatie zorgvuldig moet 
worden afgewogen. Wanneer propofol wordt gebruikt, dan lijkt het starten met een lage 
dosering en vervolgens titreren op basis van het sedatief effect de minste invloed op de 
bloeddruk te hebben en lijkt daarmee de veiligste of minst onveilige strategie. 
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